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Ryan L. Minster, PhD
University of Pittsburgh, 2011
Osteoporosis, sarcopenia and changes in fat distribution with age increase risk of fractures, aect
quality of life, and are of major public health signicance. Investigations into the genetic architec-
ture of endophenotypes of these conditions could lead to better prediction of who is at greatest risk
as well as revealing targets for therapies to delay disease onset or diminish their eects on aicted
individuals. Covariation among these conditions may be due to pleiotropy, although little is known
about the specic genes involved. I explored relationships among twenty-two measures of arm and
leg bone mineral density and geometry, arm and leg lean mass and arm and leg fat mass using data
from two populations of Afro-Caribbeans from the island of Tobago: a sample of 1,937 unrelated
men aged ≥ 40 years and a set of 470 men and women aged ≥ 18 years in seven extended pedigrees
(mean family size = 67). I also performed genomewide association (GWA) studies of lumber spine
and femoral neck bone mineral density (BMD) and fractures in an older (aged ≥ 70 years) pop-
ulation of European and African Americans (n = 1,663 and 1,139 respectively). Hierarchical and
principal component (PC) analysis revealed three clusters: (1) a “geometry group” that comprises
mostly bone geometry traits and leanmass (PC1); (2) a “density group” that comprises mostly BMD
traits (PC2); and (3) a “fat mass group” that comprises measures of fat mass (PC3). Estimates of
residual heritability ranged from 0.206 to 0.763 (p < 0.007 for all traits). Linkage analysis revealed
signicant evidence (LOD > 3.3) for quantitative trait loci (QTLs) on two chromosomes: 10q for
PC1 and tibial periosteal circumference and 21q for PC3 and arm fat mass. GWA analyses of BMD
and fractures in European and African Americans revealed several dozen potential candidate loci
with suggestive levels of signicance (p ≤ 5 × 10−6), the most promising of which is SLC4A7 on
iv
3q24.1, a sodium bicarbonate cotransporter expressed in osteoclasts. Thus, I present evidence for
specic QTLs with pleiotropic eects on multiple body composition traits, as well as loci associated
with areal BMDand fracture risk. Additional analyses of these regions could reveal genes that jointly
inuence susceptibility to osteoporosis, sarcopenia and obesity.
Keywords: pleiotropy, osteoporosis, sarcopenia, bone mineral density, fractures, GWAS, linkage
analysis.
v
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. INTRODUCTION
. PUBLIC HEALTH SIGNIFICANCE
Osteoporosis, sarcopenia and changes in body fat distribution are complex, age-related conditions
that result from the eects of genes and environmental factors. Osteoporosis is a common degener-
ative disorder of the skeleton that aects aging women and men worldwide. It is characterized by
reduced bone mass and deteriorated bone microarchitecture. In the United States, approximately 4–
6 million women and 1–2 million men over the age of 50 (that is, 13%–18% of women over 50 and
3%–6% of men over 50) have osteoporosis. An additional 13–17 million women and 8–13 million
men (that is 37%–50% of women and 28%–50% of men) have the associated condition osteopenia,
low bone mineral density, which is considered a precursor to osteoporosis [Looker et al. 1997].
The decreased bone mass and degraded bone structure increase the risk of fractures with a
concomitant increase in morbidity and mortality. An estimated 2 million fractures were attributed
to osteoporosis in 2005, of which nearly 300,000 are fractures of the hip. It is projected that fractures
due to this disorder will increase to 3 million per year by 2025 [Burge et al. 2007]. Worldwide, for
2000, the estimated incidence of osteoporotic fractures was 9million, with 56.2million people living
with fracture-related disability and a total of 5.8 million disability-adjusted life-years lost due to this
condition [Johnell and Kanis 2006].
Fractures in the elderly oen result in loss of independence and a decline in quality of life; 20%
of those who suer a hip fracture and were ambulatory prior to injury require long-term care post-
fracture. Just 15% of hip fracture patients can walk unaided six months post-fracture [National Os-
teoporosis Foundation 2008]. More than a quarter of hip fracture patients die within a year of injury
[van Staa et al. 2001]. The economic burden of treatments is signicant. For 2005 the estimated cost
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of treating incident fractures in the United States is estimated to be $16.9 billion and is predicted to
rise to $25.3 billion by 2025 [Burge et al. 2007].
Muscle tissue quality and mass also decline with age. This phenomenon, called sarcopenia, or
muscle wasting, has traditionally been dened by low muscle mass, typically greater than two stan-
dard deviations (SD; a table of abbreviations can be found in Appendix A) below the young adult
mean [Baumgartner et al. 1998]. However, because loss of muscle mass is not strictly equivalent to
age-related degeneration in muscle function [Clark and Manini 2008], the denition has been ex-
panded to additionally require low muscle function, as measured by strength or performance, with
cutos dependent on the clinical tools used tomeasure them [Cruz-Jento et al. 2010]. For instance
an individual with a skeletal muscle mass index two standard deviations below the adult mean and a
gait speed of ≤ 0.8 m/s would be classied as sarcopenic. This condition aects 19%–23% of women
and 24%–27% of men over the age of 64 [Iannuzzi-Sucich et al. 2002; Chien et al. 2008] and 31%
and 53% of women and men over the age of 80 [Iannuzzi-Sucich et al. 2002]. Because of the known
relationship between bone strength and mechanical stress, sarcopenia may account for part of the
age-related reduction in bone mass [Pearson and Lieberman 2004].
The distribution of fat tissue changes with age; in particular fat deposition increases in the skele-
tal muscle tissue and bone marrow [Kuk et al. 2009]. The increased fat deposition in the muscle tis-
sue is thought to contribute to sarcopenia [Karasik and Kiel 2008] and in the bone marrow to osteo-
porotic fracture risk [Wehrli et al. 2000]. Visser et al. [2002] found that reducedmuscle attenuation—
indicative of increased intramuscular fat—was associated with lower leg physical function indepen-
dently of total body fat and muscle area. Additionally, it has been observed that increases in body
mass index (BMI) have been associated with reduced risk of hip fractures [Schott et al. 1998; De
Laet et al. 2005] as well as increases in bone mineral density, suggesting that increased adiposity
has a protective eect against osteoporosis [Beck et al. 2009]. However, other studies have reported
increased risks of limb fractures in obese adults [e.g., Gnudi et al. 2009].
To date, considerable research has been done to identify genetic and environmental factors inu-
encing osteoporosis, sarcopenia and body fat distribution separately. However, our current knowl-
edge of development, as well as results from epidemiological studies, indicate that a common set
of genetic and environmental factors may inuence all three tissue types (details are described be-
low). Identication of pleiotropic relationships among bone, muscle and fat traits could lead to a
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greater understanding of the mechanisms involved in the growth, maintenance, dysregulation and
senescence of the musculoskeletal and adipose systems. For example, although osteoporosis can
develop as the result of hormonal disorders or prolonged use of glucosteroids, in most cases the
bone mass loss and structural deterioration appear to be a component of organismal senescence.
The Haversian remodeling that occurs as part of adult bone maintenance is altered as a result of dis-
ease, accumulated microtrauma, and decline in muscle input via mechanical loading [Karasik and
Kiel 2008]. Studies of the relationships between these systems could reveal insights that lead to the
development of new therapies to prevent, delay the onset of or mitigate the eects of osteoporosis,
sarcopenia and changes in fat distribution.
Because osteoporosis, sarcopenia and changes in fat distribution are complex, relatively late-
onset traits, many studies have been performed using underlying endophenotypes of these condi-
tions, including loss of bone quality, loss of muscle quality and adiposity. An endophenotype is a
biological marker, highly associated with an illness or disorder, that could conceivably serve as a in-
termediate between genotype and gross phenotype. For example, bone mineral density oen serves
as an endophenotype for osteoporosis.However endophenotypesmay also be complex traits to quan-
tify, and there is no one single measure that can completely capture the total complexity. Some of
the surrogates for osteoporosis, sarcopenia and age-related changes in fat are briey explored below.
. ENDOPHENOTYPES
.. Measures of bone quality
Detection and diagnosis of osteoporosis is usually accomplished by dual-energy x-ray absorptiom-
etry (DXA), which determines bone mineral density (BMD) by measuring the absorption of x-rays
by the subject’s bones. As BMD increases, so does the absorption of the radiation by the bone tissue.
BMD can bemeasured at various skeletal sites. Hip BMD (right or le proximal femur) is one of the
main predictive risk factors for osteoporosis [Black et al. 1992]. The World Health Organization’s
(WHO) diagnostic criteria for osteoporosis are based upon BMD. The International Society of Clin-
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ical Densitometry recommends, as a standard, BMD measurement at the spine and the hip [Leib
et al. 2004].
Osteopenia is dened as the condition of having a BMD value between 1 and 2.5 standard de-
viations (SD) below the mean in young adults; whereas osteoporosis is dened as having a BMD
value < 2.5 SD below the reference mean [Kanis et al. 1994;World Health Organization 1994]. DXA
BMD measurements can be taken at various sites in the body, and it is unilateral measurement at
the hip (right or le proximal femur) that is the standard within the WHO criteria. Most genetic
studies of osteoporosis and BMD have been of femoral neck and lumbar spine BMD [e.g., Pocock
et al. 1987; Harris et al. 1998; Xiong et al. 2009].
Bone mineral density can also be measured by peripheral quantitative computed tomography
(pQCT). pQCT uses multiple cross-sectional x-ray scans to construct a volumetric model of bone
mineral density distribution, while DXAmeasures areal density. Areal BMD can be confounded by
bone size, and so tends be over-estimated in large bones [Carter et al. 1992]. pQCT also enables
the dissection of the bone into its trabecular and cortical components (the spongy bone typical
of bone ends or epiphyses, and the compact bone typical of the sha or diaphysis, respectively)
and provides measures of bone mineral density and bone mineral content for them. It also provides
metrics of bone geometry such as periosteal circumference, endosteal circumference and trabecular
and cortical area. Recent studies have begun to explore measurements by this method [e.g., Wang
et al. 2007b; Yerges et al. 2009].
Other densitometric measures include speed of sound as measured by quantitative ultrasound
(QUS) (at distal radius, diaphyseal tibia, calcaneus), broadband ultrasound attenuation by QUS (at
calcaneus) [Karasik et al. 2004; Moayyeri et al. 2009] and bone mineral content as measured by
single photon densitometer (at forearm) [Pocock et al. 1987].
Bone geometry can also contribute to bone strength. It is oen measured by DXA, and more
recently by pQCT. Metrics available from DXA scans include length, width, cross-sectional area,
subperiosteal width, buckling ratio, cortical thickness and section modulus of the femoral neck;
width, cross-sectional area, subperiosteal width, center of mass, area moment of inertia and section
modulus of the femoral sha; femoral neck–sha angle; pelvic axis length; and femoral head, calcar
and medulla width [Koller et al. 2001; Karasik et al. 2009]. Another measure of bone geometry is
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cortical index, the ratio of combined cortical thickness to bone diameter, ofmetacarpal bones, which
can be obtained from x-ray lms [Karasik et al. 2000; Ginsburg et al. 2001].
A nal common measure of bone quality is the main clinical manifestation of osteoporosis:
fracture. Total fractures, wrist fracture and vertebral fractures are oen examined in studies, and
both fracture prevalence and incidence have been considered [Deng et al. 2001; Styrkarsdottir et al.
2008].
Bone quality is a function of bone mineral content and density, macroarchitecture or geometry
such as bone angle and cortical thickness and microarchitecture such as lattice structure in the
trabecular bone and osteon structure in cortical bone. No particular measure captures the picture
of bone quality completely, and methods that incorporate information from multiple assessments
of the bone quality could prove fruitful.
.. Measures of muscle quality
Muscle biopsy is most accurate in assessing sarcopenia and muscle quality, but is not practical for
large research studies. Lower leg lean mass as measured by DXA has been considered a reliable sur-
rogate for muscle quality [Visser et al. 1998a; Broadwin et al. 2001; Visser et al. 2002; Huygens et al.
2004; Karasik et al. 2009]. However, it has also been reported that loss of isokinetic knee extensor
strength was about three times greater than loss of leg leanmass as measured by DXA in individuals
ages 70–79 [Goodpaster et al. 2006], suggesting thatmassmay not be a complete indicator ofmuscle
strength. Other measures of muscle mass and quality include total lean body mass as assessed by
DXA [Goodpaster et al. 2006], thighmuscle cross-sectional area andmuscle attenuation (ameasure
of fat inltration) as assessed by computed tomography (CT) [Goodpaster et al. 2006], percentage
of body mass as assessed by bioelectrical impedance analysis [Broadwin et al. 2001] and specic
torque (strength per unit mass) as measured by dynamometer [Goodpaster et al. 2006].
.. Measures of adiposity
Obesity, or excess body fat, which is not an age-related condition per se, is dened by the body
mass index (BMI), the ratio of weight and squared height in metric units, and so BMI is a common
substitute for adiposity [Thorleifsson et al. 2008]. An individual is categorized as obese when his
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or her BMI ≥ 30 kg/m2. Other measures of adiposity found in the literature include obesity as a
dichotomous trait [Meyre et al. 2009]; waist–hip ratio; waist circumference [Lindgren et al. 2009];
hip circumference [Polašek et al. 2009]; brachial circumference [Polašek et al. 2009]; total body fat
mass as measured by DXA [Hsu et al. 2005]; percentage of fat mass as measured by bioelectric
impedance analysis [Broadwin et al. 2001]; intra-abdominal fat as measured bymagnetic resonance
imaging (MRI); visceral fat area and volume, subcutaneous fat area and volume [Norris et al. 2009],
and muscle attenuation (a measure of fat inltration) as measured by CT [Goodpaster et al. 2006];
and the ratio of visceral to subcutaneous fat area [Norris et al. 2009].
. GENETIC EPIDEMIOLOGYOF BONE QUALITY, MUSCLE QUALITY AND
ADIPOSITY
.. Heritability, Quantitative Trait Loci&Candidate Genes Inuencing Bone Quality Traits
Studies of bone mineral density and content, bone geometry and fracture risk have indicated that
these traits have large genetic components of the phenotypic variance. In general, heritability of areal
BMD ranges from 0.54 to 0.92 across multiple skeletal sites, for men and women and for dierent
ethnic groups [Pocock et al. 1987; Karasik et al. 2004; Wang et al. 2007b]. Similarly, heritability of
volumetric BMD ranges from 0.29 to 0.73 [Wang et al. 2007b], and measures of bone geometry
range between 0.58 and 0.83 [Koller et al. 2001].
Given the moderate to high heritability of areal BMD and bone geometry traits, many linkage
studies using data on sibling pairs and families have been performed and numerous quantitative
trait loci (QTLs) have been detected [e.g., Koller et al. 2000, 2001; Deng et al. 2002; Peacock et al.
2005; Shen et al. 2005; Xiong et al. 2006; Demissie et al. 2007]. Two meta-analyses of genomewide
linkage studies have been conducted [Lee et al. 2006; Ioannidis et al. 2007], and they reported three
putative QTLs on 1p13–q23 [Ioannidis et al. 2007], 9q31–q33 [Ioannidis et al. 2007] and 16pter–
p12.3 [Lee et al. 2006]. There has been little consistency among the QTLs identied by the various
studies, and these studies have not identied a specic gene or polymorphism that inuences bone
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quality with one exception: LRP5 (low density lipoprotein receptor–related protein 5), a gene in the
Wnt-signaling pathway [Johnson et al. 1997; Koay et al. 2004; Ferrari et al. 2004]
Many candidate gene association studies have been conducted on bone quality traits to further
pinpoint specic involved genes andhave producedmixed results.Nonetheless, eects of several can-
didate genes, such as LRP5, ESR1 (estrogen receptor 1) and BMP2 (bone morphogenetic protein 2)
on bone quality phenotypes have been replicated. Recent meta-analyses of genomewide association
studies (GWAS or GWA studies) across multiple populations have both replicated previous candi-
date genes results, such as LRP5 [Richards et al. 2008],ESR1 [Styrkarsdottir et al. 2008],TNFRSF11B
(tumor necrosis factor receptor superfamily, member 11b; osteoprotegerin) [Styrkarsdottir et al.
2008; Richards et al. 2008] and TNFSF11 (tumor necrosis factor ligand superfamily, member 11; re-
ceptor activator of nuclear factor κB ligand; or RANKL) [Styrkarsdottir et al. 2008], and expanded
the list of potential genes, such as ADAMTS18 (a disintegrin-like and metallopeptidase domain–
containing protein 8) and TGFBR3 (transforming growth factor, β receptor III) [Xiong et al. 2009],
involved in these phenotypes. GWAS performed on ve large populations of individuals of Euro-
pean ancestry (total n = 19,195) has revealed a total of 20 loci inuencing lumbar spine BMD and
femoral neck BMD asmeasured by DXA [Rivadeneira et al. 2009]. Of these 20 loci, seven—ZBTB40
(zinc nger and bric à brac–tramtrack–broad-complex domain containing 40), ESR1, TNFRSF11B,
LRP5, SP7 (Sp7 transcription factor; osterix; or OSX), TNFSF11 and TNFRSF11A (tumor necrosis
factor receptor superfamily member 11a; receptor activator of nuclear factor κB; or RANK)—were
previously identied candidate genes [Styrkarsdottir et al. 2008, 2009; Richards et al. 2008]. Thus
the GWA studies have revealed additional molecular pathways that may inuence BMD and subse-
quently, fracture risk.
A more complete accounting of candidate gene results can be found at the Human Genome
Epidemiology (HuGE) Navigator (hugenavigator.net) [Yu et al. 2008] or at the National Center for
Biotechnology Information’s (NCBI)AssociationResults Browser (www.ncbi.nlm.nih.gov/projects/
gapplusprev/sgap_plus.htm). A catalog of genomewide association study results is maintained by
the Oce of Population Genetics at the National Human Genome Research Institute (NHGRI)
at genome.gov/gwastudies. However, neither candidate gene studies nor genomewide association
studies have revealed any genes that account for more than a small fraction of the total phenotypic
variance.
7
.. Heritability,QuantitativeTrait Loci&CandidateGenes InuencingMuscleQualityTraits
Lean muscle mass has substantial genetic contributions; the heritability of lean body mass has been
estimated to range from 0.6 to 0.8 in Australian female twins [Seeman et al. 1996], and from 0.7 to
0.9 in brothers [Huygens et al. 2004]. Another study, of leg lean mass in Afro-Caribbean men and
women revealed a lower heritability of 0.18–0.23 [Prior et al. 2007]. Linkage analyses using twins,
nuclear families and sibling pairs have found multiple quantitative trait loci [Arden and Spector
1997; Hsu et al. 2005; Blain et al. 2006; Livshits et al. 2007]. As yet, the genes underlying variation
in muscle mass traits remain largely unknown. To date just one genomewide association study of
lean mass has been conducted, which produced a promising candidate gene, TRHR (thyrotropin-
releasing hormone receptor), in a European American discovery sample with replication in two
further European American samples and a Hàn Chinese sample [Liu et al. 2009a].
.. Heritability, Quantitative Trait Loci& Candidate Genes Inuencing Adiposity Traits
The heritabilities of adiposity measures, such as BMI and fat mass have been estimated to be quite
high: estimates for BMI range from 0.2 to 0.8 [Maes et al. 1997], and estimates for fat mass range
from 0.63 to 0.71 [Hsu et al. 2005].Myriad genomewide linkage analyses have been performed, such
that, by 2005, 253 quantitative trait loci for fatmeasures have been reportedwith 52 regions observed
in multiple studies. Signicant associations with obesity, BMI, body weight, body composition or
fat distribution have been reported for 127 candidate genes [Rankinen et al. 2006].
Subsequent whole-genome association studies have replicated several of these genes, such as
PPARG (peroxisome proliferator-activated receptor γ) [Fox et al. 2007], ADIPOQ (adiponectin)
[Fox et al. 2007; Ling et al. 2009] andMC4R (melanocortin receptor 4) [Loos et al. 2008; Willer et al.
2008; Thorleifsson et al. 2008; Meyre et al. 2009; Heard-Costa et al. 2009]. One novel gene reported
by genomewide association studies is FTO (Fatso homolog or fat mass and obesity–associated) [Pe-
ters et al. 1999], which has been replicated across een genomewide association studies [Frayling
et al. 2007; Scuteri et al. 2007; Hinney et al. 2007; Loos et al. 2008; Willer et al. 2008; Thorleifsson
et al. 2008; Meyre et al. 2009; Cho et al. 2009; Cotsapas et al. 2009; Heard-Costa et al. 2009; Scherag
et al. 2010; Speliotes et al. 2010; Wan et al. 2010; Dorajoo et al. 2011; Wang et al. 2011].
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. SOURCES OF COVARIATION
Epidemiological studies have shown that there is correlation between bone-, muscle- and fat-related
measures of body composition. As noted above, it has been suggested that obesitymay have a protec-
tive eect against osteoporosis [Beck et al. 2009]. Indeed, BMI is used in theWHOFRAX algorithm
for determining 10-year fracture risk when hip BMD is unavailable. Body weight is considered a
strong predictor of bone mass in both men and women [Glauber et al. 1995]. Studies have shown
that high body fat and high body mass index are associated with greater muscle mass [Visser et al.
1998a,b] as well as increased fat inltration into the muscle [Kelley et al. 1991; Ryan and Nicklas
1999]. Finally, a strong, positive correlation between muscle strength and bone mass is well docu-
mented [Karasik and Kiel 2008].
There is evidence of ethnic dierences in the relationship between fat and muscle traits. A com-
parison of muscle attenuation in African American and European American women revealed that
the African American women had lowermuscle attenuation, indicatingmore fat inltration. A com-
parison in men revealed no such dierence [Visser et al. 2002].
Both muscle mass and body fat percentage are associated with total body BMD in women,
whereas inmen,musclemass but not body fat is positively associatedwith BMD [Visser et al. 1998b].
In another study, fat mass and BMDwere correlated (r = 0.48) in premenopausal women, but again
not in men [Reid et al. 1992].
There are multiple potential mechanisms behind the covariation in bone, muscle and fat traits.
These include coordinated patterns of development, intertwined homeostasis, mechanical eects
and, of particular interest here, genetic eects.
.. Developmental&Homeostatic
The diverse lineages of bone, muscle and fat tissue descend from the same germ layer in embryonic
development and from the same multipotent stromal cells—mesenchymal stem cells—during later
organismal maintenance. The signaling pathways that allocate the stem cells to osteogenesis, myo-
genesis and adipogenesis are complex, and it is dicult to conceive of how variation in an element
of those pathways would not cause covariant eects. For example, bone morphogenetic protein 2
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(BMP2), a member of the transforming growth factor-β super-family, plays a role in the dierenti-
ation of the stem cells. Its presence at high levels promotes osteo- or chrondrogenesis and inhibits
myogenesis; at low levels, it promotes adipogenesis. This control is achieved by regulating the ex-
pression of transcription factors such as MyoD and myogenin (muscle), Runx2 (bone) and PPARγ
(fat) [Devaney et al. 2009].
During adult maintenance, the mesenchymal stem cells are present in multiple tissues, such as
bonemarrow, periosteum, local so tissues, vasculature and in circulation [Barry andMurphy 2004].
It has been hypothesized that osteoblastogenesis need not solely arise fromdierentiation ofmarrow
and periosteal stem cells, but could come from other local tissues [Schindeler et al. 2009]. Not only
does muscle tissue serve as an potential alternative source of precursor cells, it may improve prog-
nosis in recovery from fracture injuries. In rats, fracture repair is delayed where there is no muscle
apposite the fracture site [Utvåg et al. 2002]. Additional evidence of the presence of osteoprogeni-
tors in muscle tissue comes from examination of heterotrophic ossication—the formation of bone
within muscle tissue—an aspect of brodysplasia ossicans progressiva. This disorder arises from
mutation in ACVR1, a bone morphogenetic protein receptor, that leads to dysregulation of BMP
signaling, such that so tissue injury results in tissue ossication [Shore et al. 2006; Billings et al.
2007].
In addition to the protective eect of obesity on osteoporosis even in non–weight-bearing bones,
evidence of the non-mechanical relationships between bone and fat comes from a study that showed
that osteocalcin, an osteoblast-specic protein, can stimulate adiponectin production in adipocytes,
which is associated with increased insulin sensitivity [Lee et al. 2007]. Conversely, there is evidence
that leptin, produced by fat cells, inuences bone growth, size and remodeling [Thomas and Bur-
guera 2002].
.. Mechanical
Another potential source of trait covariation is mechanical. The mechanostat theory proposes that
bone strength adapts primarily in response to muscle load on the bones [Frost 2003]. As muscles
grow stronger, they generate more strain, to which the bones respond by growing stronger, above
and beyond the usual remodeling. Conversely, in activities such as space ight, when mechanical
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strains are minimize, there is profound bone degeneration [Graebe et al. 2004]. It is estimated that
40% of bone strength is due to mechanical use [Frost and Schönau 2000]. So while much of the cor-
relation is likely mechanical, or environmental, the physiological response to these environmental
stressors must be regulated by a biological mechanism in bone that could be subject to variation by
genetic factors [Karasik and Kiel 2008].
Obesity-induced mechanical loading seems to be a contributing factor in the positive relation-
ship between fat mass and BMD. Indeed, at weight-bearing sites, most of the eect seems to be due
to mechanical loading. At non–weight-bearing sites, adiposity is more important, possibly due to
metabolic factors [Glauber et al. 1995]. However, the strength of this eect may dier between men
and women, and some studies have observed the association in women but not men [Thomas and
Burguera 2002].
.. Genetic
Evidence of a genetic source to muscle, bone and fat covariation abounds, although it is not always
consistent [Nguyen et al. 1998]. Substantial genetic correlations have been reported between lean
bodymass andBMDandbone geometry, with correlations ranging from0.28 to 0.72 [Sun et al. 2006;
Videman et al. 2007]. Genetic correlations between leg leanmass and hip geometry in another study
ranged from 0.087 to 0.454 [Karasik et al. 2009]. Potential QTLs inuencing pairs of traits have also
been identied by bivariate linkage analysis. Analyses have identied loci linked to both leg lean
mass and bone geometry [Karasik et al. 2009], lean body mass and BMD [Wang et al. 2007d], body
fat mass and BMD (with loci specic to women and to men identied) [Tang et al. 2007], and body
fat mass and body leanmass (again withmale- and female-specic loci suggested) [Zhao et al. 2008].
There is evidence that variation in at least one gene specically,BMP2, is pleiotropic. Variation in a 3′
post-transcriptional regulatory motif of BMP2 has been associated with eects on subcutaneous fat
volume and lean mass in directions consistent with its hypothesized eects on mesenchymal stem
cell dierentiation [Devaney et al. 2009]. Also, given the allometric demands of the mechanical
system, which must maintain the relationship between the size and growth of a component to the
size and growth of the organism, it is expected that gross muscle and bone morphology has evolved
to covary to keep the system functioning [Churchill 1996].
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. STUDY APPROACH ANDMETHODOLOGY
The overall goal of this project was to assess whether variation in bone, leanmass and fat mass traits
are inuenced by variation in a similar set of genes and/or environmental factors. To achieve this
overall goal, I rst determined the phenotypic relationships among these trait categories and derive
multivariate endophenotypes within and between categories in a population of African ancestry
(the Tobago Bone Health Study). Second, I determined the heritability of these traits and endophe-
notypes using data on families with African ancestry (the Tobago Family Health Study). Third, I
used linkage analyses to determine whether QTLs inuence one or more traits among these cate-
gories within these families. Finally, I performedGWA studies on two bone traits (lumbar spine and
femoral neck BMD) and twomeasures of fractures in a group of European- and African-ancestry in-
dividuals for whom data on BMD, fractures and > 2.6 million genotypes are available. These results
were compared and contrasted with each other. Because I was also interested in whether possible
genetic and environmental covariation among the trait categories diers between men and women,
the GWAS analyses were also performed in men and women separately. A brief discussion of the
study populations, the traits, genetic markers and the statistical and genetic methods that were used
to address these specic goals are described below.
.. Study populations
I used data from three study populations: the Tobago Bone Health Study; the Tobago Family Health
Study; and theDynamics of Health, Aging and Body Composition Study. These populations were se-
lected for several reasons: (1) phenotypic and genotypic datawere already available; (2) relationships
among phenotypes and genotypes could be assessed using a variety of family- and population-based
approaches; and (3) potential similarities and dierences between ethnic groups could be assessed.
A brief summary of the available populations and the genetic data available for them can be
found in Table 1.1.
The Tobago Bone Health Study (TBHS) arose from the collection of DXA and pQCT scans of
individuals recruited for the Tobago Prostate Cancer Survey, a longitudinal study of prostate cancer
prevalence in Tobagonian men aged 40 years or older. Tobago is one of the two main islands that
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Table 1.1: Study Populations
n
Study Relationships Nationality Ancestry Women Men Genotypes
Tobago Bone Health
Tobago Family Health
Dynamics of Health, Aging
& Body Composition
unrelated
7 pedigrees
unrelated
unrelated
Tobago
Tobago
U.S.A.
U.S.A.
African
African
African
European
—
284
651
784
1,937
186
488
879
sporadic
6,000 (linkage panel)
2.6 million
3.0 million
make up the Republic of Trinidad and Tobago o the coast of Venezuela in the southern Caribbean.
The ancestry of the Tobago population has been estimated to be approximately 94% African, 5%
European and 1% Native American [Miljkovic-Gacic et al. 2005]. For this study I examined the
data from 1,937 unrelated men of African descent—individuals who report four grandparents of
African ancestry.
The unrelatedmen fromTBHS served as potential probands for the Tobago FamilyHealth Study
(TFS). Individuals with the largest families were recruited rst. In all, seven families of African
descent were collected for a total of 470 individuals—284 women and 186 men. Family sizes are
153, 97, 96, 49, 28, 26 and 21 (mean family size = 67.14). Generations per family ranged from four
to seven. Reported relationships include 365 parent–ospring, 473 full siblings, 104 grandparent–
grandchild, 1,099 avuncular, 89 half-siblings and 1,364 cousins. Pedigrees can be found inAppendix
B.
The Dynamics of Health, Aging and Body Composition Study (HealthABC) is a longitudinal
study of African American and European American men and women. Data are available for 2,802
individuals—1,139 African Americans and 1,663 EuropeanAmericans—between the ages of 68 and
80. The individuals were drawn equally from two sites: Pittsburgh, Pennsylvania, and Memphis,
Tennessee.
.. Traits
... Bone, muscle and fat traits I examined twenty-two phenotypes in this study (Table 1.2).
These phenotypes are available for the Tobago Men and the Tobago Families. I analyzed lumbar
spine and femoral neck BMD in the HealthABC participants. A few traits related to body composi-
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tion, such as body mass index, standing height and total fat mass, were not included in the current
analyses because (1) they were highly collinear with another trait, (2) they were a linear modica-
tion of one of the traits of interest or (3) they were a trait of which another trait was a component.
For example, periosteal circumference and total area are simple linear transformations of each other,
so only the circumference was included. On the other hand, tibia length is a component of standing
height; therefore the component trait, tibia length, was retained.
Table 1.2: Endophenotypes Examined in This Study
Arm Leg
Radius length (mm)
Lean mass (g)
Fat mass (g)
at 4% radius
Total area (mm2)
Trabecular BMD (mg/cm3)
at 33% radius
Cortical area (mm2)
Cortical BMD (mg/cm3)
Cortical thickness (mm)
Periosteal circumference (mm)
Endosteal circumference (mm)
Tibia length (mm)
Lean mass (g)
Fat mass (g)
at 4% tibia
Total area (mm2)
Trabecular BMD (mg/cm3)
at 33% tibia
Cortical area (mm2)
Cortical BMD (mg/cm3)
Cortical thickness (mm)
Periosteal circumference (mm)
Endosteal circumference (mm)
at 66% tibia
Total BMD (mg/cm3)
Cortical BMD (mg/cm3)
For the Tobago participants, the length of the tibia is measured from the medial malleolus to
the medial condyle of the tibia, and forearm length was measured from the olecranon to the styloid
process of the ulna. Arm and leg lean and fat mass were measured by whole body DXA using a
QDR 4500W densitometer (Hologic, Bedford, MA, USA). Scans were analyzed with the soware
QDR 8.26a. The remaining sixteen traits were determined by pQCT. Single axial tomographic slices
of the distal epiphyseal and diaphyseal radius and tibia were scanned using an XCT 2000 densito-
meter (StraTecMedizintechnik, Pforzheim, Germany) according to standardizedmeasurement and
analysis procedures. Measurements were taken at 4% and 33% of the length of the bone proximal
to the distal endplate to assess trabecular and cortical bone respectively. Additional measurements
were also taken at 66% of the tibia. Image processing was performed using StraTec soware ver-
sion 5.5E. All 4% scans were analyzed using identical parameters for contour-nding trabecular
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bone compartments. All 33% scans were analyzed using identical parameters to determine the vol-
umetric BMD of cortical bone compartments.
For HealthABC participants, areal bone mineral density was measured using DXA at the proxi-
mal femur and thewhole body.Measurementswere takenusing aQDR4500A (soware version 9.03;
Hologic, Bedford,MA,USA). Femoral neckBMD(FNBMD)was derived from the femoral neck sub-
region of the proximal femur scan, and lumbar spine BMD (LSBMD) was derived from the lumbar
spine subregion of the whole body scan. Quality assurance procedures were employed at both study
sites to ensure scanner reliability and identical scan protocols. To assess longitudinal performance
of the scanners, an anthropometric spine phantom was scanned daily, and a hip phantom, weekly
[Cauley et al. 2007].
... Covariates Demographic characteristics, medical history and lifestyle habits were ascer-
tained by questionnaire at the clinical sites. Subjects were classied as current smokers (yes/no); in-
dividuals who had smoked < 100 cigarettes over their lifetime were classied as nonsmokers. Data
on alcohol consumption was also obtained by questionnaire (drinks/week). Subjects were asked
whether a doctor or other healthcare provider had ever informed them that they had arthritis, di-
abetes, hypertension or cardiovascular disease. Hypertension was dened as a diastolic blood pres-
sure exceeding 90 mmHg, systolic blood pressure exceeding 140 mmHg or currently taking blood
pressure medication. Diabetes was dened as fasting glucose level > 126 mg/dl or currently taking
diabetes medication.
I initially considered age, age squared, sex, age × sex, age squared × sex, current smoking status,
current alcohol use, parity, menopause status, vitamin D use, diabetes and arthritis as covariates
for the heritability models of the phenotypes from the Tobago Bone Health Study and Tobago Fam-
ily Study. Covariates were evaluated using variance-components models that take into account the
nonindependence of family members. Aer considering the eect size of each potential covariate
in those models, age, age squared and sex were retained to be tested in all models, and menopause
status was included in the models of cortical BMD. Age, age squared and sex were screened for
inclusion in the model using a retention threshold of α = 0.1.
For the analyses of BMD in the HealthABC participants, age, age squared, weight, clinical site
and ancestry principal components (PCs) were used as covariates consistent with models employed
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by the other studies participating a meta-analysis of FNBMD and LSBMD. For the analyses of frac-
tures in the HealthABC populations, age, age squared, weight, standing height, clinical site and
ancestry PCs were included as covariates. Sex was also included as a covariate when fractures in
men and women were analyzed together.
.. Genetic Markers
... Linkage markers A single-nucleotide polymorphism (SNP) linkage panel of 6,090 SNPs
[Innium HumanLinkage-12 Assay (Illumina)] was genotyped on the TFS participants. This panel
covers 93.2% of the genome, and the assays were performed by the University of Pittsburgh Core
Genetics Laboratory.We performed quality control measures and excluded SNPs (1) with a call rate< 90%, (2) not in Hardy–Weinberg equilibrium (p < 0.001) and (3) with a minor allele frequency< 0.05. The Markov chain Monte Carlo algorithm as implemented in LOKI [Heath 1997] was em-
ployed to calculate the multipoint identity-by-descent (MIBD) estimates, and these MIBDs were
used in multipoint linkage analyses (described below). LOKI is unable to process SNP at interval
of less than one centimorgan so a subset of 1,516 of these markers at intervals > 1 cM were used to
calculate multipoint identity-by-descent (MIBD).
All of the markers that passed the initial quality control procedures were used to verify relation-
ships among the TFS members. Cotterman’s k’s, which reect allele-sharing between individuals,
were calculated for every pair of participants using RELPAIR [Boehnke and Cox 1997; Epstein et al.
2000] and compared to the hypothetical allele-sharing for the relationships as reported. Putative er-
roneous relationships were examined and corrected, and relationships that could not be conclusively
categorized were removed.
... Association markers For all subjects in HealthABC, genotyping of genetic markers was
performed by theCenter for InheritedDisease Research (CIDR) using the IlluminaHuman1M-Duo
BeadChip system. Samples were removed from the data if the sample failed overall (< 97% SNPs
genotyped), if the chromosome sex did not match the reported sex or if rst-degree relatedness was
detected using the SNP data. SNPs were removed if the SNP had a minor allele frequency (MAF)< 1%, was called with < 97% success, or had a Hardy–Weinberg equilibrium (HWE) test p value <
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10−6. A total of 1,151,215 autosomal SNPswere successfully genotyped in 1,663 EuropeanAmerican
individuals and were carried forward to imputation.
Imputation was performed using MACH 1.0.16 [Li et al. 2010b] and the HapMap II phased
haplotypes [Frazer et al. 2007] as the reference. Genotypes were available for 914,263 SNPs based
on the HapMap CEPH (Centre d’Étude du Polymorphisme Humain) reference panel (rel. 22, b36).
A total of 2,543,887 genotyped and imputed autosomal SNPswere ultimately available for analysis as
part of the “HapMap SNP” set. A total of 40,949 chromosomeXSNPswere successfully genotyped in
all European Americans subjects. An additional 40,818 SNPs were imputed using a method similar
to that used for the autosomes for a total of 81,767 X chromosome SNPs. The chromosome X SNPs
were included in the HapMap SNP set for a total of 2,625,654 SNPs. The HapMap imputation was
performed by Yongmei Liu and Kurt Lohman of Wake Forest University.
A second set of genotyped and imputed SNPs was prepared from the 1.2 million successfully
genotyped SNPs and 1,663 subjects using the 1000 Genomes reference haplotypes (June 2010 re-
lease) [Abecasis et al. 2010]. A total of 6,858,264 genotyped and imputed autosomal SNPs were
available as part of the “1000 Genomes SNP” set. The 1000 Genomes imputation was performed by
Michael Nalls at the National Institutes of Health.
.. Statistical Methods
... Phenotype analyses – Specic Aim  Overall questions: What are the phenotypic relation-
ships amongmeasures of bonemineral density and geometry, leanmass and fatmass atmultiple skeletal
sites? Do these relationships vary by age?
There are several ways to assess phenotypic relationships among a set of measures. I employed
two in my project: hierarchical clustering and principal components analysis. These methods of elu-
cidating phenotype relationships should be performed on samples of unrelated individuals as the
strong correlations between family members can introduce excessive covariance that not represen-
tative of the population from which the sample is drawn.
Cluster analysis [Tryon 1939] is a method for grouping data into meaningful ‘clusters’ based
upon the structure of the data. The particular type of clustering that I employed to examine struc-
ture in the body composition phenotypes is agglomerative hierarchical clustering. Hierarchical clus-
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tering organizes the data into a tree structure, or dendrogram, based on similarities between the
observations, such that more similar observations are closer together in the dendrogram. The Eu-
clidean distance metric was the pairwise Pearson product-moment correlation coecient between
each pair of traits. The complete linkage (or furthest neighbor) method was used to determine the
proximity of the clusters, where the distance d between two elements x and y in clusters A and
B is max{d(x , y) ∶ x ∈ A, y ∈ B} [Sørensen 1948; Everitt et al. 2001]. Unsupervised clustering
algorithms such as this have the advantage of using the information in the data itself to determine
the clusters, rather than potentially biased group assignment by a human [Tan et al. 2005]. How-
ever, while this method can elucidate data structure, it does not provide interpretation [Hill and
Lewicki 2007]. Complete linkage clustering is useful if the data reects groups that cluster together
in non-elongated clusterings, but is inappropriate if the clusterings are elongated [Hill and Lewicki
2007]. This clustering was accomplished using hclust() as implemented in R. The resulting dendro-
grams were plotted adjacent to heatmaps of the matrix of the pairwise correlations using heatmap().
Dendrograms and heatmaps were created and compared for phenotypes from TBHS.
Principal components analysis is a method for orthogonalizing or decorrelating collinear data
to elucidate underlying structure among the data. The data’s dimensions are recast along new axes
using linear combinations such that each of the new dimensions, or principal components, maxi-
mally explains a dimension of the variance and is orthogonal to all the other dimensions. The prin-
cipal components are subsequently ordered by decreasing variance. Those new dimensions with
the smallest variances can be excluded, thereby allowing the retention of information from all traits
while reducing the number of dimensions. Principal components analysis was performed in R using
prcomp(), which generates the component loadings and enumerates the component variances. All
traits were scaled and centered prior to this analysis. The principal components themselves were
generated using predict(). Those rst n principal components that explain at least 80% of the vari-
ance were retained for further analysis. Principal components were generated for the traits from
TBHS. The principal components for TFS, used in heritability and linkage analyses, were generated
using the TFS phenotypes and the TBHS loadings.
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... Heritability – Specic Aim  Overall questions: What are the genetic relationships among
measures of bone mineral density and geometry, lean mass and fat mass? Are they heritable? Is there
evidence of pleiotropy?
Genetic relationships among the traits were explored using two standardmethods of calculating
the portions of the variance of the traits and covariance between the traits that is genetic: heritability
and genetic correlation, respectively.
Heritability (h2) is the fraction of the phenotypic variance that is genetic (h2 = σ2G/σ2P). The resid-
ual heritability (h2r ) is the portion of the phenotypic variance, less the variance attributable to known
environmental factors (σ2E) such as age and sex, that is genetic [h2r = σ2G/(σ2P − σ2E)]. The heritability
and residual heritability were estimated by partitioning the phenotypic variance (σ2P) into three com-
ponents: that attributable to additive genetic factors (σ2G), that attributable to known environmental
factors (σ2E) and that attributable to unknown genetic and environmental factors. The additive ge-
netic variance is estimated using the kinships of the individuals in the pedigrees and the variance
between them. The statistical signicance of the covariates and heritabilities is calculated using the
likelihood ratio test, comparing models with and without the parameter in question. A threshold of
α = 0.1 was used to determine which covariates to retain in the model. The heritability analysis was
accomplished using SOLAR 4.2.0 [Almasy and Blangero 1998a]. Potential covariates were assessed
based on previous evidence of their involvement [Wang et al. 2007c]. Age, age squared, sex, sex ×
age, sex × age squared, smoking status, alcohol consumption, pregnancy status, menopause status,
vitamin D supplement use, diabetes status and arthritis status were considered initially as known
environmental factors in the analysis. The variance due to known environmental factors was com-
pared in models with and without covariates which may be subject to pleiotropy with the study
phenotypes; this allowed assessment of their impact on the model. Heritabilities were calculated
using the traits and pedigrees from TFS.
High heritabilities in each of two traits and a high degree of phenotypic correlation do not nec-
essarily mean that a high degree of genetic correlation is also present [Chen et al. 2009]. However,
genetic correlation can be derived from a decomposition of the phenotypic correlation (ρP) into
genetic (ρG) and environmental (ρE) components. The relationship between ρP, ρG and ρE is given
by
ρP = ρG√h2r1√h2r2 + ρE√1 − h2r1√1 − h2r2 .
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This genetic correlation could be due a gene or set of genes aecting both traits, i.e. pleiotropy; sim-
ilarly the environmental correlation reects how two phenotypes are co-aected by the same (un-
measured) environmental factors. As with heritability, the genetic correlations are estimated using
the kinships of the individuals and the variance–covariances between them.
Heritabilities and genetic correlations have been traditionally been estimated using family data
because the relationships between the individuals of whom the observations are taken are known.
However, some recent studies have indicated that given the recent plethora of marker information
available on individuals in a population, examination of the shared markers can illuminate distant
relationships among them and so allow calculation of these statistics in “unrelated” individuals or
even facilitating the construction of pedigrees [Lee et al. 2008; Purcell et al. 2009; Riester et al. 2009].
... Genomewide linkage analyses – SpecicAim Overall questions: Do specic quantitative
trait loci inuence individual or joint measures of bone mineral density and geometry, lean mass and
fat mass in individuals with African ancestry?
To explore whether specic genes inuenced my phenotypes individually, jointly or both, I con-
duced genomewide linkage analyses (GWLS). Linkage analysis has been a powerful tool in genetics
for many years and is carried out with family data because of the necessity of following transmis-
sion of common markers between family members with similar traits. Linkage analysis’ strengths
lie in the use of familial relationships and the linkages of transmitted markers with traits. It does
not rely on the identity of a specic allele for detection of a linked locus. It is robust to population
substructure because the relationships between the individuals are known and indeed are part of the
model. However, it does require the collection of large families, and only regions that are strongly
linked to the quantitative trait can be detected, that is, the presumed QTL must have a relatively
large eect. When such a region is detected, the genomic region under the linkage peak can con-
tain hundreds of genes. One way to identify potential QTLs is to perform association analyses of
genes under the linkage peaks. GWA analyses can also be used as an agnostic approach to identify
common polymorphisms that inuence traits.
Multipoint linkage analysis, like heritability analysis, uses variance components methods, ex-
tending them to include the eect of presumed quantitative trait loci (σ2QTL) as a component of the
genetic variance (σ2G).Multipoint identity-by-descent probabilities are estimated for all relative pairs
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at every marker using a Markov chain Monte Carlo method [Heath 1997]. The QTL eect is esti-
mated using maximum likelihoodmethods based on the expected covariance of relative pairs given
their identity by descent at an arbitrary chromosomal location in tight linkage with the presumed
QTL. The likelihood ratio test is used to assess the linkage model compared to the simpler poly-
genic model with no variance due to that QTL. The ndings are reported as logarithm of the odds
(LOD) scores (i.e., the log10 of the likelihood ratio). Inated LOD scores are adjusted for potential
phenotype distribution eects by comparing the scores against an empirical distribution generated
for 10,000 simulated, unlinked markers [Blangero et al. 2000]. I took LOD = 2.5 as suggestive evi-
dence of linkage based on linkage analysis of a simulated phenotype. The simulated phenotype was
constructed by summing the allele dosage of seven adjacent SNPs on chromosome 3. The resulting
QTL had a peak LOD score of 129.2; the peak LOD score outside this region was 1.67.
... Genomewide association analyses – Specic Aim  Overall questions: Do specic SNPs
(or genes) inuence two measures of BMD: lumbar spine and femoral neck BMD in populations with
European and African ancestry?
The promise of GWA studies was rst proposed by Risch and Merikangas in 1996. A GWAS
is a study that tests for association at hundreds of thousands to millions of variant sites across the
genome without an a priori hypothesis about which genes or other genetic elements may be associ-
ated with the trait of interest. The causal sequence variation is not assumed to be in the marker set,
but the method requires a set of markers suciently dense to capture associations with functional
sites not directly tested, via linkage disequilibrium. Unlike linkage analysis, GWAS generally makes
use of data from unrelated individals, thus it is usually easier to collect large samples for association
analysis compared to the large pedigrees required for linkage analysis. Furthermore, compared to
GWLS, GWAS can detect small eect sizes and can highlight much smaller regions. However, they
are susceptible to false positives due to population stratication and false negatives due to allelic
heterogeneity. They also require dense coverage. For this reason, and also to compare results from
studies assayed using dierent genotyping platforms, additional SNPs are oen imputed [Scheet and
Stephens 2006; Burdick et al. 2006; Li et al. 2010b] using reference haplotypes derived from the In-
ternational HapMap Project [Altshuler et al. 2005; Frazer et al. 2007] or the 1000 Genomes Project
[Abecasis et al. 2010].
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Because increased SNP density is required to cover the genome, the number of SNPs necessar-
ily increases, and so does the number of statistical tests, with a concomitant increase in the number
of false positive results. The number of traits examined can further inate this false positive rate.
For example, I tested ∼2.6 million SNPs against two individual traits for a total of ∼5 million tests.
This should theoretically produce 250,000 statistically signicant false positive signals at α = 0.05,
the traditional threshold for unlikeliness. Methods such as the Bonferroni (αp = αe/n) or Šidák
[αp = 1 − (1 − αe)1/n] correction can be employed, but are thought to be too conservative given
that each SNP test is not completely independent of its neighbors. Such corrections also reduce the
power of the study, making true positives more dicult to detect. Permutation tests can simulate
the null distribution and so provide empirical likelihoods [Churchill and Doerge 1994], but are
computationally expensive. Another problem with genomewide SNP screens is not theoretical, but
empirical. The most signicantly associated SNPs just seem to have a small eect size. For example,
the two strongest associations reported by Xiong et al. [2009] in a genomewide association study
of hip and spine BMD account for just 1% of the phenotypic variance. To compensate for this, ex-
tremely large samples are required to detect these small eects, and thus, results of my analyses were
also contributed to a large consortium, comprising a total of 34,191 individuals with femoral neck
and lumbar spine data (the Genetic Factors for Osteoporosis, or GEFOS, Consortium). These con-
sortium results have not yet been published, Therefore, I present results from the HealthABC study,
both as an test of previously known candidate genes, and as GWA results, but fully recognize that
my sample size is inadequate to detect small eect sizes. In general, GWLS and GWASmethods can
be considered as complementary, rather than competitive, as each is capable of detecting a dierent
suite of associated variants and loci.
I performed single SNP–single trait GWAanalysis on lumber spine and femoral neck BMD from
a cohort of unrelated individuals with European ancestry using linear regression of quantitative
traits on genotyped markers to pinpoint associations between them. I used an additive model, y =
µ + βx + ε, wherein y is the quantitative trait of interest, x is the genotype scored as the number
of eect alleles, µ is the expected value of the phenotype, ε is the error and β is the additive eect
of an allele on the phenotype. For the analysis of the X chromosome in male subjects, the eect
allele was coded as 2 if present. All analyses were performed using the statistical soware ProbABEL
[Aulchenko et al. 2010], which is designed to process imputed genotype probabilities and allele
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dosages that are not conned to integer values. Data were available on ∼2.6 million assayed and
imputed genotypes for individuals of European descent and ∼3 million for individuals of African
descent.
... Genomewide association analyses – Specic Aim  Overall questions: Can the identied
genes be replicated in another population of similar ancestry? Can they be replicated in a population of
dierent ancestry? Are they similar in men and women? Do any of these loci overlap the linkage signals
obtained from the family study?
Replication is a mainstay of scientic investigation, and is particularly important in my analy-
ses because of the number of tests involved. Replication of results in a comparable population is
necessary to begin the process of weeding out those spurious results. The results of genomewide
association analyses must be followed up with examination of the positive results in comparable
populations. There are two appropriate approaches to replication: exact replication and ne map-
ping [Clarke et al. 2007]. Exact replication involves examining the selfsame SNP and phenotype in
a sample drawn from a similar population. However, such precise replication is oen not accom-
plished, and replication is reported when a neighboring SNP and a related phenotype are found to
be associated. Such studies do not mean to intentionally obfuscate the eld, but are oen the result
of limits of available data sets that may not include the identical SNP and phenotype originally re-
ported. The second approach is ne mapping: the examination of other local variation in addition
to the initially identied SNP. Such additional examined variation is considered justied because
the SNPs chosen for genomewide studies are usually selected for genome coverage. Therefore there
may be other variants nearby that could have greater correlation with the phenotype or indeed even
be a functional causal inuence on the phenotype. In general the exact replication study is more
balanced in power, eciency and cost. Fine mapping may be indicated when the initial nding is
weak and the surrounding region has high linkage disequilibrium. However, the identication of an
association with a SNP other than the original can be dicult to interpret [Clarke et al. 2007]. Since
sequence data from the 1000Genomes Project became available [Abecasis et al. 2010], some of these
concerns have been mitigated. Many researchers impute additional SNPs in the region where the
signicant GWA result is observed [Scheet and Stephens 2006; Burdick et al. 2006; Li et al. 2010b]
and combine results across multiple studies. Analyses of these additional data may facilitate identi-
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cation of potentially functional SNPs that inuence the trait. However, statistical identication of
a potential functional SNP would need to be replicated in another population, and the mechanism
would need to be determined using molecular or cell biology methods.
In addition to assessing possible replication of results between the GWLS preformed in the TFS
and the GWAS of the African Americans and European Americans in HealthABC, I also compared
my results with external data resources such as the HuGE Navigator and NHGRI catalog of pub-
lished genomewide association studies.
. SPECIFIC AIMS
1 Examine the phenotypic variation and covariation in bone, muscle and fat traits. (Chapter 2)
(a) Select bone,muscle and fat phenotypes in theTobagoBoneHealth Study and theTobago Family
Health Study based on completeness of data, literature studies and correlation with other traits.
(b) Construct composite phenotypes by hierarchical cluster analysis and principal component anal-
ysis using data on the Tobago Bone Health Study. Use these techniques to assess the relation-
ships between the various traits. Do the traits fall into a few large groups or many small ones?
Do the clusters make sense biologically? Are the relationships revealed by the cluster analy-
sis consistent with those revealed by the principal components? Do the composite traits make
sense biologically?
2 Determine the eects of covariates and genetic factors on the individual and composite traits using
data from the Tobago Family Health Study. (Chapters 2 and 3)
(a) Determine the heritability of composite traits versus individual traits.
(b) Locate QTLs for the individual and composite phenotypes to genetic regions using linkage
analysis methods on data from the Tobago Family Health Study. Is there any overlap of QTLs
between the composite traits and the individual traits that make them up, or among any of the
traits?
(c) Determine the genetic correlation among the individual traits.
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3 Identify loci (SNPs) associated with variation in two bone traits (lumber spine and femoral neck
BMD) in European Americans using data from the Dynamics of Health, Aging and Body Com-
position Study by performing (1) agnostic GWA and (2) replication of previously identied loci.
(Chapter 4)
(a) Test for associations with 2.5 million genotypes (both assayed and imputed) for the autosomes
and X chromosome in European Americans.
(b) Fine map suggestive and signicant loci (SNPs) using data imputed from the 1000 Genomes
Project.
(c) Test whether suggestive or signicant SNPs aect an important clinicalmeasure of osteoporosis:
fracture risk.
(d) Test whether 20 SNPs (or loci) identied in a previous consortium also inuence femoral neck
or lumbar spine BMD or fracture risk in HealthABC participants.
4 Determine whether loci inuencing lumbar spine and femoral neck BMD in African Americans
identied by association analyses are (1) the same as those in European Americans and (2) overlap
with QTL regions for bone traits identied in the Tobago Family Health Study. (Chapter 5)
(a) Test for associations with 3-million SNP genotypes (both assayed and imputed) for the auto-
somes in African Americans and determine whether there is any overlap with the European
American results or the linkage results from the Tobago Family Study.
(b) Test whether 20 SNPs (or loci) identied in a previous consortium study also inuence femoral
neck or lumbar spine BMD in HealthABC participants.
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. PHENOTYPE CHARACTERIZATION IN AFRO-CARIBBEANMEN
. INTRODUCTION
Common geriatric disorders of body composition such as osteoporosis, sarcopenia and age-related
fat redistribution aict millions of people worldwide. Understanding their etiology and interrelat-
edness could aid in developing interventions that could delay their onset or mitigate their impact.
However, such disorders have complex origins and interact in complicated ways that hinder the
ability to capture them with a simple, easily interpretable outcome measure.
Osteoporosis, for instance is oen characterized by bone mineral density (BMD). This single
trait provides a slice of information, but does not adequately capture the macro- and microarchi-
tecture of the bones nor the variation in BMD at dierent sites in the skeleton. Characterizing the
interrelatedness of a variety of body composition traits and the development of composite endophe-
notypes could improve our ability to determine risk factors or biomarkers, including genetic mark-
ers.
The aim in this chapter is to examine the phenotypic relationships between twenty-two bone-,
muscle- and fat-related traits and to construct composite endophenotypes from them in the Tobago
Bone Health Study (TBHS) and Tobago Family Health Study (TFS). Additionally, the heritabilities
of the individual and composite traits will be determined for the TFS participants.
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. METHODS
.. Study Populations
Populations from two studies were examined in this chapter: the Tobago BoneHealth Study (TBHS)
and the Tobago Family Health Study (TFS).
TBHS is a follow-up study of the Tobago Prostate Cancer Survey, a collection of approximately
3,170 men over the age of 40 who participated in a population-based prostate cancer screening
study on the island of Tobago, Trinidad and Tobago [Bunker et al. 2002]. Approximate 60% of study-
eligible men representative of the island’s parishes participated in the Cancer Survey between 1998
and 2003. For TBHS, body composition was assessed at a follow-up examination (2004–2007) us-
ing peripheral quantitative computed tomography (pQCT) and dual-energy x-ray absorptiometry
(DXA). TBHS included 2,031 of the men from the Cancer Survey as well as 451 new participants. In
general, this this population has low (∼6%) non-African admixture [Miljkovic-Gacic et al. 2005]. For
the current study, I examined 1,937 unrelated men of African descent—individuals who reported
four grandparents of African ancestry.
TFS is a study of genetic and environmental factors inuencing a variety of phenotypes, includ-
ing body composition, lipid proles, etc., also conducted on Tobago. Probands for TFS were chosen
from the Tobago Prostate Cancer Survey [Bunker et al. 2002]. Families of probands with the largest
self-reported sibships were recruited rst and all family members were recruited without regard to
any disease or trait. Data are available on a total of 470 individuals comprising 284 women and 186
men in seven large multigenerational families of African descent of sizes: 153, 97, 96, 49, 28, 26 and
21 (mean family size = 67.14). Genotypes from a 6,000-SNP linkage panel, described below, were
used to verify reported familial relationships, and aer cleaning a total of 4,206 relative pairs were
available for analysis, including 365 parent–ospring, 473 full siblings, 104 grandparent–grandchild,
1,099 avuncular, 89 half-siblings and 1,364 cousins and 712 more distant relationships.
Both studies were approved by the Institutional Review Boards of the University of Pittsburgh
and the Tobago Division of Health and Social Sciences and all participants gave written, informed
consent.
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.. Phenotypes
Twenty-two bone-,muscle- and fat-related phenotypes were analyzed . As previously described (Sec-
tion 1.5.2.1) the traits weremeasured bywhole body dual-energy x-ray absorptiometry (DXA) using
a QDR 4500W densitometer (Hologic) or peripheral quantitative computed tomography (pQCT)
using an XCT 2000 densitometer (StratecMedizintechnik). Briey, themuscle- and fat-related traits
were measured by DXA and comprised means of the right and le measures of both arm and leg
lean mass and fat mass. Two bone-related traits were also obtained using DXA: tibia length and ra-
dius length. DXA scans were analyzed using the soware QDR 8.26a. Radius length was measured
from the olecranon to the styloid process of the ulna. Tibia length was measured from the medial
malleolus to the medial condyle of the tibia. The other sixteen bone-related traits were measured
by pQCT. Scans were taken at the various sites to assess the dierent bones types present at each
location—primarily trabecular bone at the epiphyseal site and primarily cortical bone at the dia-
physeal site. Single axial tomographic slices of the distal epiphyseal (4% of length) and diaphyseal
(33% or 66% of length) radius and tibia were scanned according to standardized measurement and
analysis procedures. Image processing was performed using Stratec soware version 5.5E. The six-
teen pQCT bone-related traits included in the current analyses are: total bone area and trabecular
BMD at 4% of the radius and of the tibia; cortical area, cortical BMD, cortical thickness, periosteal
circumference and endosteal circumference at 33% of the radius and of the tibia; and total BMD
and cortical BMD at 66% of the tibia. All of these traits were available in both the TFS population
and the TBHS population, and measured in the same manner. I did not include traits, such as body
mass index or standing height, that were highly collinear with the chosen traits.
.. Statistical Analyses
Initial statistical analyses were performed in R 2.11.1 [R Development Core Team 2008]. All mea-
sures underwent a series of quality control procedures. I rst assessedwhethermeasurements varied
across time.Measurements that exhibited correlation with the clinic date were adjusted using locally
weighted polynomial regression (LOESS) with the best t determined by minimizing Akaike’s infor-
mation criterion. Traits adjusted for clinic date in TBHS are tibia length, tibial total area, tibial corti-
cal area, tibial cortical thickness, tibial total density and 66%-tibial cortical density; and in TFS, tibia
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length, tibia total density and 66%-tibial cortical density. Trait distributions were subsequently in-
spected for non-normality, and the relative value of potential transformations were assessed using
Shapiro–Wilk tests. Transformations that substantially reduced non-normality were applied. The
same transformation per trait was applied in both the TBHS and TFS data sets. Arm fat mass and
radial and tibial periosteal circumference were transformed by natural logarithms, whereas leg fat
mass and radial and tibial endosteal circumference were transformed by square roots. No other
traits were modied. Observations that were greater than four standard deviations (SD) from the
mean were classied as outliers and were removed. In the TBHS cohort, an average of three observa-
tions (range: 0–13) were removed from each trait. The traits from which more than four data were
removed were tibia length (n = 9), radial cortical density (n = 9), tibial cortical density (n = 13),
radial cortical thickness (n = 5) and 66%-tibial cortical density (n = 8). In the TFS cohort, no more
than two outlying observations were removed from any trait.
Relationships among traits were explored using hierarchical clustering and principal component
analysis methods. Hierarchical clustering was accomplished using the pairwise phenotypic Pearson
correlation as the distance metric. The resulting dendrograms were plotted adjacent to heatmaps of
the correlations, with the traits ordered according the clustering analysis. Based on previous reports
[Sheu et al. 2009], I performed a secondary analysis of the TBHS participants stratied by older and
younger than age 60. This cuto was selected to create two groups of approximately equivalent size.
Next, I developed composite phenotypes using linear combinations of the bone, fat, and lean
traits. Principal component analysis of the twenty-two traits in TBHS was performed, and the rst
n eigenvectors (principal component loadings) that accounted for at least 80% of the total variance
that were obtained from TBHS were used to calculate principal components (PCs) for the TFS pop-
ulation. Heritability of these PCs as well as the individual endophenotypes was then estimated using
methods described below.
.. Genetic Analysis
The residual heritabilities of the traits and the principal components were estimated in TFS us-
ing SOLAR (Sequential Oligogenic Linkage Analysis Routines) 4.2.0 [Almasy and Blangero 1998b;
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Amos 1994]. Covariates were assessed as described in Section 1.5.2.2. Age, age squared, sex and
menopause status were screened for signicance and included in the model if signicant at α = 0.1.
. RESULTS
.. Subject Characteristics
The general characteristics and endophenotypes of the subjects in TBHS and TFS are presented in
Tables 2.1 and 2.2. In general, the TBHS participants are older than the TFSmembers, which reects
each study’s design. Body mass index (BMI) is higher among the TBHS men (27.5 kg/m2) and the
TFS men (26.7 kg/m2), and the women higher still (29.3 kg/m2). The men in both TBHS and TFS
smoked at about the same rate (∼11%), but very few women (∼1%) smoked. About 30% of the TFS
men drank > 1 drink/week, whereas the TBHS men drank less (18.3%). Very few of the women
drank more than one drink a week (2.5%). Supplemental calcium and vitamin D use was greatest
in the TBHS men, with ∼20% and ∼30% taking the respective supplements. The TFS Women took
vitamin D at about the same rate (∼18%), but fewer took supplemental calcium (∼25%). The TFS
men took the supplements at rates of ∼9% and ∼8% respectively. Prevalence of hypertension and
diabetes was similar in both TFS men and TFS women: hypertension, 30.4% vs 27.4%; diabetes,
13.1% vs 17.6%, respectively. The TFS women had greater rates of cardiovascular disease (CVD)
and arthritis compared to the TFS men: CVD, 6.0% vs 3.8%; arthritis, 12.1% vs 7.0%. About 32% of
women were post-menopausal.
For nearly all endophenotypes, the TFS and TBHS men have similar values. The TFS men gen-
erally have greater radial trabecular BMD values compared to the TBHS men (240.9 mg/cm3 vs
207.1 mg/cm3). For fourteen of the twenty-two traits, women had smaller values than both the TFS
and TBHS men. However, the TFS women had much greater arm and leg fat mass. Tibia and radial
trabecular BMD and tibial total BMD values in the women were larger than the TBHS men but
smaller than the TFS men. Women had higher values for cortical BMD at 33% radius and 33% and
66% tibia than both the TBHS men and the TFS men.
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Table 2.1: Tobago Characteristics
TFS (n = 470)
TBHS (n = 1, 937) Men (n = 186) Women (n = 284)
Characteristic mean/n SD/% mean/n SD/% mean/n SD/%
Age (yr)
Anthropometric
BMI (kg/m2)
Waist circumference (cm)
Height (cm)
Weight (kg)
Lifestyle
Current smoking
Alcohol consumption (> 1drink/week)
Walking (min/week)
Television viewing time (h/week)
Current milk consumption (times/week)
Current caeine consumption (mg/day)
Current suppl. vitamin D use
Current suppl. calcium use
Medical conditions
Hypertension
Diabetes
Cardiovascular disease
Arthritis
Reproductive
Current oral contraceptive use
Parity
Postmenopausal
58.9
27.5
93.1
175.0
84.4
203
354
59.7
2.4
—
—
372
575
—
318
—
—
—
—
—
10.4
4.9
11.7
6.9
16.4
10.5%
18.3%
65.0
1.2
—
—
19.2%
29.7%
—
16.4%
—
—
—
—
—
42.7
26.7
90.4
177.3
84.0
21
55
53.5
16.6
3.9
90.2
18
16
57
24
7
13
—
—
—
17.0
4.9
12.2
7.1
17.2
11.4%
29.6%
73.0
8.5
2.8
162.3
9.4%
8.3%
30.4%
13.1%
3.8%
7.0%
—
—
—
42.7
29.3
89.9
166.0
81.1
2
7
44.2
15.5
4.7
79.5
52
70
78
50
17
34
94
219
91
16.7
7.0
16.8
8.9
19.4
0.7%
2.5%
109.5
7.7
2.9
83.2
18.4%
24.8%
27.4%
17.6%
6.0%
12.1%
33.0%
77.1%
31.9%
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Table 2.2: Tobago Phenotypes
TFS (n = 470)
TBS (n = 1937) Men (n = 186) Women (n = 284)
Characteristic Abbrev. mean SD mean SD mean SD
Arm
Radius length (mm)
Lean mass (g)
Fat mass (g)
at 4% radius
Total area (mm2)
Trabecular BMD (mg/cm3)
at 33% radius
Cortical area (mm2)
Cortical BMD (mg/cm3)
Cortical thickness (mm)
Periosteal circumference (mm)
Endosteal circumference (mm)
Leg
Tibia length (mm)
Lean mass (g)
Fat mass (g)
at 4% tibia
Total area (mm2)
Trabecular BMD (mg/cm3)
at 33% tibia
Cortical area (mm2)
Cortical BMD (mg/cm3)
Cortical thickness (mm)
Periosteal circumference (mm)
Endosteal circumference (mm)
at 66% tibia
Total BMD (mg/cm3)
Cortical BMD (mg/cm3)
radLength
armLean
armFat
r4TotArea
r4TrabDen
r33CrtArea
r33CrtDen
r33CrtThk
r33PeriC
r33EndoC
tibLength
legLean
legFat
t4TotArea
t4TrabDen
t33CrtArea
t33CrtDen
t33CrtThk
t33PeriC
t33EndoC
t66TotDen
t66CrtDen
308.4
4377.4
1091.9
345.9
207.1
116.8
1212.1
3.6
43.6
20.8
416.7
10976.6
2897.9
1190.0
227.5
354.3
1177.0
5.7
80.5
44.8
652.6
1122.7
17.3
775.2
690.3
57.9
49.7
14.5
25.1
0.4
3.2
3.9
27.6
1676.5
1190.6
148.1
41.5
43.4
24.9
0.7
5.4
7.1
80.1
27.8
305.7
4420.6
912.9
354.5
240.9
117.1
1212.7
3.7
43.4
20.1
398.9
11391.0
2816.3
1251.8
259.9
346.9
1181.6
5.6
79.5
44.3
696.3
1138.2
17.2
767.3
668.3
61.6
38.5
13.2
22.1
0.4
3.2
4.0
28.3
1689.6
1431.0
153.3
35.7
49.5
24.2
0.7
6.1
7.0
78.5
24.7
281.3
3026.6
2474.7
255.1
209.0
83.4
1221.9
3.2
36.4
16.3
374.8
8640.6
5506.1
996.3
241.9
266.3
1186.2
4.8
71.3
41.4
689.0
1143.5
18.8
714.4
1689.0
45.5
40.4
10.9
26.3
0.5
2.9
4.2
30.1
1627.0
1923.6
134.8
34.2
40.2
29.9
0.7
5.4
6.8
90.6
33.5
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.. Hierarchical Clustering Analysis
To simultaneously assess relationships among the measures of bone, muscle and fat traits in the arm
and leg (these traits were unadjusted for covariates), I performed hierarchical clustering analysis on
all twenty-two traits for the TBHS men and obtained a dendrogram and heatmap (Figure 2.1).
As can be seen, two large clusters of traits were identied that can be loosely described as (1) a
“geometry group,” that also includes lean mass, and (2) a “density group,” that also includes cortical
thickness and endosteal circumference (Table 2.3). Measures of arm and leg fat mass are correlated
with lean mass, and so are loosely contained in the “geometry group”, but uncorrelated with the
bone traits. Overall, the strongest correlations are between the same trait measured in the arm and
leg, for example, tibial and radial cortical thickness. The only exceptions to this arm–leg pairing are
the radial endosteal circumference, tibial endosteal circumference and tibial total BMD triad and
the three measures of cortical BMD (33% radius and 33% and 66% tibia). The heatmap highlights
correlation substructure not visible in the somewhat one-dimensional dendrogram. There are “is-
lands” of correlation between the major clusters, for example, cortical thickness (“density group”) is
moderately correlated with cortical area and lean mass (“geometry group”). Additionally endosteal
circumference (“density group”) and periosteal circumference (“geometry group”) are correlated.
Hierarchical clustering analysis of the TBHS men stratied into two age groups, those aged
60 years and older and those younger, reveals the same overall pattern (Figures 2.2 and 2.3). There
are two notable dierences however. Firstly, for both age groups, fat mass sorts out more noticeably
into its own cluster. Secondly, among the < 60 men, the correlation between the “density” group
traits is less than among the ≥ 60 men and less than in the overall analysis.
.. Principal Component Analysis
We next performed principal component analyses to develop composite traits that may represent
underlying endophenotypic dimensions. The rst seven PCs based on the phenotypic correlations
among the twenty-two bone,muscle and fat traits account for 79.4% of the total phenotypic variance.
The trait loadings (eigenvectors) and cumulative variances (eigenvalues) for the rst ten PCs are
given in Table 2.4. To further illustrate the contributions of each trait to the eigenvectors, a plot of
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Figure .: Phenotypic Correlations in TBHS participants
The colors indicate the degree of correlation with red equivalent to r = 1 and purple, to
r = 0, so that the greater the correlation the “hotter” the color. Abbreviations for the traits
can be found in Table ..
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Table 2.3: Hierarchical Clustering Groups
“Density Group” “Geometry Group” “Fat Mass Group”
r4TrabDen r33PeriC armFat
t4TrabDen t33PeriC legFat
r33CrtDen r4TotArea
t33CrtDen t4TotArea
t66CrtDen radLength
t66TotDen tibLength
r33CrtThk r33CrtArea
t33CrtThk t33CrtArea
r33EndoC armLean
t33EndoC legLean
the rst three principal components, with the unsigned loading components of each eigenvector
rescaled from 0 to 1, is presented in Figure 2.4.
The PC composite endophenotypes recapitulate many of the relationships among the traits as
illustrated by the clustering analysis. For example, PC1 accounts for 26% of the total trait variance
and primarily contains contributions from the “geometry” traits, but also includes endosteal circum-
ference. PC2 accounts for 20% of the variance and has large contributions from the “density” traits,
but also includes contributions from cortical area (a “geometry” trait). Both arm and leg lean mass
measures contribute to both PC1 and PC2, whereas fat mass is the largest contributor to PC3; PC3
accounts for 10% of the variance. PC4–PC7 comprise a mix of traits and each accounts for ≤ 8% of
the variance.
.. Heritability
To determine whether the composite traits derived from phenotypic relationships may represent
eects of a common set of genes, I simultaneously estimated heritability and screened for the eects
of sex, age, age squared andmenopause status. I also analyzed each individual bone-,muscle- and fat-
related measure. The results are presented in Table 2.5 and graphically in Figure 2.5. For all traits
but 66%-tibia total BMD and PC7, sex was highly signicant (p < 0.0001). Age and age squared
were borderline signicant to highly signicant for 24 of the 29 analyzed traits. Menopause status
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Figure .: Phenotypic Correlations in TBHS participants (age ≥ 60)
The colors indicate the degree of correlation with red equivalent to r = 1 and purple, to
r = 0, so that the greater the correlation the “hotter” the color. Abbreviations for the traits
can be found in Table ..
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Figure .: Phenotypic Correlations in TBHS participants (age < 60)
The colors indicate the degree of correlation with red equivalent to r = 1 and purple, to
r = 0, so that the greater the correlation the “hotter” the color. Abbreviations for the traits
can be found in Table ..
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Table 2.4: Tobago Men Principal Components
PC1 PC2 PC3 PC4 PC5 PC6 PC7 PC8 PC9 PC10
Cum. Var.
t33CrtThk
r33CrtThk
t4TrabDen
r4TrabDen
r33EndoC
t33EndoC
t66TotDen
r33CrtDen
t66CrtDen
t33CrtDen
legFat
armFat
r33PeriC
t33PeriC
r4TotArea
t4TotArea
radLength
tibLength
t33CrtArea
r33CrtArea
legLean
armLean
0.259
0.030
0.026
0.096
0.111
−0.274
−0.267
0.207
0.152
0.178
0.181
−0.135
−0.109
−0.321
−0.337
−0.246
−0.263
−0.224
−0.219
−0.210
−0.238
−0.263
−0.237
0.458
0.367
0.352
0.249
0.251
−0.175
−0.212
0.276
0.220
0.226
0.219
0.102
0.117
0.058
0.034
0.007
0.006
0.112
0.090
0.300
0.249
0.236
0.244
0.565
−0.003
−0.117
0.207
0.135
−0.068
−0.033
0.017
−0.241
−0.240
−0.263
0.483
0.516
−0.177
−0.105
−0.236
−0.139
−0.070
−0.051
−0.057
−0.206
0.162
0.195
0.642
−0.195
0.028
−0.354
−0.267
−0.247
0.077
−0.122
0.334
0.190
0.223
0.185
0.115
−0.285
−0.006
−0.094
0.052
0.345
0.315
−0.168
−0.208
0.185
0.144
0.704
−0.225
−0.159
0.095
−0.051
0.275
0.098
0.037
0.165
0.367
0.353
0.220
0.277
0.214
−0.120
0.221
0.165
−0.246
−0.373
−0.235
0.081
0.016
0.127
0.753
−0.430
0.174
0.300
0.469
−0.157
0.502
−0.005
0.144
0.063
−0.074
−0.077
−0.079
−0.055
0.278
−0.225
0.075
0.009
0.008
−0.118
0.054
−0.019
−0.036
0.797
−0.143
0.571
−0.213
−0.207
−0.390
−0.013
0.025
−0.190
−0.118
−0.195
0.059
0.057
−0.027
−0.122
0.179
0.169
−0.074
−0.327
−0.197
0.296
−0.021
0.038
0.837
0.171
−0.142
−0.030
−0.044
−0.180
0.080
0.090
0.108
0.004
−0.084
−0.018
−0.055
−0.332
0.263
0.166
0.523
−0.313
−0.239
0.303
−0.352
0.158
−0.038
0.868
0.114
0.137
−0.198
−0.249
−0.018
0.202
−0.103
0.151
0.063
0.080
0.257
0.233
0.083
0.330
−0.293
−0.274
−0.287
−0.037
0.328
0.147
−0.286
−0.300
0.897
−0.063
−0.091
−0.135
−0.210
0.084
0.148
0.678
−0.339
0.396
−0.198
−0.045
−0.024
0.034
0.097
−0.241
−0.002
0.218
−0.070
0.036
−0.026
0.020
0.023
Loading components ≥ 2 and ≤ −2 are typeset in bold and loading components between −2 and 2 in gray.
This threshold was chosen arbitrarily to highlight the relative contributions of each trait to the loadings.
The traits from the “density” group are highlighted in light red; the traits from the “fat mass” group, in light
yellow; and the traits from the “geometry” group, in light blue.
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Figure .: First Three Principal Components of Phenotypes in TBHS participants
The unsigned loading components of each eigenvector were rescaled from  to  (within
each eigenvector) aid in visualizing the distribution of the endophenotypes among the
PCs.
was a signicant covariate for the three measures of cortical BMD (p < 1.20 × 10−9). In general, the
covariates accounted for more of the variation in “geometry” traits (16%–70%) versus the “density”
traits (8%–34%). Covariates accounted for ∼42%–59% of the variation in the rst four PCs and 1%–
16% of the next three PCs. Aer accounting for the signicant covariates, the residual heritabilities
of the composite endophenotypes and the individual measures of bone, muscle, and fat range from
0.206 for radial cortical thickness to 0.763 for tibial trabecular density.
All heritability estimates are statistically signicant (p value range: 0.007 to 1.02 × 10−22). The
heritabilities of the composite traits range from 0.306 for PC7 to 0.696 for PC1 (p value range: 0.001
to 9.87×10−14). There are no obvious relationships between the residual heritabilities of the individ-
ual components and the composite traits, in part because heritabilities of the individual traits vary
widely. The heritability of PC3 (h2r = 0.539) falls above the two measures of fat mass, arm fat mass
(0.535) and leg fat mass (0.449).
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Table 2.5: Tobago Families Heritabilities
Covariates p
Trait n h2r S.E. p Age Age2 Sex Menopause σ2E
t4TrabDen
t33PeriC
t4TotArea
PC1
r4TrabDen
r33PeriC
t33EndoC
r4TotArea
armLean
r33CrtArea
t33CrtDen
PC3
armFat
t66TotDen
PC4
legLean
legFat
t66CrtDen
PC2
t33CrtArea
PC6
PC5
radLength
t33CrtThk
r33EndoC
r33CrtDen
PC7
tibLength
r33CrtThk
419
419
419
388
439
439
419
436
443
439
416
388
443
422
388
443
443
420
388
420
388
388
439
420
437
434
388
420
439
0.763
0.729
0.720
0.696
0.691
0.680
0.671
0.648
0.611
0.605
0.553
0.539
0.535
0.530
0.524
0.493
0.449
0.446
0.439
0.435
0.414
0.382
0.382
0.330
0.321
0.316
0.306
0.288
0.206
0.092
0.097
0.084
0.115
0.096
0.096
0.104
0.090
0.101
0.097
0.096
0.122
0.105
0.106
0.100
0.110
0.103
0.110
0.117
0.095
0.122
0.104
0.099
0.107
0.101
0.094
0.117
0.102
0.107
2.42 × 10−18
2.19 × 10−18
1.02 × 10−22
9.87 × 10−14
1.62 × 10−16
4.09 × 10−18
1.26 × 10−14
4.65 × 10−17
1.80 × 10−11
1.17 × 10−14
6.31 × 10−12
9.00 × 10−7
3.09 × 10−10
5.84 × 10−9
3.30 × 10−9
3.92 × 10−8
3.77 × 10−8
2.20 × 10−6
7.00 × 10−6
2.94 × 10−8
6.00 × 10−6
7.00 × 10−7
7.43 × 10−9
1.33 × 10−4
5.80 × 10−6
1.81 × 10−5
1.47 × 10−3
1.63 × 10−4
7.06 × 10−3
5.79 × 10−18
3.01 × 10−5
8.38 × 10−7
2.46 × 10−11
9.65 × 10−11
1.58 × 10−4
4.34 × 10−7
5.85 × 10−2
1.60 × 10−4
7.51 × 10−2
1.28 × 10−12
2.30 × 10−7
1.55 × 10−2
3.07 × 10−5
8.49 × 10−2
2.29 × 10−2
1.77 × 10−2
4.34 × 10−8
7.31 × 10−4
1.41 × 10−8
1.39 × 10−3
2.95 × 10−2
1.22 × 10−3
9.50 × 10−3
1.02 × 10−3
2.25 × 10−2
9.24 × 10−2
9.08 × 10−6
1.55 × 10−2
4.66 × 10−2
4.26 × 10−13
1.07 × 10−14
3.47 × 10−14
2.84 × 10−3
2.74 × 10−6
8.87 × 10−4
1.46 × 10−8
6.91 × 10−8
8.03 × 10−5
1.27 × 10−10
5.17 × 10−18
8.18 × 10−8
1.89 × 10−2
1.51 × 10−6
2.92 × 10−10
2.63 × 10−16
2.03 × 10−8
8.20 × 10−8
1.56 × 10−47
9.22 × 10−63
1.75 × 10−58
2.82 × 10−18
3.79 × 10−98
5.33 × 10−7
4.51 × 10−73
1.72 × 10−73
2.51 × 10−122
9.25 × 10−8
2.06 × 10−59
9.14 × 10−44
2.26 × 10−47
3.34 × 10−57
2.23 × 10−54
3.48 × 10−7
4.22 × 10−41
5.14 × 10−62
1.69 × 10−4
1.23 × 10−11
4.75 × 10−37
3.92 × 10−32
1.01 × 10−22
3.63 × 10−13
5.56 × 10−16
1.18 × 10−32
9.69 × 10−12
1.20 × 10−9
7.00 × 10−14
0.161
0.386
0.477
0.464
0.200
0.611
0.098
0.500
0.501
0.702
0.291
0.490
0.388
0.079
0.423
0.439
0.425
0.263
0.443
0.482
0.110
0.164
0.320
0.325
0.237
0.278
0.007
0.161
0.341
The traits from the “density” group are highlighted in light red; the traits from the “fat mass” group, in light yellow;
and the traits from the “geometry” group, in light blue. PCs 1, 2 and 3 are highlighted with the color of the groups
that contribute most to their eigenvectors. The PCs are in boldface text. σ2E is the variance attributable to the modeled
covariates.
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Figure .: Tobago Families Residual Heritabilities
PC– not shown in this gure for clarity.
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. DISCUSSION
With an aim to examine the relationships among endophenotypes of body composition in a popu-
lation of African descent, I explored the relationships of twenty-two bone-, muscle and fat-related
measures of the arm and leg in 1,937 Afro-Caribbean men from Tobago. Hierarchical clustering re-
vealed that the traits sorted into three general groups: (1) a “density group” consisting ofmeasures of
cortical and trabecular BMD as well as cortical thickness and endosteal circumference, (2) a “geome-
try group” consisting ofmeasures of bone length, periosteal circumference, bone area and leanmass,
and (3) a “fatmass” group consisting arm and leg fatmass. It was also observed that the gross pattern
of clustering remains the same over time, as analyses of men stratied into an older and younger
cohort produced the same patterns. Although there was evidence that the internal correlation of the
“density group” increases with age.
To develop composite endophenotypes that might reect underlying trends among the body
composition traits, principal components were developed in TBHS and were found to be generally
analogous to the results of the hierarchical clustering. The loadings from the rst seven PCs were
applied to the same set of phenotypes of the TFS participants to generate a set of PCs for genetic
analysis.
To assess the genetic contribution to the twenty-two individual and seven composite endophe-
notypes, residual heritabilities were calculated for all traits. The heritabilities ranged from modest
(0.206) to high (0.763), and all were statistically signicant. There was no apparent pattern or clus-
tering of the traits from dierent groups, nor of the PCs, although the higher ordinal PCs tended
to have greater heritability. That is in general, the greater the proportion of total sample variance
attributable to a PC, the greater the proportion of genetic variance for that PC. The most dominant
PC consists of mainly “geometry” traits with additional contributions from the two measures of en-
dosteal circumference. This PC also had high heritability (h2r = 0.696) indicating that traits such as
bone length and bone area are inuenced more by genetic contributions than PC2, which consists
mainly of “density” traits. PC2 has a moderate heritability (0.439) and may be more highly aected
by environmental inputs.
The creation of heritable principal components formeasures of body composition points toward
pleiotropic relations among each PCs’ components. These PCs could be extended to gene mapping,
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to identify loci that aect multiple measures. The characterization of such genes could enhance our
understanding of the genetic architecture of body composition.
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. GENOMEWIDE LINKAGE STUDY IN AFRO-CARIBBEANS
. INTRODUCTION
Osteoporosis, sarcopenia and changes in body fat distribution are complex, age-related conditions
that result from the eects of genes and environmental factors [Pocock et al. 1987; Seeman et al. 1996;
Maes et al. 1997; Koller et al. 2000, 2001; Karasik et al. 2004; Huygens et al. 2004; Hsu et al. 2005;
Wang et al. 2007b; Prior et al. 2007]. Considerable research has been done to identify genes inuenc-
ing endophenotypes for osteoporosis, sarcopenia and body fat distribution separately. For example,
linkage and whole genome association studies have identied genes inuencing areal bone mineral
density (BMD), e.g., LRP5 (low density lipoprotein receptor–related protein 5), ESR1 (estrogen re-
ceptor 1), TNFRFS11B (tumor necrosis factor receptor superfamily, member 11b; osteoprotegerin;
or OPG), TGFBR3 (transforming growth factor, β receptor III) [Richards et al. 2008; Styrkarsdottir
et al. 2008; Xiong et al. 2009]; lean mass, e.g., TRHR (thyrotropin-releasing hormone receptor) [Liu
et al. 2009a]; and body mass index (BMI), e.g., PPARG (peroxisome proliferator –activated recep-
tor γ), ADIPOQ (adiponectin),MC4R (melanocortin 4 receptor), FTO (Fatso homolog) [Fox et al.
2007; Thorleifsson et al. 2008; Willer et al. 2008; Timpson et al. 2008; Ling et al. 2009; Meyre et al.
2009; Heard-Costa et al. 2009]. However, variation in these known genes does not account for all
of the known genetic variation in these bone-, muscle- and fat-related traits, indicating that addi-
tional genetic variants remain to be identied. In addition, few studies have been performed among
individuals with non-European ancestry. Genetic studies of additional endophenotypes, such as vol-
umetric measures of cortical and trabecular bone may reveal additional loci that inuence suscepti-
bility to osteoporosis, sarcopenia and body fat redistribution. Furthermore, our current knowledge
of embryonic and fetal development, as well as results from epidemiological studies, indicate that a
common set of genetic and environmental factors may inuence all three traits [Glauber et al. 1995;
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Churchill 1996; Frost 2003; Shore et al. 2006; Sun et al. 2006; Lee et al. 2007; Wang et al. 2007d;
Videman et al. 2007; Karasik and Kiel 2008; Devaney et al. 2009; Schindeler et al. 2009; Karasik et al.
2009]. Thus, genetic analyses of several traits simultaneously, in populations with diering ancestry,
may reveal additional loci.
Using multivariate methods, I have identied clusters of endophenotypes for bone, muscle and
fat traits and developed measures of composite phenotypes (Chapter 2). Individually, similar en-
dophenotypes have been reported to be heritable among individuals with European [Hsu et al. 2005;
Karasik et al. 2009] and African ancestry [Hsu et al. 2005; Wang et al. 2007b], however, few studies
have been done to identify quantitative trait loci (QTLs) that inuence these traits among individ-
uals of European ancestry [Thomas and Burguera 2002; Liu et al. 2004; Chinappen-Horsley et al.
2008; Karasik et al. 2009] or of African ancestry [Koller et al. 1998]. In this chapter, to identify QTLs
that inuence the endophenotypes or composite traits, I performed variance components linkage
analyses and compared the results of these analyses to determine if QTLs inuence more than one
trait. Then, I estimated the genetic correlation among traits for which evidence of pleiotropic QTLs
is observed.
. METHODS
.. Study Population
In this chapter I used the participants in the Tobago Family Health Study (TFS) described in Chap-
ter 2. Briey, the TFS population comprises 470women andmen (ages ≥ 18 years) in sevenmultigen-
erational families of African descent (mean family size = 67; total number of relationships: 4,206).
Pedigrees can be found in Appendix B.
This study was approved by the Institutional Review Boards of the University of Pittsburgh
and the Tobago Division of Health and Social Sciences and all participants gave written, informed
consent.
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.. Phenotypes
The twenty-two bone-, muscle- and fat-related endophenotypes and seven composite endopheno-
types analyzed in Chapter 2 were carried forward for analysis in this chapter. The muscle-related
traits were arm and leg lean mass measured by dual-energy x-ray absorptiometry (DXA). The fat-
related traits were arm and leg fat mass, also measured by DXA. Bone geometry traits were tibia and
radius length, measured byDXA, and total bone area at 4% of the radius and of the tibia and cortical
area, cortical thickness, periosteal circumference and endosteal circumference at 33% of the radius
and of the tibia, measured by peripheral quantitative computed tomography (pQCT). BMD traits
were trabecular BMD at 4% of the radius and of the tibia, cortical BMD at 33% of the radius and of
the tibia and total BMD and cortical BMD at 66% of the tibia and were also determined by pQCT.
Composite endophenotypes were generated by principal component (PC) analysis as described
in Chapter 2. Briey, because the individuals in TFS are not independent, the eigenvectors were
calculated using the same twenty-two bone-, muscle- and fat-related phenotypes in 1,937 unrelated
men of African ancestry from the Tobago Bone Health Study (TBHS), a study of body composition
also preformed as a follow up of the Tobago Prostate Cancer Survey. The eigenvectors were then
applied to the phenotypes in TFS to produce principal components. The rst seven PCs, which
account for > 80% of the overall variance, represent combinations of three general groups groups of
traits, dened as “geometry,” “density” and “fat-related.” The traits that compose each group can be
found in Table 2.3.
.. Markers
The 470 individuals from TFS were genotyped on an Innium HumanLinkage-12 BeadChip Assay
(Illumina), a single-nucleotide polymorphism (SNP) linkage panel that covers 93.2% of the genome.
Aer excluding SNPs with a call rate < 90%, a Hardy–Weinberg equilibrium p value < 0.001, a mi-
nor allele frequency (MAF) < 0.05 and that were incompatible with multipoint identify-by-descent
(MIBD) estimation using LOKI [Heath 1997] (that is, less than 1 cM apart), a total of 1,516 autoso-
mal SNPs remained. The nal SNP set had a median MAF = 0.325 with median spacing of 1.92 cM.
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.. Statistical Analyses
Initial statistical analyses were performed in R 2.11.1 [R Development Core Team 2008]. All 22
bone-, muscle- and fat-related measures underwent a series of quality control procedures described
inChapter 2 including transformations to normality and outlier removal. Seven composite endophe-
notypeswere generated as described above and inChapter 2. The eects of covariates and estimation
of heritability of the twenty-two traits and seven endophenotypes were also previously described
(Chapter 2). For the univariate and bivariate analyses described below, I analyzed the residuals of
the twenty-two individual and seven composite traits derived from the heritability analyses.
.. Genetic Analysis
Univariate linkage analysis, bivariate linkage analysis and bivariate correlation decomposition were
accomplished using SOLAR (Sequential Oligogenic Linkage Analysis Routines) 4.2.0 [Almasy and
Blangero 1998b;Amos 1994]. Adjustment for covariateswas performed as described in Section 1.5.2.2.
Univariate multipoint variance-components linkage analysis was performed for each trait and PC
using LOKI-calculated MIBDs for the autosomes only. A likelihood ratio test for linkage was con-
ducted by comparing the likelihoods of the models with and without the QTL, given the data. Log-
arthim of the odds (LOD) scores were calculated by taking the log10 of the test statistic. A LOD
score greater than 2.5 was taken as suggestive evidence of linkage, based upon background noise
in a simulated linkage analysis of a trait constructed as the sum of several SNPs’ allele dosages (Sec-
tion 1.5.4.3). The 2 LOD condence interval of eachQTLwas taken as the width from themaximum
LOD out to the maximum − 2 on each side. To adjust for potential ination due to residual pheno-
typic sibling correlation or deviations from normality, a simulation of the null distribution for each
trait that showed evidence of a QTL was generated to calculate an empirical LOD adjustment con-
stant [Allison et al. 1999; Blangero et al. 2000, 2001].
Bivariate linkage analysis, which tests for simultaneous linkage of two traits to a genetic region,
was performed for those pairs of traits for which there was evidence of linkage at the same locations.
The correlation (ρP) between each pair of traits was also decomposed into two components:
genetic (ρG) and environmental (ρE). Models with the estimated genetic correlation were tested
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against models with ρG = 0 and ρG = 1 to assess whether genetic elements underlying each pair of
traits are independent or completely the same, respectively.
. RESULTS
.. Subject Characteristics
Characteristics of the subjects in TFS are presented in Tables 2.1 and 2.2 and are described in Sec-
tion 2.3.1.
.. Univariate Linkage Analysis
Univariate linkage analysis was performed on twenty-two traits and seven composite endopheno-
types. Eight endophenotypes mapped to one location each on the genome with LOD scores greater
than 2.5, and one endophenotypemapped to two locations (Table 3.1). Two endophenotypesmapped
to locations with LOD scores greater than 3.3. If LOD = 3.3 is taken as equivalent to p = 0.05 for a
genomewide scan [Lander and Schork 1994], then testing for 29 traits would be expected to produce
1.45 false positives. With two seen here, there appears to be an excess. None of the traits required
signicant adjustment for ination (range 0.96–1.16); only radial cortical BMD required downward
adjustment (k = 0.96). I detected signicant evidence for a QTL on chromosome10q26.3–qter that
inuenced both PC1 and tibial periosteal circumference (LOD scores of 3.45 and 3.12 respectively
(Figure 3.2). Another signicant QTL inuencing both arm fat mass and PC3 mapped to chromo-
some 21pter–q21.1 with LOD scores of 3.66 and 2.82 (Figure 3.6). Leg fat mass, arm lean muscle
mass and leg lean muscle mass also had non-signicant linkage peaks at this location with LOD
scores of 1.81, 2.09 and 1.86 (Figure 3.6). I also identied several regions with suggestive evidence
for QTLs. A 38.2 Mb region from 1p31.1 to 1p34.1 showed linkage to PC4 with a peak LOD of 2.76
(Figure 3.1). A region on 10q21.1–q23.1 showed linkage to radial cortical density (peak LOD = 2.52;
Figure 3.2). Two traits also showed linkage to chromosome 12, tibia cortical thickness and radial cor-
tical density, with LODs of 2.67 and 2.97 (unadjusted) respectively; however, they did not map to
overlapping regions of the chromosome (12q12–q21.31 and 12q24.23–qter; Figure 3.3). A 20.5 Mb
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region from 17pter–p11.2 was linked to radial total area (LOD= 2.62; Figure 3.4). Finally, a 10.4Mb
region from 20p12.3–p12.1 was linked to radial periosteal circumference (LOD = 2.72; Figure 3.5).
Genomewide plots of all 29 traits can be found in Figures C1–C29 in Appendix C.
Table 3.1: Univariate LOD Scores
Position
Peak Genetic Physical
Trait n Covariates h2r Chr cM LOD h2QTL Cytogenetic (cM) (Mb)
PC4
r33CrtDen
PC1
t33PeriC
t33CrtThk
r33CrtDen
r4TotArea
r33PeriC
armFat
PC3
388
428
388
419
420
428
436
439
443
388
A, A2, S
A, A2, S, M
A, S
A, A2, S
A2, S
A, A2, S, M
A, A2, S
A, A2, S
A, A2, S
A, A2, S
0.524
0.316
0.696
0.729
0.330
0.316
0.648
0.680
0.535
0.539
1
10
10
10
12
12
17
20
21
21
97
87
182
190
88
175
33
29
7
12
2.76
2.52
3.45
3.12
2.67
2.97
2.62
2.72
3.66
2.82
0.445
0.361
0.485
0.368
0.330
0.313
0.334
0.414
0.315
0.372
1p34.1–p31.1
10q21.1–q23.1
10q26.3–qter
10q26.3–qter
12q12–q21.31
12q24.23–qter
17pter–p11.2
20p12.3–p12.1
21pter–q21.1
21pter–q21.1
81–118
76–114
176–190
173–190
59–100
145–191
0–51
14–40
0–14
0–18
46.4–84.6
59.9–84.6
131.4–135.4
130.7–135.4
44.0–84.0
117.3–132.3
0.0–20.5
5.2–15.6
0.0–19.3
0.0–21.2
A = age; A2 = age squared; S = sex; M = menopause. h2r is the residual heritability of the trait. h2QTL is the
estimated residual heritability due to a QTL at this locus.
.. Bivariate Genetic Correlation and Linkage Analyses
To further investigate the whether the univariate linkage signals for a QTL on chromosome 21 for
arm and leg lean and fat mass were due to coincident linkage or possible pleiotropic eects of a QTL,
I estimated bivariate genetic correlations for the fat and lean mass traits (Table 3.2) and performed
bivariate linkage analyses for four pairs of traits: arm fat mass/leg fat mass, arm lean mass/leg lean
mass, arm fat mass/arm lean mass and leg fat mass/leg lean mass (Figure 3.7 and Table 3.3). To
further investigate whether the univariate linkage signals for a QTL on chromosome 10 indicated a
QTL with pleiotropic eects, I also estimated the genetic correlations of the major components of
PC1 (Table 3.4).
The heritabilities of arm and leg lean and fat mass are moderate (ranging from 0.42 to 0.58,
p < 3.77 × 10−8 for all) and the genetic correlations between arm and leg fat and arm and leg lean
mass were high, 0.78 (pρG=1 = 1.00 × 10−7) and 0.84 (pρG=1 < 6.00 × 10−7), respectively. The genetic
49
0 50 100 150 200 250 300
0
1
2
3
4
Genetic Distance (cM)
LO
D
PC4
Figure 3.1: Chromosome 1 Univariate QTL
The solid gray line is at LOD = 3.3, statistical signicance in this study. The dashed gray line is at LOD = 2.5,
suggestive signicance in this study.
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Figure 3.2: Chromosome 10 Univariate QTLs
The solid gray line is at LOD = 3.3, statistical signicance in this study. The dashed gray line is at LOD = 2.5,
suggestive signicance in this study.
50
0 50 100 150
0
1
2
3
4
Genetic Distance (cM)
LO
D
r33CrtDen
t33CrtThk
Figure 3.3: Chromosome 12 Univariate QTLs
The solid gray line is at LOD = 3.3, statistical signicance in this study. The dashed gray line is at LOD = 2.5,
suggestive signicance in this study.
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Figure 3.4: Chromosome 17 Univariate QTL
The solid gray line is at LOD = 3.3, statistical signicance in this study. The dashed gray line is at LOD = 2.5,
suggestive signicance in this study.
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Figure 3.5: Chromosome 20 Univariate QTL
The solid gray line is at LOD = 3.3, statistical signicance in this study. The dashed gray line is at LOD = 2.5,
suggestive signicance in this study.
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Figure 3.6: Chromosome 21 Univariate QTLs
The solid gray line is at LOD = 3.3, statistical signicance in this study. The dashed gray line is at LOD = 2.5,
suggestive signicance in this study.
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correlation for arm fat and arm lean mass was also high, 0.703, while leg fat and leg lean mass were
moderate, 0.53. All four pairs of traits examined in the bivariate linkage analysis exhibited signicant
or potential bivariate linkage on chromosome 21 at the same location as univariate analyses of each
trait separately, as well as PC3, in which both fatmass traits are amajor contributor (Figure 3.7). The
LOD2df scores were 2.94, 3.30, 1.72 and 1.72 for arm fat/leg fat mass, arm lean/arm fat mass, arm
lean/leg lean mass and leg lean/leg fat mass respectively. Thus, this QTL is likely to have pleiotropic
eects on the fat and lean mass related traits.
There is also potential evidence of a pleiotropic locus on chromosome 10q26.3–qter where pu-
tative QTLs for both the composite trait PC1 and the individual trait tibial periosteal circumference
overlap (Figure 3.2). The individual traits that make up PC1, including tibial periosteal circumfer-
ence, all exhibit moderate to high genetic correlation (Table 3.4), ranging from 0.358 to 0.888.
Table 3.2: Genetic Correlations — Lean Muscle and Fat Mass
legFat armFat legLean armLean
legFat
armFat
legLean
armLean
0.449 0.776
0.535
0.526
0.426
0.493
0.601
0.703
0.839
0.611
The genetic correlations are located in the top triangle of the matrix.
Heritabilities for each trait are set in boldface text down the diagonal. If
ρG = 0 was not rejected the estimate of ρG is not shown, and if ρG = 1
was not rejected, the estimate is in gray.
. DISCUSSION
As epidemiological evidence accumulates and developmental processes are better understood, the
interrelationships between variation in bone, muscle and fat tissues, including variation that ex-
tends to conditions such as osteoporosis, sarcopenia and age-related changes in fat distribution,
have become more apparent. In the past two decades, several genes have been identied that inu-
ence endophenotypes for these conditions. Nonetheless, these genes do not account for all of the
known heritability of these endophenotypes, and thus more genes need to be located and under-
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Figure 3.7: Chromosome 21 Bivariate QTLs
The solid gray line is at LOD = 2.5, suggestive signicance in this study. The bivariate LOD2df scores are not
strictly comparable to the univariate LOD scores because each is tested with a dierent number of degrees
of freedom. They are displayed together here to illustrate their positional overlap.
Table 3.3: Bivariate LOD Scores on 21pter–q21.1
Trait 1 Trait 2 Peak
Trait h2r1 h
2
QTL1 Trait h
2
r2 h
2
QTL2 LOD2df
armFat 0.535 0.316 legFat 0.449 0.199 2.65
armLean 0.611 0.215 armFat 0.535 0.309 2.92
armLean 0.0.611 0.268 legLean 0.493 0.243 1.46
legFat 0.449 0.203 legLean 0.493 0.205 1.71
h2r1 and h
2
r2 are the residual heritabilities of the rst and sec-
ond trait respectively. h2QTL1 and h
2
QTL1 are the estimated
residual heritabilities due to a QTL at this locus for the rst
and second trait respectively.
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Table 3.4: Genetic Correlations — PC1
r33 t33 t33 r33 t4Tot r4Tot rad tib t33Crt r33Crt leg arm
EndoC EndoC PeriC PeriC Area Area Length Length Area Area Lean Lean
r33EndoC
t33EndoC
t33PeriC
r33PeriC
t4TotArea
r4TotArea
radLength
tibLength
t33CrtArea
r33CrtArea
legLean
armLean
0.321 0.877
0.671
0.864
0.888
0.729
0.880
0.753
0.842
0.680
0.573
0.580
0.578
0.592
0.720
0.591
0.602
0.595
0.633
0.697
0.648
0.467
0.600
0.602
0.407
0.358
0.382
0.562
0.586
0.461
0.619
0.683
0.288
0.587
0.434
0.804
0.654
0.302
0.447
0.490
0.443
0.435
0.718
0.557
0.651
0.951
0.469
0.587
0.573
0.446
0.618
0.605
0.537
0.594
0.721
0.658
0.536
0.400
0.900
0.647
0.691
0.668
0.493
0.310
0.490
0.502
0.383
0.277
0.437
0.430
0.508
0.617
0.839
0.611
The genetic correlations are located in the top triangle of the matrix. Heritabilities for each trait are set in boldface
text down the diagonal. If ρG = 0 was not rejected the estimate of ρG is not shown, and if ρG = 1 was not rejected,
the estimate is in gray.
stood. Linkage analysis methods have been used successfully to identify genes that inuence many
traits, including traits related to the endophenotypes examined here. Conducting linkage analysis
on multiple related traits as well as on composites of those traits could aid in identifying genes with
pleiotropic eects.
Nine traits and/or composite endophenotypes exhibited suggestive evidence for QTLs at eight
autosomal locations: PC4 at 1p34.1–p31.1, radial cortical density on 10q21.1–q23.1, PC1 and tib-
ial periosteal circumference on 10q26.3–qter, radial cortical density at 12q12–q21.31, tibial corti-
cal thickness at 12q24.23–qter, radial total area at 17pter–p11.2, radial periosteal circumference at
20p12.3–p12.1, and PC3 and arm fat mass at 21pter–q21.1. Thus, except for two pairs of traits, I ob-
served no overlap of QTLs. This result is somewhat surprising given the known developmental and
phenotypic correlations among these traits. However, quantitative trait linkage analyses will only
detect QTLs that have a relatively large eect on the traits of interest. Additionally, the sample size is
small and although extended multigenerational pedigrees enhance the ability to trace transmission
of characters and alleles between relatives, I might not have the power to detect more subtle eects
that might be characteristic of pleiotropy.
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Two of the prospective QTLs in particular have good evidence to support them: 10q26.3–qter
and 21pter–q21.1.
.. q.–qter
Principal component 1 has signicant contributions from “geometry” traits—periosteal circumfer-
ence, total bone area, bone length, cortical bone area and lean mass—as well as some contributions
from “density” traits—endosteal circumference and 66% tibial total density. Both PC1 and tibial pe-
riosteal circumference show evidence of aQTL located in a ∼4.7Mb region of chromosome 10q26.3–
qter. The two linkage peaks virtually overlap; although PC1 peaks at 10qter whereas tibial periosteal
circumference peaks just proximal to the end of the chromosome. This region of the chromosome
includes 47 genes. There is a potential candidate gene about 1 Mb distal to the peak LOD score at∼134.0 Mb: ADAM8 (a disintegrin-like and metalloprotease domain–containing protein 8), which
has been shown to be involved in osteoclastogenesis [Choi et al. 2001; Peeters et al. 2003; Rood-
man 2006; Rao et al. 2006; Granholm et al. 2007] and to potentially play a role in bone response to
inammatory conditions [Ainola et al. 2009; Ishizuka et al. 2010].
.. pter–q.
The fat- andmuscle-related traits, bivariate pairs thereof and PC3 all exhibit evidence of linkagewith
various levels of signicance to 21pter–q21.1, a 21.2 Mb region encompassing the proximal half of
chromosome 21 including the centromere. However, the rst SNP available for chromosome 21 is
at 15 Mb (4 cM) on 21q11.2. Considering the more limited region from 21q11.2 to q21.1, there
are 21 genes in the region. One potential candidate gene, PDE3A (phosphodiesterase 3A, cGMP-
inhibited), is expressed in adipose tissues [Löbbert et al. 1996] and has altered expression correlated
with weight loss following Roux-en-Y gastric bypass surgery [Kim et al. 2008].
.. Other Suggestive Quantitative Trait Loci
LEPR (leptin receptor) on 1p31.3, under the PC4 linkage peak on 1p34.1–p31.1, has been examined
for associations with body composition traits, primarily adiposity, with mixed results [for review
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see Paracchini et al. 2005]. Mutation in the homologous rat gene is responsible for the extreme
obesity phenotype of the Zucker fatty rat [Phillips et al. 1996; Takaya et al. 1996], which also serves
as an animalmodel for ossication of posterior longitudinal ligament (OPLL) [Okano et al. 1997]. A
small study of Japanese OPLL patients (n = 172) and controls (n = 93) showed amodest association
between LEPR variants and degree of OPLL [Tahara et al. 2005]. The broad linkage region (40 Mb)
for radial cortical thickness on 12q12–q21.31 includes slightly less than half of the q arm of 12.VDR
(vitamin D receptor), located on 12q13.11, is associated with vitamin D–dependent rickets type 2A
[Hughes et al. 1988; Kristjansson et al. 1993] and has been suggested to play a role in height [Xiong
et al. 2005]. However, evidence is not strong for the role of common variation in VDR to modify
BMD or fracture risk [Uitterlinden et al. 2006]. Missense polymorphisms in P2RX7 (purinergic
receptor P2X, ligand-gated ion channel, 7), which is located on 12q24 under a linkage signal for
radial cortical BMD, have been associatedwith vertebral fractures [Ohlendor et al. 2007], and P2X7
knockout mice exhibit reduced bone mineral content and increased trabecular bone resorption [Ke
et al. 2003]. AQTL for osteoporosis andhip and spineBMDhas previously been reported on 20p12.3
and BMP2 has been proposed to be the candidate gene for this linkage result [Styrkarsdottir et al.
2003].
.. General Conclusion
Strong evidence for two potential QTLs have been observed in this study of a set of twenty-two
individual and seven composite endophenotypes: one QTL located on 10q26.3–qter for PC1 and
tibia periosteal circumference and another QTL on 21pter–q21.1 for PC3 and arm fat mass. Fine-
mapping of these putative QTLs in a similar population using association analysis with genotyped
and imputed SNPs covering the regions under the linkage signals will be necessary to identify causal
variants.
Measures of body composition, particularly bone-related traits, have not been thoroughly stud-
ies in populations of African ancestry. Further studies in African-ancestry populations such as the
population of Tobago could increase our understanding of that particular population as well as pro-
viding a comparison for populations with European, Asian or Native American ancestry.
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. GENOMEWIDE ASSOCIATION STUDY IN EUROPEAN AMERICANS
. INTRODUCTION
The promise of genomewide association studies (GWAS) was rst proposed by Risch and Merikan-
gas in 1996. In the 15 years since that initial proposal, 918 GWAS of complex traits and disor-
ders (as of June 16, 2011, according to the National Human Genome Research Institute (NHGRI),
www.genome.gov/gwastudies) have been performed, and many loci have been identied. The ef-
fect sizes of these loci have oen proven to be small, and therefore GWA studies can require very
large sample sizes to have adequate statistical power to detect such eects. Such large samples have
required the collaboration of multiple studies into meta-analysis consortia.
Thirteen GWA studies of areal bone mineral density (BMD) of the hip or spine have been pub-
lished to date [Kiel et al. 2007; Richards et al. 2008; Styrkarsdottir et al. 2008; Xiong et al. 2009;
Timpson et al. 2009; Styrkarsdottir et al. 2009; Paternoster et al. 2010; Koller et al. 2010; Guo et al.
2010b; Gupta et al. 2011; Duncan et al. 2011], as well as ve studies of osteoporosis [Liu et al. 2009b;
Guo et al. 2010a; Hsu et al. 2010; Karasik et al. 2010; Tung et al. 2011]. These studies ranged in
size from large single populations (1,141 participants) [Kiel et al. 2007] to large consortia of mul-
tiple single studies. One of the largest consortia for studies of osteoporosis and bone-related traits
is the Genetic Factors for Osteoporosis (GEFOS) Consortium, a collaboration of researchers from
Australia, Canada, China, Greece, Iceland, the Netherlands, Sweden, the United Kingdom and the
United States who are interested in identifying the common risk gene variants for osteoporosis. In
2009 the GEFOS Consortium analyzed data on areal BMD of the spine and femoral neck in 19,195
Northern Europeans and identied single-nucleotide polymorphisms (SNPs) in 20 loci associated
with these two traits (Rivadeneira et al.). The consortium is currently completing a larger GWAS of
lumbar spine and femoral neck bone mineral density in 34,191 individuals from multiple studies
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with replication of signicant and suggestive loci in an additional 50,933 subjects (bone mineral
density) and 31,016 fracture cases and 102,444 controls [Estrada et al. 2010a,b, 2011].
In this chapter, I present the results of my contributions to the Consortium’s eorts—GWA stud-
ies of areal BMD of the femoral neck and lumbar spine in European American participants in the
Dynamics of Health, Aging, and Body Composition (HealthABC) study, which were part of the cur-
rent GEFOS discovery cohort. I also present results of GWA studies of fracture risk in these subjects,
which were part of the GEFOS fracture follow-up case and control cohorts. Finally, I report on the
results of replication and ne mapping of twenty previously identied loci [Rivadeneira et al. 2009]
in HealthABC using SNPs imputed from 1000 Genomes Project data [Abecasis et al. 2010].
. METHODS
.. Study Population
The Dynamics of Health, Aging and Body Composition Study (HealthABC) is a multicenter lon-
gitudinal study of changes in body composition among older men and women ascertained to be
disability-free at baseline. The study population comprises 3,075men and women, ages 70–79 years.
Approximately a third of the men (n = 488) and half of the women (n = 651) are African American;
the remainder, European American (n = 1, 663; Table 4.1). Subjects were recruited in Pittsburgh,
Pennsylvania, and Memphis, Tennessee. Individuals in HealthABC were designated as European
Americans or African Americans based on eigenanalyses of their genotypes, including ancestry in-
formative markers. These analyses were performed bymy colleagues atWake Forest University. The
current GWA analyses were done using data on European Americans (784 women and 879 men).
The institutional review boards at both clinical centers approved the study, and all participants
provided written informed consent.
.. Bone Mineral Density
Areal bone mineral density (BMD) was measured using dual-energy x-ray absorptiometry (DXA)
scans of the whole body and proximal femur as described in Section 1.5.2.1. Femoral neck BMD
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(FNBMD) was available for 868 European American men and 775 European American women.
Lumbar spine BMD (LSBMD) was available for 870 European American men and 778 European
American women.
.. Fractures
Fracture incidents for HealthABC participants were recorded aer the individuals were enrolled in
the study. Fracture sites (e.g., pelvis or femur), fracture types (fragility, traumatic, pathologic, stress,
other and unknown) and age at fracture for each incident were recorded. For the current analyses,
two classes of fractures were dened: “all types” and “non-vertebral.” “All types of fracture” cases
included individuals who had any fractures during the study excluding fractures that resulted from
excessive trauma and fractures of the ngers, toes and skull. No medical records nor radiographic
evidence were required for this category. Non-vertebral fracture cases included subjects who had
any fractures during the study except those as a result of excessive trauma and those of the ngers,
toes, skull and vertebrae. Radiographic evidence was required for this category.
.. Genotyping and Imputation
Genotyping of the HealthABC participants was performed by the Center for Inherited Disease Re-
search (CIDR) using the Illumina Human1M-Duo BeadChip system. The following quality control
measures were implemented: All data on individual samples were removed from the data if the
genotyping for the sample failed overall (< 97% SNPs genotyped), if the chromosome sex did not
match the reported sex or if rst-degree relatedness was detected using the single-nucleotide poly-
morphism (SNP) data. All data on specic SNPs were removed from the data le if the SNP had a
minor allele frequency (MAF) ≤ 1%, was called with ≤ 97% success, or had a Hardy–Weinberg equi-
librium (HWE) test p value≤ 10−6. A total of 1,151,215 autosomal SNPswere successfully genotyped
in 1,663 European American individuals and were carried forward to imputation.
Imputation was performed using MACH 1.0.16 [Li et al. 2010b] and the HapMap II phased
haplotypes [Frazer et al. 2007] as the reference. Genotypes were available for 914,263 SNPs based
on the HapMap Centre d’Étude du Polymorphisme Humain (CEPH) reference panel (rel. 22, b36).
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A total of 2,543,887 genotyped and imputed autosomal SNPs were ultimately available for analysis
as part of the “HapMap SNP” set.
A total of 40,591 chromosome X SNPs were successfully genotyped in all European Americans
subjects. An additional 37,607 SNPs were imputed using a method similar to that used for the au-
tosomes for a total of 78,198 chromosome X SNPs. The chromosome X SNPs were included in the
“HapMap SNP set” for a total of 2,622,085 SNPs.
Follow-up studies and ne mapping were done using data from a second set of 6,858,264 geno-
typed and imputed autosomal SNPs that were available as part of the “1000 Genomes SNP set.”
Approximately 1.2 million SNPs (autosome and X-chromosome) were successfully genotyped and
available on 1,663 European American subjects. The additional ∼5.6 million SNPs were imputed
using the 1000 Genomes [Abecasis et al. 2010] reference haplotypes (June 2010 release).
The HapMap imputation and initial quality control was performed by Yongmei Liu and Kurt
Lohman ofWake Forest University. The 1000Genomes imputation was performed byMichael Nalls
of the National Institutes of Health.
.. Statistical Analysis
... Association analysis methods Three analyses were performed for each trait: men only,
women only, and both sexes together (pooled-gender).
For FNBMD and LSBMD, residuals of each untransformed trait were generated in men and
women separately. To maintain consistency across all studies participating in GEFOS, the following
covariates were incorporated into the linear regression model for BMD: age, age squared, weight,
clinical site and ancestry principal components (PCs). For the pooled-gender analyses, the residuals
from the men and the women were combined.
For the fractures, logistic regression was performed with age, age squared, weight, standing
height, clinical site and ancestry PCs as covariates. For the pooled-gender analyses, sex was also
included as a covariate. These analyses were performed using R 2.11.1 [R Development Core Team
2008].
Regression analyses were performed using additive allele-dosage models in ProbABEL 0.1-3
[Aulchenko et al. 2010]. ProbABEL allows for the use of imputation-generated genotypic probabil-
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ities in regression analysis without constraining the AA/AB/BB genotypes to 1/0/0, 0/1/0 or 0/0/1.
Sandwich standard errors (SE) were calculated to control for ination caused by small population
size and low allele frequencies. The association results were ltered for imputation quality (r2 > 0.3)
[Li et al. 2010b] and minor allele frequency (> 5%) to remove low quality and rare SNPs that could
produce spurious results. The genomic control correction factor λ [Devlin and Roeder 1999; Ba-
canu et al. 2002] was calculated for each of the four traits in each of the three analysis groups (men,
women and pooled-gender) from the p values with the lowest decile removed using the GenABEL
[Aulchenko et al. 2010] package in R. Odds ratios (OR) for fracture risk were calculated as eβ. The
upper and lower 95% condence intervals were calculated as eβ±z97.5%SE.
The thresholds for signicance and suggestiveness of associated loci, p < 5×10−8 and p < 5×10−6
respectively, will be used here [Frazer et al. 2007; Pe’er et al. 2008]. These are the same thresholds
used in the GEFOS consortium analyses. Similarly, “associated” loci were dened as regions 1 Mb
up- and downstream of SNPs with the most signicant p values (“peak SNPs”).
... Statistical power Power of the GWA analyses for the HealthABC cohort was estimated
using QUANTO 1.2.4 [Gauderman and Morrison 2006]. For the quantitative BMD traits, power
was modeled to detect a SNP that accounted for 0.5% of residual variance of a trait. This parameter
was chosen based upon the results of Rivadeneira et al. [2009]. For the discrete fracture traits, power
was modeled to detect an odds ratio of 1.5 with a population prevalence of 15%. These parameter
choices are based upon the typical odds ratios reported for GWAS (www.genome.gov/gwastudies);
the population prevalence is based upon the non-vertebral fracture incidence observed in Health-
ABC.
... Replication and ne mapping In addition to the GWAS described above, the 20 previ-
ously identied loci [Rivadeneira et al. 2009] were examined for associations with FNBMD and LS-
BMD in the HealthABC cohort. The most signicant SNP at each locus, as reported by Rivadeneira
et al., was taken as the midpoint of a 2 Mb region. The 1000 Genomes SNPs within each region
were tested for association, in the pooled-gender residual sets only, using ProbABEL as above. The− log10-transformed p values for each SNP vs physical position for the interesting loci presented
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below were annotated with recombination rates and gene positions using LocusZoom 1.1 [Pruim
et al. 2010].
. RESULTS
.. Subject Characteristics
Characteristics of the European American subjects in the HealthABC study are presented in Ta-
ble 4.1, and dierences between women and men were assessed using t tests, Wilcoxon rank sum
tests or χ2 tests as appropriate.Women andmen in the study had similar ages (73.6 years vs 73.9 years
respectively), rates of smoking (7.7% vs 5.2% respectively), activity levels, (85.8 vs 82.7 kcal/kg/wk
respectively) as well as rates of hypertension (45.4% vs 42.1%, respectively) and cardiovascular dis-
ease (7.6% vs 7.2% respectively). Compared to women, men were signicantly (p < 10−8 for all)
taller, heavier and had larger waist circumferences and body mass indices (BMIs). The men also
drank more than women (45.1% vs 29.1%) and had nearly twice the prevalence of diabetes (14.0%
vs 7.6%). Arthritis was almost twice as common in women as men (15.1% vs 8.7%). The dierences
in height, weight, waist circumference, BMI, alcohol consumption, diabetes prevalence and arthritis
prevalence were statistically signicant (all p < 0.001).
Both measures of areal BMD were greater in men (FNBMD and LSBMD each p < 2.2 × 10−16).
Fracture incidence was greater in women (all fractures p = 1.56 × 10−11; non-vertebral fractures
p = 6.10 × 10−10).
.. Genomewide Association Analysis of Bone Mineral Density
Genomewide association analysis was performed in 868 men and 775 women with measured FN-
BMD and in 870 men and 778 women with measured LSBMD using 2,622,085 genotyped and
HapMap-imputed SNPs. Between 410,334 and 412,055 SNPs were removed to due poor imputation
quality or small minor allele frequencies, leaving between 2,210,030 and 2,211,751 SNPs available
for analysis. (Dierent numbers of SNPs were available for each analysis due to MAF dierences
among the groups.) Aer performing quality control, I calculated the genomic control ination fac-
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Table 4.1: HealthABC Population Characteristics
Men (n = 879) Women (n = 784)
Characteristic mean/n SD/% mean/n SD/% p
Age (yr)
Anthropometric
BMI (kg/m2)
Waist circumference (cm)
Height (cm)
Weight (kg)
Lifestyle
Current smoking
Alcohol (> 1drink/week)
Activity (kcal/kg/week)
Medical conditions
Hypertension
Diabetes
Cardiovascular disease
Arthritis
BMD
Femoral neck (g/cm3)
Lumbar spine (g/cm3)
Fracture Incidence
All types of fractures
Non-vertebral fractures
73.9
27.1
101.9
173.6
81.6
46
396
82.7
370
123
63
76
766.0
1079.7
109
88
2.9
3.7
11.7
6.4
12.4
5.2%
45.1%
64.9
42.1%
14.0%
7.2%
8.7%
126.4
206.0
12.4%
10.0%
73.6
26.1
96.1
159.4
66.4
60
228
85.8
356
60
60
118
650.1
913.5
199
165
2.8
4.5
12.4
5.8
12.1
7.7%
29.1%
63.5
45.4%
7.6%
7.6%
15.1%
108.7
174.3
25.4%
21.1%
0.056
4.60 × 10−8< 2.20 × 10−16< 2.20 × 10−16< 2.20 × 10−16
0.056
2.97 × 10−11
0.112
0.194
3.92 × 10−5
0.838
7.41 × 10−5
< 2.20 × 10−16< 2.20 × 10−16
1.56 × 10−11
6.10 × 10−10
SD = standard deviations
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tor λ for each analytical group and trait; these values ranged from 1.01 to 1.02, which is within the
acceptable range for GWAS studies (Table 4.2). The quantile–quantile (QQ) plots of the FNBMD
and LSBMD pooled-gender analysis are presented in Figures 4.1 and 4.2. The striking deviation
from the expected slope in the QQ plot of p values for the FNBMD analysis (Figure 4.1) is elimi-
nated when the 72 SNPs on chromosome 3p24.1 with p values ≤ 5 × 10−6 are removed; this locus
is discussed further below. Finally, I calculated the power to detect SNPs that account for 0.5% of
the residual phenotypic variance in the HealthABC cohort at two signicance levels, p ≤ 5 × 10−6
(for suggestive association) and p ≤ 5× 10−8 (for signicant association). As expected because of its
sample size, the HealthABC cohorts had low power to detect associations (Table 4.2).
Table 4.2: European American BMD Analyses
n Power*
Trait Sex Samples SNPs p = 5 × 10−8 p = 5 × 10−6 λ
FNBMD Men 868 2,211,751 0.0004 0.0066 1.02
Women 775 2,210,047 0.0003 0.0047 1.01
Pooled 1,643 2,211,517 0.0049 0.0450 1.02
LSBMD Men 870 2,211,717 0.0004 0.0066 1.02
Women 778 2,210,030 0.0003 0.0048 1.01
Pooled 1,648 2,211,496 0.0050 0.0455 1.01
*Additive model, R2 = 0.005
The results of the GWA analyses of FNBMD and LSBMD overall, and in men and women sep-
arately are presented as Manhattan plots in Figures 4.3, 4.4 and in Figures E1–E4 in Appendix E.
Of the 13,266,558 tests performed for the two BMD phenotypes examined in three groups (men,
women and pooled-gender), 192 tests of 189 SNPs in 28 loci reached the suggestive threshold of
5× 10−6. None reached the genomewide signicance threshold of 5× 10−8. Across both phenotypes
and all groups, the most signicant 26 autosomal and 2 X-chromosomal SNPs per locus are listed
in Table 4.3. Two regions, 13q33.3 and 16q21 (Figure G19 and Figures G23 and G24 respectively),
showed suggestive association with both LSBMD and FNBMD. In fact, for the 13q33.3 region, the
same SNP, rs17382033, had the minimal p value for both traits [FNBMD (p = 1.33 × 10−7) and LS-
BMD (p = 2.23 × 10−6)]. This SNP is within 80 kb of TNFSF13B, a member of the tumor necrosis
factor superfamily. In contrast, the suggestive association in the 16q21 region may be attributable
to two dierent loci 4.5 Mb apart. The SNP associated with LSBMD in men is closest to NDRG4
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Figure 4.1: QQ Plot FNBMD Pooled* Figure 4.2: QQ Plot LSBMD Pooled
* “Pooled” here refers to the pooled-gender analyses.
(N-myc downstream regulated gene family member 4), whereas the SNP associated with FNBMD
overall is closest to CDH8 (cadherin 8, type 2). A complete list of the 188 results with p values less
than 5 × 10−6 can be found Tables F1–F6 in Appendix F.
Plots of the − log10-transformed p values against the physical positions within each of the 28
loci are presented in Figures G1–G28 in Appendix G. A complete list of the 192 tests with p values
less than 5 × 10−6 can be found in Tables F1–F6 in Appendix F.
None of the 26 autosomal loci seen here overlap with the 20 loci reported by Rivadeneira et al.
[2009]. This is not surprising given my power to detect the eect sizes reported in the GEFOS study
(−0.120 < β < 0.107); there was just 13% power to detect the largest eect size (β = −0.120 for
rs9533090 [Rivadeneira et al. 2009]) associated with a SNP with a MAF of 50% at p = 5 × 10−6
with the pooled-gender sample. Additionally, dierences in genetic background and environmental
factors could account for dierences in associations between reported SNPs and the examined traits.
One way to assess whether the same or dierent genes in an associated region inuence one or
more traits (for example, the 16q21 region) is to plot all SNP associations across a region. Such plots
may also facilitate ne mapping, and perhaps identication, of possible functional SNPs. To gain
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Figure 4.3: Manhattan Plot FNBMD Pooled
Figure 4.4: Manhattan Plot LSBMD Pooled
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Table 4.3: BMD Loci – European Americans
Nearest Distance
Locus SNP Position Gene (kb) Alleles MAF Type β SE p Trait
1q23.1 rs2054993 156772592 OR6Y1 10.9 G/T 0.44 I −0.239 0.050 1.92 × 10−6 FNM
2q36.3 rs13010707 227250306 IRS1 54.0 C/T 0.13 I −0.356 0.075 2.09 × 10−6 LSM
2q37.3 rs6718108 240102747 HDAC4 115.2 A/G 0.33 G 0.252 0.055 4.98 × 10−6 LSW
3p24.1 rs11717372 27202560 NEK10 29.5 G/A 0.26 I 0.202 0.040 5.17 × 10−7 FNP
3p14.1 rs9813487 69115174 C3orf64 0.0 T/C 0.20 I 0.290 0.062 3.08 × 10−6 LSM
4p16.1 rs10804984 6700002 MRFAP1 4.7 C/A 0.32 I 0.278 0.057 1.12 × 10−6 LSW
5q14.3 rs2973839 91112451 LOC100129716 360.2 A/G 0.11 I 0.354 0.077 3.63 × 10−6 FNM
5q15 rs3909479 94813710 FAM81B 1.8 C/T 0.10 G −0.272 0.058 2.48 × 10−6 FNP
5q32 rs318373 143300064 HMHB1 119.6 T/C 0.47 G −0.248 0.053 3.09 × 10−6 LSW
6p25.1 rs736004 5067728 LYRM4 0.0 C/T 0.10 G −0.422 0.088 1.56 × 10−6 FNW
7q21.11 rs1397005 80718618 SEMA3C 332.0 A/G 0.28 G 0.271 0.059 4.26 × 10−6 LSW
7q34 rs10954649 138789091 KLRG2 0.0 C/T 0.35 G −0.247 0.052 1.87 × 10−6 FNM
8p22 rs13252590 16566118 FGF20 328.6 A/T 0.47 I 0.174 0.035 6.45 × 10−7 FNP
8p21.3 rs12114940 22104735 BMP1 0.0 T/G 0.45 G 0.173 0.036 1.71 × 10−6 FNP
8q22.1 rs278530 94279598 LOC642924 148.3 C/T 0.31 G −0.257 0.056 4.52 × 10−6 LSW
12q24.13 rs12309051 112610534 RBM19 128.4 C/T 0.33 G −0.171 0.037 4.69 × 10−6 LSP
12q24.31 rs12578256 123368433 FAM101A 1.9 T/A 0.18 I −0.296 0.063 2.33 × 10−6 LSM
13q33.1 rs640960 100560051 NALCN 0.0 C/T 0.27 G 0.295 0.058 4.26 × 10−7 LSW
13q33.3 rs17382033 107839404 TNFSF13B 80.6 C/A 0.09 G 0.329 0.062 1.33 × 10−7 FNP
14q23.1 rs1113590 61073336 PRKCH 0.0 A/C 0.09 I 0.478 0.091 1.40 × 10−7 LSW
15q14 rs16962904 34443595 C15orf41 215.5 A/G 0.33 I −0.284 0.057 7.48 × 10−7 FNW
15q25.3 rs957029 85753369 NCRNA00052 167.8 G/C 0.23 I 0.296 0.059 4.91 × 10−7 FNM
16q21 rs11076239 57038674 NDRG4 16.4 G/A 0.32 I 0.247 0.054 4.39 × 10−6 LSM
16q21 rs2962454 61494729 CDH8 866.5 G/A 0.24 G 0.191 0.040 2.33 × 10−6 FNP
19q12 rs2190800 33143105 LOC148189 166.4 T/G 0.42 G 0.229 0.049 3.21 × 10−6 FNM
19q13.11 rs8109254 37388860 ZNF507 139.5 A/C 0.05 I 0.514 0.111 3.66 × 10−6 FNM
Xp21.1 rs331360 32169468 DMD 86.0 G/A 0.23 G −0.176 0.038 3.40 × 10−6 LSM
Xq28 rs11795763 149755133 CD99L2 0.0 T/C 0.16 I −0.338 0.069 8.67 × 10−7 FNW
Alleles are given in the form: major allele/minor allele. The minor allele is modeled as the eect allele. FNP = femoral
neck BMD pooled. FNM = femoral neck BMD in men. FNW = femoral neck BMD in women. LSP = lumbar spine
BMD pooled. LSM = lumber spine BMD in men. LSW = lumber spine BMD in women. SNP types: G = genotyped; I =
imputed.
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insights into the genetic architecture of the suggestive regions of association, including information
on recombination and linkage disequilibrium, as well as associations with additional imputed SNPs,
I plotted the − log10-transformed p values for each SNP in each region against the physical posi-
tions within each of the 28 loci (Figures G1–G28 in Appendix G). Although none of these regions
obtained genomewide signicance, I present results from the 3p24.1 region to illustrate this pro-
cess. The most signicant SNP in the 3p24.1 locus is rs11717372 (Figure 4.5). This locus was also
examined in the 1000 Genomes SNP set, and the results are presented in (Figure 4.6). Seventy-one
additional HapMap SNPs in this region have p values less than 5×10−6, and all are in linkage disequi-
librium with rs11717372 (r2 > 0.834, D′ > 0.947). The nearest gene to rs11717372 is NEK10 (never
in mitosis a (NIMA)–related kinase 10), 29.5 kb distal to the SNP. The remaining correlated SNPs
stretch from this most signicant SNP to approximately the midpoint of the gene. The addition of
the 1000 Genomes SNPs does not narrow the associated region.
.. Genomewide Association Analysis of Fracture Risk
Among the 1,661 individuals for whom data were available, 308 individuals had fractures and 253
had non-vertebral fractures. Starting with a total of 2,608,508 genotyped and HapMap-imputed
SNPs available on these individuals, 368,264 SNPs were removed due to low imputation quality or
rarity, leaving 2,240,244 SNPs available for continued analysis. Genomic control ination factors
were acceptable, λ ranged from 1.00 to 1.02 (Table 4.4), and inspection of the quantile–quantile
plots of the FNBMD and LSBMD pooled analysis revealed no concerns (Figures 4.7 and 4.8). As
with the analyses of the areal BMD traits, I had limited power to detect signicant associations in
the HealthABC cohort.
The results of the GWA analyses of the all fractures and non-vertebral fractures pooled-gender
analyses are presented in Figures 4.9 and 4.10. Plots of the analyses inmen and women can be found
in Figures E5–E8 in Appendix E. Of the 13,441,464 statistical tests executed for the two denitions
of fractures examined in three sets (men, women and pooled-gender), 51 tests of 49 SNPs in 20
loci reached the suggestive threshold of 5 × 10−6. Of those, 9 tests in 9 SNPs at 1 locus reached the
genomewide signicance threshold of 5 × 10−8. All nine of these SNPs are located on 9q31.3, are in
high LD (r2 = 1) and have low MAFs of 0.062–0.064. The low MAF, and so small numbers in the
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Figure 4.5: Association between FNBMD and HapMap SNPs around rs11717372 (3p24.1)
This gure displays the SNPs between putative recombination hotspots at 27.0 Mb and 27.8 Mb. The
SNP with the lowest p value in the analysis at this locus is denoted by a purple diamond. The other
SNPs are color-coded according to correlation (HapMap Phase II CEU) with themost signicant SNP,
from red indicating 0.8 < r2 < 1.0 to dark blue indicating 0.0 < r2 < 0.2. Known genes, with their exon,
introns and orientation notes are plotted below the SNPs. HapMap recombination rates (cM/Mb) are
plotted as a blue line behind the SNPs. SNP coverage is noted by tick marks above the plot.
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Figure 4.6: Association between FNBMD and 1000 Genomes SNPs around rs11717372 (3p24.1)
This gures displays the SNPs between the same putative recombination hotspots at 27.0 Mb and
27.8 Mb as Figure 4.5. The SNP with the lowest p value in the analysis at this locus is denoted by a
purple diamond. The other SNPs are color-coded according to correlation (1000 Genomes June 2010
CEU) with the most signicant SNP, from red indicating 0.8 < r2 < 1.0 to dark blue indicating 0.0 <
r2 < 0.2. Known genes, with their exon, introns and orientation notes are plotted below the SNPs.
HapMap recombination rates (cM/Mb) are plotted as a blue line behind the SNPs. SNP coverage is
noted by tick marks above the plot.
71
Table 4.4: European American Fracture Analyses
Power at odds-ratio = 1.5
n p = 5 × 10−8 p = 5 × 10−6
Trait Sex Cases Controls SNPs 0.05* 0.25* 0.50* 0.05* 0.25* 0.50* λ
All Types Men 109 769 2,240,896 0.0000 0.0017 0.0037 0.0006 0.0201 0.0367 1.00
Women 199 584 2,240,896 0.0001 0.0098 0.0231 0.0017 0.0741 0.1340 1.00
Pooled 308 1,353 2,240,896 0.0005 0.0829 0.1697 0.0075 0.3087 0.4726 0.99
Non-Vertebral Men 88 790 2,240,896 0.0000 0.0008 0.0017 0.0004 0.0115 0.0208 1.00
Women 165 618 2,240,896 0.0000 0.0058 0.0135 0.0012 0.0506 0.0924 1.01
Pooled 253 1,408 2,240,896 0.0003 0.0457 0.0979 0.0048 0.2115 0.3419 1.00
* Minor allele frequency
Figure 4.7: QQ Plot All Fractures Pooled* Figure 4.8: QQ Plot Non-Vert. Fractures Pooled
* “Pooled” here refers to the pooled-gender analyses.
72
minor-allele homozygote class, suggests that this result may be spurious [Lam et al. 2007; Tabangin
et al. 2009]. At MAF = 0.06, just one of the fracture cases would be predicted to be homozygous.
The 20 most signicant SNPs per locus and phenotype/group are given in Table 4.5 and a complete
list of the 51 tests with p values less than 5× 10−6 can be found in Appendix F Tables F7–F12. Also,
for each of the 20 suggestive regions, plots of the − log10-transformed p values against the physical
positions for all SNPs within each of the 20 regions were made (Figures H1–H20 in Appendix H.)
None of these plots are notable, especially because none of the 28 potential candidate loci for BMD
(Table 4.3) are signicantly associated with either fracture trait (data not shown). Thus, none of the
28 potential candidate loci show clinical signicance in this analysis.
.. Replication of GEFOS Results
In the current analytical setting, I would not expect to publish results from a GWAS of the Health-
ABC cohort because of its small sample size. However, this cohort could be used for replication
and possibly ne mapping of consortium results. To this end, a total of 96,842 1000 Genomes SNPs
in 20 previously identied candidate loci [Rivadeneira et al. 2009] were tested for association with
FNBMD and LSBMD. Aer employing the same exclusion criteria described in the previous two
sections to remove poorly imputed and rare variants, 74,246 SNPs–an average of 3,712 per locus–
remained for analysis. Results of the replication analysis of the most signicant SNP at each of the
20 loci observed by Rivadeneira et al. are given in Table 4.6.
Plots of the results of the replication analysis for all 20 loci are presented in Figures I1–I20 in
appendix I. The best examples of replication are for CTNNB1 (β-catenin), ESR1 and TNFRSF11B
(Figures 4.11, 4.12 and 4.13, respectively; see also Figures I4, I7 and I10). For Figures 4.11–4.13 the
purple diamond indicates the replicated SNP rather than the most signicant SNP on the plot.
The SNP with the greatest signicance reported by Rivadeneira et al. near CTNNB1 is rs87938
for FNBMD, for which I observe a p value of 3.01 × 10−4 for LSBMD and 0.022 for FNBMD in the
HealthABC participants. Nearby SNPs show greater signicance in HealthABC, with rs62259232,
30.5 kb proximal to rs87938, giving a p value of 3.12 × 10−5 for LSBMD. Rivadeneira et al. reported
associations of both FNBMD and LSBMD with SNPs near ESR1. The peak SNP observed in that
study (rs2504063) is not signicant in HealthABC (p = 0.296 for LSBMD; p = 0.133 for FNBMD).
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Figure 4.9: Manhattan Plot All Fractures Pooled
Figure 4.10: Manhattan Plot Non-Vertebral Fractures Pooled
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Table 4.5: Fracture Loci – European Americans
Nearest Distance
Locus SNP Position Gene (kb) Alleles MAF Type OR 95%CI p Trait
2p24.1 rs7567544 20256283 SDC1 7.8 G/C 0.45 I 0.52 (0.40, 0.68) 3.10 × 10−6 AFW
2q12.2 rs7575679 106373899 PLGLA 0.0 G/A 0.13 I 2.51 (1.71, 3.70) 3.05 × 10−6 AFP
3p14.3 rs9654002 54461737 ESRG 179.5 A/C 0.37 I 2.54 (1.70, 3.79) 4.82 × 10−6 NVM
3q24 rs6809471 146615470 PLOD2 654.4 G/A 0.32 G 0.41 (0.29, 0.58) 3.11 × 10−7 AFM
4p16.1 rs6849590 7483478 PSAPL1 0.0 G/A 0.26 G 0.55 (0.44, 0.71) 2.01 × 10−6 NVP
4q34.2 rs17688188 177708053 VEGFC 133.6 G/A 0.26 I 1.82 (1.41, 2.35) 4.33 × 10−6 AFW
6p21.31 rs9368834 34968742 ANKS1A 0.0 T/G 0.11 G 2.74 (1.81, 4.14) 1.67 × 10−6 NVM
7p14.1 rs2329399 39508393 POU6F2 37.5 A/C 0.42 G 0.60 (0.49, 0.74) 3.05 × 10−6 NVP
7q36.3 rs288746 155299433 SHH 1.7 A/G 0.12 G 2.51 (1.70, 3.69) 3.26 × 10−6 NVM
8p23.1 rs4840583 11673355 NEIL2 0.0 C/T 0.46 G 1.80 (1.42, 2.29) 1.52 × 10−6 AFW
8p21.2 rs10096579 24165000 ADAM28 42.5 G/T 0.15 G 2.15 (1.56, 2.97) 2.99 × 10−6 NVW
9q31.3 rs10979528 110621948 ACTL7B 34.7 T/G 0.06 I 0.35 (0.26, 0.48) 1.61 × 10−11 NVM
10p14 rs2296734 7851413 KIN 0.0 G/C 0.43 I 0.45 (0.33, 0.61) 4.64 × 10−7 AFM
12p13.2 rs2607894 10635183 KLRAP1 0.0 G/T 0.38 G 0.43 (0.31, 0.61) 1.14 × 10−6 NVM
14q13.1 rs17100963 32932268 NPAS3 0.0 G/A 0.08 G 2.98 (1.96, 4.51) 2.71 × 10−7 AFM
15q25.3 rs7164422 84331644 AGBL1 154.6 A/G 0.06 G 3.14 (2.00, 4.93) 6.28 × 10−7 AFM
18q23 rs12955627 73834676 GALR1 723.6 T/C 0.20 I 1.77 (1.40, 2.24) 1.53 × 10−6 AFP
Xp22.2 rs4073740 12206155 FRMPD4 0.0 G/A 0.24 G 1.75 (1.39, 2.20) 1.57 × 10−6 NVM
Xq22.2 rs2983097 102552937 NGFRAP1 33.3 A/G 0.06 G 2.04 (1.54, 2.72) 9.25 × 10−7 NVP
Xq22.3 rs4893537 108857735 ACSL4 0.0 T/C 0.06 G 1.82 (1.41, 2.36) 4.99 × 10−6 NVP
Alleles are given in the form:major allele/minor allele. Theminor allele ismodeled as the eect allele. AFP = all fractures
pooled. AFM = all fractures in men. AFW = all fractures in women. NVP = non-vertebral fractures pooled. NVM =
non-vertebral fractures in men. NVW = non-vertebral fractures in women. SNP types: G = genotyped; I = imputed.
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Table 4.6: Replication Analysis of GEFOS BMD SNPs in HealthABC
Nearest Distance GEFOS HealthABC FNBMD HealthABC LSBMD
Locus SNP Gene (kb) Trait β β SE p β SE p
1p36.12 rs7524102 ZBTB40 79.9 LSBMD 0.094 0.042 0.044 3.41 × 10−1 0.060 0.055 2.77 × 10−1
1p31.3 rs1430742 GPR177 14.1 LSBMD 0.105 0.005 0.041 9.12 × 10−1 0.065 0.061 2.83 × 10−1
2p16.2 rs11898505 SPTBN1 0.0 LSBMD 0.067 0.048 0.038 2.01 × 10−1 −0.003 0.050 9.51 × 10−1
3p22.1 rs87938 CTNNB1 103.3 FNBMD −0.070 −0.077 0.034 2.16 × 10−2 −0.140 0.039 3.01 × 10−4
4q22.1 rs1471403 MEPE 7.3 LSBMD 0.068 0.038 0.037 3.01 × 10−1 −0.014 0.048 7.68 × 10−1
5q14.3 rs1366594 MEF2C 176.1 FNBMD −0.085 −0.074 0.033 2.57 × 10−2 −0.013 0.043 7.53 × 10−1
6q25.1 rs2504063 ESR1 36.1 LSBMD −0.078 −0.054 0.036 1.33 × 10−1 −0.044 0.042 2.96 × 10−1
7p14.1 rs1524058 STARD3NL 81.7 LSBMD −0.070 −0.067 0.035 5.86 × 10−2 −0.133 0.047 4.67 × 10−3
7q21.3 rs7781370 FLJ42280 0.7 FNBMD −0.083 −0.066 0.036 6.63 × 10−2 −0.037 0.046 4.25 × 10−1
8q24.12 rs2062377 TNFRSF11B 43.0 LSBMD 0.094 0.134 0.034 8.72 × 10−5 0.114 0.047 1.51 × 10−2
11p15.2 rs7117858 SOX6 293.5 FNBMD 0.088 0.080 0.043 5.91 × 10−2 0.048 0.056 3.96 × 10−1
11p13 rs16921914 DCDC5 73.4 LSBMD 0.077 0.008 0.039 8.36 × 10−1 0.056 0.047 2.36 × 10−1
11p11.2 rs7932354 ARHGAP1 0.1 FNBMD 0.073 0.031 0.041 4.47 × 10−1 −0.017 0.053 7.50 × 10−1
11q13.2 rs599083 LRP5 0.0 LSBMD −0.067 −0.074 0.037 4.63 × 10−2 −0.091 0.046 4.88 × 10−2
12q13.13 rs2016266 SP7 0.0 LSBMD 0.070 0.011 0.038 7.71 × 10−1 0.075 0.045 9.48 × 10−2
13q14.11 rs9533090 AKAP11 54.0 LSBMD −0.120 0.009 0.035 8.00 × 10−1 −0.003 0.049 9.49 × 10−1
16q24.1 rs10048146 FOXL1 95.4 LSBMD −0.093 −0.041 0.044 3.54 × 10−1 −0.034 0.059 5.68 × 10−1
17q21.31 rs228769 HDAC5 0.0 FNBMD 0.081 0.110 0.043 1.09 × 10−2 0.108 0.053 4.12 × 10−2
17q21.31 rs9303521 CRHR1 56.4 LSBMD −0.068 0.043 0.036 2.31 × 10−1 0.003 0.044 9.39 × 10−1
18q21.33 rs884205 TNFRSF11A 1.4 LSBMD −0.078 −0.029 0.040 4.72 × 10−1 −0.012 0.053 8.27 × 10−1
The trait and β for each SNP as reported by GEFOS [Rivadeneira et al. 2009] are given for comparison. The same eect
alleles that were used in the GEFOS models were also used here.
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However, a cluster of SNPs 190 kb centromeric to this reported SNP have much lower p values; the
minimum p value is 1.54×10−5 for FNBMD. SNPs near TNFRSF11Bwere also associated with both
FNBMD and LSBMD in the report by GEFOS. The most signicant SNP rs2062377 also showed
good evidence of association in the HealthABC participants, but just for FNBMD (p = 8.72× 10−5)
and not LSBMD (p = 0.015). rs6469792, 1 kb distal to rs2062377 wasmore signicant inHealthABC
at p = 1.45 × 10−5 for FNBMD.
. DISCUSSION
.. Association with Bone Mineral Density
In agnostic tests of association between two measures of bone mineral density and genomewide
markers in the HealthABC cohort, 27 loci were identied as suggestive based upon a p value thresh-
old of 5×10−6. However, no SNPs reached genomewide signicance (5×10−8) and none of these 27
loci overlap with previously identied loci for either BMD or osteoporosis [e.g., Rivadeneira et al.
2009]. Given the low power of this study to detect previously reported eect sizes, this result is not
entirely surprising. The eect sizes reported by Rivadeneira et al. [2009] range from −0.120 to 0.107
(< 0.7% of the residual variance). This study had 13% power to detect the extremes of that range at
p = 5 × 10−6. A sample of 4,045 would be necessary to detect this eect size with 80% power (MAF= 0.5, β = −0.120). Dierences in the genetic background and in environmental factors could also
result in the lack of association between reported SNPs and traits. Nonetheless, a few of the results
are potentially interesting.
The most promising locus of suggestive signicance is on 3p24.1 (p = 5.17 × 10−7 for FNBMD
(Figure 4.6). A previously identied candidate region lies on 3p22.1, with CTNNB1 as the high-
lighted gene in that region [Rivadeneira et al. 2009]. This locus, however, lies 13.9 Mb distal to
region with the lowest p value in the HealthABC cohort, and it is unlikely that the HealthABC sug-
gestive SNPs, which lie between recombination hotspots at 27.0 Mb (r = 30.3 cM/Mb) and 27.8 Mb
(r = 54.7 cM/Mb), are showing association with causal variants in the region around CTNNB1. The
association signals in the HealthABC cohort are closer to the NEK10 locus. NEK10 encodes NIMA
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Figure 4.11: Association between LSBMD and 1000 Genomes SNPs around CTNNB1 (3p22.1)
This gures displays the SNPs within a 2 Mb window centered on rs87938, which is denoted by a
purple diamond. The other SNPs are color-coded according to correlation (1000 Genomes June 2010
CEU) with the most signicant SNP, from red indicating 0.8 < r2 < 1.0 to dark blue indicating 0.0 <
r2 < 0.2. Known genes, with their exon, introns and orientation notes are plotted below the SNPs.
HapMap recombination rates (cM/Mb) are plotted as a blue line behind the SNPs. SNP coverage is
noted by tick marks above the plot.
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Figure 4.12: Association between FNBMD and 1000 Genomes SNPs around ESR1 (6q25.1)
This gures displays the SNPs within a 2 Mb window centered on rs2504063, which is denoted by a
purple diamond. The other SNPs are color-coded according to correlation (1000 Genomes June 2010
CEU) with the most signicant SNP, from red indicating 0.8 < r2 < 1.0 to dark blue indicating 0.0 <
r2 < 0.2. Known genes, with their exon, introns and orientation notes are plotted below the SNPs.
HapMap recombination rates (cM/Mb) are plotted as a blue line behind the SNPs. SNP coverage is
noted by tick marks above the plot.
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Figure 4.13: Association between FNBMD and 1000 Genomes SNPs around TNFRSF11B (8q24.12)
This gures displays the SNPs within a 2 Mb window centered on rs2062377, which is denoted by a
purple diamond. The other SNPs are color-coded according to correlation (1000 Genomes June 2010
CEU) with the most signicant SNP, from red indicating 0.8 < r2 < 1.0 to dark blue indicating 0.0 <
r2 < 0.2. Known genes, with their exon, introns and orientation notes are plotted below the SNPs.
HapMap recombination rates (cM/Mb) are plotted as a blue line behind the SNPs. SNP coverage is
noted by tick marks above the plot.
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(never in mitosis a)–related kinase 10 (Nek10). Nek10 is a mediator of G2/M cell cycle arrest aer
ultraviolet irradiation [Moniz and Stambolic 2010] and variants in this locus have been associated
with breast cancer risk [Ahmed et al. 2009].
Amore promising candidate gene, located just 3.3 kb distal toNEK10, is SLC4A7, which encodes
solute carrier family 4, sodium bicarbonate cotransporter, member 7, also known as sodium bicar-
bonate cotransporter 3 (NBC3) [Pushkin et al. 1999] or electroneutral sodium bicarbonate cotrans-
porter (NBCn1) [Aalkjær andHughes 1991; Choi et al. 2000]. Two SNPs with p values of 1.85×10−5
and 5.58 × 10−5 in the 1000 Genomes imputed data are located within the 3′-untranslated region
(UTR) of SLC4A7 (rs41295960 and rs41276515, SLC4A7:c.*1076A>G and SLC4A7:c.*1525A>G re-
spectively). No other SNPs with p values less than 10−4 are located within the annotated transcrip-
tion region, but one SNP, rs9871261 (p = 1.98 × 10−4), lies 31.6 kb upstream of the SLC4A7 tran-
scription start site. NCBn1 is expressed in osteoclasts [Bouyer et al. 2006], the cells that resorb bone
during bone remodeling. Indeed, it has been localized to the rued border of the cell that faces the
resorptive cavity and has been shown to be necessary for hydroxyapatite degradation [Riihonen et al.
2010]. This protein has also been reported to reside in the membranes of matrix vesicles budding
from osteoblast-like cells [Thouverey et al. 2011], although Riihonen et al. did not see evidence of
its presence in osteoblasts.
Slc4a7 has also been knocked-out in mice, and these animals exhibited blindness and auditory
impairment similar to Usher syndrome [Bok et al. 2003]. No skeletal abnormalities were noted, but
they probably were not assessed for, given the presence of the other severe impairments. If silencing
of Slc4a7 results in decient osteoclast activity, the resulting skeletal phenotype would presumably
be osteopetrosis, similar to that seen in op/opmice [Marks and Lane 1976]. op/opmice have a mu-
tation in Csf1 [Yoshida et al. 1990], the gene encoding colony stimulating factor-1 (CSF-1), which
together with receptor activator of nuclear factor κB ligand (RANKL) is necessary for osteoclasto-
genesis.
Although there are no reports of association of variants in the SLC4A7 locus with BMD, the
recent evidence of its function in osteoclasts and osteoblasts combinedwith the association observed
in the HealthABC European Americans makes this an excellent candidate gene for additional work.
Because none of the functional variation in SLC4A7 shows evidence of association with variation in
BMD, it is likely that the association is not due to variation in the protein’s function as a consequence
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of changes to its amino acid sequence, but rather due to variation in regulation of its expression.
Also, if this locus truly does inuence variation in areal BMD, the eect size observed—1.6% of the
residual variance—is probably overestimated due to the winner’s curse, and this could be one reason
for why it hasn’t been observed in other GWAS.
Prior to publishing this result, a necessary rst step is replication in another, similar population,
such as the Study of Osteoporotic Fractures (SOF) in women or the Osteoporotic Fractures in Men
(MrOS) Study, to reduce the likelihood of type I error. Although testing for replication in a similar
population increases the probability of detecting true signals, replication in a population with a
dierent linkage disequilibriumpattern could aid in narrowing the region of association, if the signal
is present. Functional studies could also be useful in determining the impact of these variants on
NBCn1 expression, bone resorptive activity, osteoclast survival and osteoclast intracellular pH.
In summary, although SLC4A7 is a highly plausible biological candidate gene, it remains possi-
ble that NEK10 is the true source of the signal in this region and that we are simply ignorant of its
role in aecting bone mineral density.
Two additional promising candidate genes include BMP1 (bone morphogenetic protein 1) on
8p21.3 and PRKCH (protein kinase C η; PKCη) on 14q23.1. BMP1 has long been known to be
involved in ossication [Wozney et al. 1988; Hopkins et al. 2007] and has recently been shown to
heighten bone repair in rats and rabbits and increase formation ofmineralized bone in vitro [Grgure-
vic et al. 2011]. Much less is known about the involvement of PKCη in bone metabolism. However,
increased expression was correlated with increased osteocalcin and bone sialoprotein expression
and alkaline phosphatase activity in dierentiating osteoblastic cells Lampasso et al. [2006], and
PRKCH was recently proposed as a candidate gene in a report of a GWAS data-mining study of
multiple bone strength traits [Gupta et al. 2011].
In considering associated markers, it is nature to initially focus on the nearest genes. However,
it is necessary to remember that putative regulatory variants (expression quantitative trait loci or
eQTLs) might not aect a nearby gene (cis-eQTLs), but could aect genes at a distant site in the
genome (trans-eQTLs) [Nicolae et al. 2010; Cox et al. 2010; Below et al. 2011].
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.. Association with Fracture Incidence
Genomewide tests for association with two denitions of fracture incidence, identied 17 potential
loci with p values < 5 × 10−6. However, none of the 17 loci associated with either fracture trait
in the HealthABC cohort overlap with the 20 candidate loci revealed by the GEFOS Consortium
[Rivadeneira et al. 2009] (see also Table 4.6). Interestingly, nine SNPs–all in high LD (r2 = 1) in
one locus had p values < 5 × 10−8. Further inspection revealed that all of these SNPs had minor
allele frequencies less than 0.064. These SNPs are located on 9q31.3. None of the other SNPs in the
region showed any evidence of association (Figure H12). Therefore, this observation is probably a
false positive due to small sample size and low allele frequency. We had 47% power to detect an
odds ratio of 1.5 with an allele frequency of 0.5 in the pooled-gender “all types of fracture” analysis.
Given that many GWAS have reported odds ratios less than this, the Health ABC cohort is severely
underpowered as a stand-alone study, but has contributed to a large consortium meta-analysis.
Nevertheless, a few of the suggestive loci for fracture risk in the HealthABC cohort have some
skeletal involvement. SNP rs6809471 on 3q24 (Figure H4) is 650 kb away from PLOD2, a gene
that encodes procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2.Homozygousmutations inPLOD2
have been shown to cause Bruck syndrome [van der Slot et al. 2003; Ha-Vinh et al. 2004], a disorder
that includes osteogenesis imperfecta [McPherson and Clemens 1997]. rs17688188 on 4q34.2 (Fig-
ure H6) near VEGFC showed association at p = 4.33× 10−6. It was the only SNP in this region with
p < 5 × 10−6. VEGFC has been observed to increase in expression and to increase bone resorption
in RANKL-stimulated mouse cells [Zhang et al. 2008].
rs288746 on 7q36.3 (Figure H9) is 1.7 kb upstream of SHH (sonic hedgehog). Sonic hedgehog
is an important cytokine in organ morphogenesis, and disruption of Shh in mice results in, among
other things, absence of the vertebral columnand ventral portion of the ribs [Chiang et al. 1996]. The
association observed here, however, is with non-vertebral fractures. Finally, two SNPs, rs12964230
and rs12955627 (Figure H17), are associated with non-vertebral fractures (p = 2.41 × 10−6) and all
types of fractures (p = 1.53 × 10−6) respectively, and are located 661.9 kb and 723.6 kb downstream
respectively of GALR1 (galanin receptor-1). Galanin, a neuropeptide, is upregulated in fractured
bones of rats, and both galanin- and GALR1-like immunoreactivity was present in the fracture cal-
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lus [McDonald et al. 2003]. McDonald et al. [2007] also showed that galanin can promote bone
formation aer fracture.
Although the statistical power in this study is poor, follow up studies of these regions could yield
important insights into fracture risk.
.. Replication of Prior GEFOS Results
I examined twenty previously identied candidate loci for LSBMD and FNBMD from Rivadeneira
et al. [2009]. Although many of the loci cited therein, such as LRP5, ESR1 and TNFSF11 have long
been associated with skeletal tissue and bone mineral density and so hardly require validation from
this study, it is interesting to see how these loci replicate in my sample of 1,663 men and women.
None of the loci showed association with either LSBMD or FNBMD in the HapMap SNP set at
p < 5×10−6. Targeted examination with the 1000 Genomes SNP set showed evidence of association
with two of the genes, CTNNB1, ESR1 TNFRSF11B, all of which are well known to be associated
with bone formation.
... CTNNB (β-catenin) A total of 2,908 SNPs were examined at this locus (Figure 4.11),
and three SNPs (rs62259232, rs391459 and rs419918) located 124.4 kb upstream of CTNNB1 have
p values ≤ 10−4. Although none of the variants had p values less than the Bonferroni–corrected
p = 1.72 × 10−5, because of the LD among the SNPs, this correction is likely overly conservative.
CTNNB1 is the gene for β-catenin, a member of the canonical Wnt signaling pathway. β-catenin is
essential (1) for dierentiation of progenitor cells into osteoblasts during embryogenesis [Day et al.
2005; Hill et al. 2005] and (2) in bone remodeling because it negatively regulates osteoprotegerin
expression in osteoblasts [Glass et al. 2005]. Despite its plausibility as a candidate gene, Rivadeneira
et al. [2009] were the rst to observe an association between variants near this gene and variation in
bone mineral density. Candidate gene studies of bone mineral density in postmenopausal Korean
women [Lee et al. 2010] and spinal fractures in Slovenians [Mencej-Bedrač et al. 2009] failed to
observe an association.
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... ESR (estrogen receptor ) A total of 4,275 SNPswere examined at this locus (Figure 4.11).
Nine SNPs had p values ≤ 10−4 across a 20 kb region located 217 kb–100 kb (depending on the tran-
script) upstreamofESR1. Examining Figures 4.12 and I7 reveals two potential signals at this locus on
either side of a 40 cM/Mb recombination peak. Rivadeneira et al. [2009] observed this as well, with
genomewide signicant signals at both locations. Styrkarsdottir et al. [2008] reported associations
between both FNBMD and LSBMD and several uncorrelated SNPs and suggest that at least three
association signals reside in this region. The SNPs seen in this study lie in the 5′-anking region of
ESR1, which has multiple promoters and transcript variants [Koš et al. 2001], and could therefore
inuence expression [Styrkarsdottir et al. 2008]. Sequence variations in ESR1 has been reported to
be associated with BMD and/or fracture risk in many studies [e.g., Ioannidis et al. 2002; Lei et al.
2010] including recent GWA studies of FN and LSBMD [Styrkarsdottir et al. 2008, 2009]. Estrogen
has long been known play a role in bone metabolism [Turner et al. 1994; Prince 1994].
... TNFRSFB (tumor necrosis factor receptor superfamily, member b; osteoprotegerin)
At the TNFRSF11B locus that encodes osteoprotegerin (OPG), 3,856 SNPs were examined (Fig-
ure 4.13) of which 61 SNPs had p values < 10−4. Again, none of the SNPs had a p value less than the
Bonferroni–corrected p-value of 1.30×10−5. The most signicant SNP (rs6469792) has a p value of
1.45 × 10−5, but, as stated above, this p value is too conservative. OPG acts as a decoy receptor for
RANKL [Sheikh and Fornace 2000; Shin et al. 2008], preventing RANKL from binding to RANK
and inhibiting osteoclastogenesis [Simonet et al. 1997]. Associations between variants in the TN-
FRSF11B region, in addition to being reported by Rivadeneira et al. [2009], have also been observed
for bone mineral density by Styrkarsdottir et al. [2008], Richards et al. [2008] and Hsu et al. [2010].
.. General Conclusions
Of the 20 previously identied candidate genes that inuence areal BMD of the lumbar spine and
femoral neck in European Americans, three of them, CTNNB1, ESR1 and TNFRSF11B were tenta-
tively replicated in my analysis of the HealthABC cohort using the 1000 Genomes SNP set. These
results are not unexpected because of the lack of power due to sample size given the estimated ef-
fect sizes. Additionally dierences between HealthABC and the samples in the meta-analysis due
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to dierent study ascertainment schemes as well as dierences in environmental factors between
the United States and Europe could lead to failures to replicate many of the prior studies results.
Nevertheless, due to the nature of the HealthABC sample, which is a uniform older healthy popula-
tion, I might have an enhanced ability to observe associations as compared to a larger meta-analysis
composed of studies which have dierent objectives and ascertainment biases.
Despite the limitations of performing aGWAS in the relatively small HealthABC cohort, I identi-
ed several potentially interesting candidate genes, especially SLC4A7, BMP1 and PRKCH for BMD
and PLOD2,VEGFC, SHH andGALR1 for fracture risk. Additional association studies are necessary
to validate these ndings in other populations. If these genes are replicated, functional studies could
be performed to determine the biological nature of the impact of variants observed in the genes on
bone mineral density and fracture risk.
86
. GENOMEWIDE ASSOCIATION STUDY IN AFRICAN AMERICANS
. INTRODUCTION
Thirteen genomewide association studies (GWAS) of bone mineral density (BMD) and four of os-
teoporosis have been conducted to date, but only two included individuals of African ancestry and
in both studies, data on African ancestry individuals were used as a replication [Xiong et al. 2009;
Koller et al. 2010]. Koller et al. and Ichikawa et al. [2010] examined femoral neck and lumbar spine
bone mineral density in 512 pre-menopausal African American women as a replication of single
nucleotide polymorphisms (SNPs) identied as part of genomewide scan in European American
women from Indiana, and also as a replication of genes identied from the large Genetic Factors for
Osteoporosis (GEFOS) Consortium study [Rivadeneira et al. 2009]. They reported replication of
SNPs in ESR1 (estrogen receptor 1), SP7 (Sp7 transcription factor; osterix), and a chromosome 4 in-
tergenic region. Xiong et al. [2009] examined lumbar spine BMD (LSBMD) and femoral neck BMD
(FNBMD) in 908 Tobagonian men of West African ancestry—subjects drawn at random from the
Tobago Bone Health Study (TBHS) that I examined in Chapter 2. Again, data on the African ances-
try individuals were used to replicate results from a GWAS performed in European ancestry U.S.
subjects. The investigators report that polymorphisms in two genes,ADAMTS18 (a disintegrin-like
and metallopeptidase domain–containing protein 8) and TGFBR3 (transforming growth factor, β
receptor III), were replicated across multiple ethnic group. Two additional GWAS, one for bone
mineral density [Kung et al. 2011] and one for osteoporosis [Guo et al. 2010a] have been conducted
using subjects of non–European descent—in these cases, Chinese fromHongKong (Kung et al.) and
Xı¯’a¯n and Chángsha¯ (Guo et al.). Therefore, no GWAS have been performed using data from indi-
viduals with African ancestry in the “discovery” cohort. Measures of several bone related traits vary
among ethnic groups. For example, areal femoral neck BMD is higher amongmen and women with
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African ancestry versus those with European ancestry [Wang et al. 2007b]. Furthermore, areal and
volumetric BMD as highly heritable in all ethnic groups. Therefore GWA studies in non–European
populations are necessary to gain a complete account of human variation inuencing BMD and
susceptibility to osteoporosis.
In the current report, I present results from the rst genomewide association study in which
African Americans are the discovery cohort, although I recognize that the sample size is small for a
GWAS. These results will be compared with the results of the GWAS conducted in the Dynamics of
Health, Aging and Body Composition (HealthABC) Study European Americans that was explored
in Chapter 4, the results of the GEFOS study of areal BMD [Rivadeneira et al. 2009], as well as the
results of the phenotype and linkage analyses inAfro-Caribbeans inChapters 2 and 3. These compar-
isons could provide insights regarding similar and disparate eects of common variants among the
dierent population groups. Finally, I use the data on African Americans to assess whether results
from the GWAS of European ancestry individuals are replicated among the African American.
. METHODS
.. Study Population
The HealthABC Study is a longitudinal study of African and European Americans (see also Chap-
ters 1 and 4). In the current study, phenotype and genotype data on 1,139 African Americans were
analyzed (651 women and 488 men). The institutional review boards at both the University of Pitts-
burgh and the University of Tennessee approved the study, and all participants gave written, in-
formed consent.
.. Phenotype Denitions
As described in Section 1.5.2.1, areal BMD was measured using dual-energy x-ray absorptiome-
try (DXA) at the proximal femur and the whole body. Measures of FNBMD were available in 480
African American men and 647 African American women, and measures of LSBMDwere available
in 483 African American men and 647 African American women.
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.. Genotyping and Imputation
Genotyping was performed by the Center for InheritedDisease Research (CIDR) using the Illumina
Human1M-Duo BeadChip system. Quality control protocols were identical to those described in
Chapter 4; samples were excluded for low call rate (< 97% SNPs genotyped), mismatch between
reported and chromosomal sex, and rst degree relatedness. 1,151,215 SNPs were successfully geno-
typed in 1,139AfricanAmerican individuals. SNPs with anMAF > 1%, a call rate > 97% and aHWE
test p value > 10−6 were used for imputation. A total of 3,021,329 SNPs were ultimately available for
analysis in the African Americans. Imputation was performed by Yongmei Liu and Kurt Lohman at
Wake Forest University using MACH 1.0.16 [Li et al. 2010b] and the HapMap II phased haplotypes
[Frazer et al. 2007] as the reference.
.. Statistical Analyses
... Association analysis methods The statistical methods used in the analysis of data from
the African American cohort from HealthABC are identical to those described in Section 4.2.5.
Briey, prior to performing association analyses, residuals of each untransformed BMD trait were
calculated separately in men and women, and these residuals were combined for the pooled-gender
analyses. To be consistent with results obtained on European American in HealthABC (see Chap-
ter 4) and other reported studies, the following covariates were included in the model: age, age
squared, weight, clinical center and ancestry principal components (PCs). Linear regression of the
residuals was performed using data from the HapMap SNP set separately in men and in women
as well as in the both sets of residuals pooled together. Regression was performed using ProbA-
BEL using the option to calculate robust (sandwich) standard errors. To remove poorly inferred
genotypes and rare variants, GWA results were ltered for imputation quality (r2 > 0.3) and minor
allele frequency (MAF > 5%). Genomic control ination factors were calculated for each of the
analysis groups. Unless stated otherwise, all analyses were performed using the statistical comput-
ing routines, R 2.11.1 [R Development Core Team 2008]. The p value thresholds for signicant and
suggestive results were 5× 10−8 and 5× 10−6, respectively, identical to those used in Chapter 4. Like-
wise, “associated loci” were dened as the regions 1 Mb up- and downstream of SNPs with the most
signicant p values (“peak SNPs”).
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... Power to detect genomewide association in the HealthABC African American cohort
Power was calculated using QUANTO 1.2.4 [Gauderman and Morrison 2006]. For BMD, power
was estimated for an additive genetic model of the SNP genotypes, in which the SNP genotypes
accounted for 0.5% of the residual variation of the trait at the two GWA levels of signicance.
... Replication and nemapping In addition to the GWAanalyses of FNBMDand LSBMD,
I also tested whether any of the 26 autosomal loci identied in the GWAS of the EuropeanAmerican
cohort ofHealthABC (Chapter 4) or whether any of the 20 loci identied by theGEFOSConsortium
[Rivadeneira et al. 2009] were associated with FNBMD or LSBMD in African Americans. The most
signicant SNP at each locus was taken as the midpoint of a 2 Mb region.
. RESULTS
.. Subject Characteristics
Characteristics of the African American subjects in the HealthABC study are presented in Table 5.1
and dierences between men and women were assessed using t tests (for normal quantitative data),
Wilcoxon rank sum tests (for non-normal quantitative data) and χ2 statistics (for frequency data).
Women and men in the study had similar ages (73.4 vs 73.5 years, respectively), activity levels
(76.0 kcal/kg/week vs 79.8 kcal/kg/week, respectively), as well as rates of diabetes and cardiovas-
cular disease (21.1% vs 22.6% and 8.9% vs 8.3%, respectively). As expected, men were signicantly
taller and heavier (173 cm vs 160 cm), but women had higher BMIs (29.6 kg/m2 vs 27.2 kg/m2), all
p values < 0.001. More men than women consumed alcohol (26.9% vs 10%) and smoked (21.4% vs
12.8%), both p values < 0.001. More than 505 of all individuals had been diagnosed with hyperten-
sion, but the frequency was signicantly higher in women than men (63.7% vs 57.0%, respectively).
The frequency of arthritis in women was more than twice that in men (12% vs 52%). As expected,
both measures of LSBMD and FNBMD were greater in men than in women (both p < 2.2 × 10−16).
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Table 5.1: HealthABC Population Characteristics
Men (n = 488) Women (n = 651)
Characteristic mean/n SD/% mean/n SD/% p
Age (yr)
Anthropometric
BMI (kg/m2)
Waist circumference (cm)
Height (cm)
Weight (kg)
Lifestyle
Current smoking
Alcohol (> 1drink/week)
Activity (kcal/kg/week)
Medical conditions
Hypertension
Diabetes
Cardiovascular disease
Arthritis
BMD
Femoral neck (g/cm3)
Lumbar spine (g/cm3)
73.5
27.2
99.4
173.0
81.5
104
131
79.8
278
110
41
25
849.2
1152.2
2.8
4.4
12.5
7.0
14.6
21.4%
26.9%
78.8
57.0%
22.6%
8.3%
5.2%
141.7
234.3
73.4
29.6
101.0
159.6
75.4
83
65
81.7
415
137
58
78
751.1
993.7
3.0
5.8
14.7
6.5
15.5
12.8%
10.0%
76.0
63.7%
21.1%
8.9%
12.0%
131.2
193.2
0.341
1.99 × 10−13
0.144< 2.20 × 10−16< 2.20 × 10−16
1.62 × 10−4
1.81 × 10−13
0.064
4.64 × 10−4
0.581
0.824
1.36 × 10−4
< 2.20 × 10−16< 2.20 × 10−16
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.. Genomewide Association Analysis of Bone Mineral Density
Genomewide association analysis was performed in 1,130 African ancestry men and women with
BMD data using 3,021,329 genotyped and HapMap-imputed SNPs. Between 561,887 and 568,273
SNPs were excluded to due poor imputation quality (r2 < 0.3) or small minor allele frequencies
(MAF < 0.05), leaving between 2,453,056 and 2,459,442 SNPs available for association analyses.
(Dierent numbers of SNPs were available for each analysis due to MAF dierences among the
groups.) The genomic control ination factor λ ranged from 1.01 to 1.03 (Table 5.2) and quantile-
quantile plots of the FNBMDandLSBMDpooled analysis are presented in Figures 5.1 and 5.2. These
results indicate that p values from GWAS analyses on the pooled-gender data are not likely to be
inated. On the other hand, p values fromGWA analyses performed in African American men and
women separately appear to be inated (see Figures D9 and D12 in Appendix D). Because results
of the GWA analyses performed in men and women separately are likely to be biased, I discuss the
results of the pooled-gender data only.
Table 5.2: African American BMD Analyses
n Power*
Trait Sex Samples SNPs p = 5 × 10−8 p = 5 × 10−6 λ
FNBMD Men 480 2,454,508 0.0000 0.0013 1.03
Women 647 2,459,452 0.0001 0.0029 1.01
Pooled 1,127 2,458,958 0.0011 0.0143 1.01
LSBMD Men 483 2,453,586 0.0000 0.0013 1.01
Women 647 2,453,068 0.0001 0.0029 1.02
Pooled 1,130 2,459,339 0.0011 0.0145 1.01
*Additive model, R2 = 0.005
Results of the GWA analyses of FNBMD and LSBMD in men and women combined (pooled-
gender) are presented as Manhatten plots in Figures 5.3 and 5.4. Of the 14,738,911 statistical tests
performed in the analyses of FNBMD and LSBMD in the pooled-gender sample, 44 SNPs in 24
loci (or regions) reached the genomewide suggestive threshold of 5 × 10−6 although none reached
the GWAS signicance threshold 5 × 10−8 (Table 5.3). For most of the loci, it is a single SNP that
crosses the suggestive threshold, even near genes known to be part of bone-related pathways like
PTH (parathyroid hormone). On the other hand, one of the loci with multiple (although highly
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Figure 5.1: QQ Plot FNBMD Pooled* Figure 5.2: QQ Plot LSBMD Pooled
* “Pooled” here refers to the pooled-gender analyses.
correlated) SNPs showing suggestive evidence of association, lies in a large intergenic region with
the nearest gene (LRRC4C, leucine rich repeat containing 4C) 1.5 Mb away (Figure 5.5).
.. Replication of Results from European American GWAS
One of the potentially most interesting results from the GWAS performed in European Americans
in HealthABC (Chapter 4), was the the association of FNBMDwith SNPs near SLC4A7. Analysis of
SNPs within the SLC4A7 region and FNBMDand LSBMD inAfrican Americans inHealthABCwas
performed to potentially replicate this result. No polymorphisms in or near SLC4A7, had p value
less than 10−6 for either trait in the pooled-gender group (data not shown). However, a modest
association between these SNPs and FNBMD in men occurs between 27 Mb and 27.6 Mb on chro-
mosome 3 (gure 5.6). The peak SNP (rs9867945;NEK10:363−5169C>T; SLC4A7:c.*49333C>T) is
associated at p = 1.07 × 10−5.
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Figure 5.3: Manhattan Plot FNBMD Pooled-Gender – African Americans
Figure 5.4: Manhattan Plot LSBMD Pooled-Gender – African Americans
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Table 5.3: BMD Loci – African Americans
Nearest Distance
Locus SNP Position Gene (kb) Alleles MAF Type β SE p Trait
1q25.3 rs2281415 183659468 IVNS1ABP 106.4 C/T 0.26 G 0.234 0.051 4.69 × 10−6 LSP
2p21 rs13408008 47519201 MSH2 0.0 T/G 0.08 I −0.341 0.075 4.86 × 10−6 LSP
2q32.1 rs6712733 188501483 GULP1 364.2 T/G 0.25 G 0.236 0.051 3.68 × 10−6 LSP
3q27.3 rs10937334 189237130 LOC339929 114.6 C/T 0.14 I −0.267 0.058 4.34 × 10−6 LSP
7p21.3 rs7794562 9671676 PER4 29.7 T/C 0.17 I −0.277 0.056 7.86 × 10−7 LSP
8p23.2 rs10216608 3032465 CSMD1 0.0 A/T 0.09 I −0.368 0.074 6.10 × 10−7 FNP
8q21.11 rs16939006 76043194 CRISPLD1 16.1 T/C 0.46 G 0.190 0.042 4.87 × 10−6 FNP
9p24.3 rs2279986 1032284 DMRT2 8.1 G/T 0.40 G −0.210 0.045 2.38 × 10−6 FNP
10p15.3 rs2813457 1562799 NCRNA00168 0.0 C/T 0.07 I −0.345 0.072 1.40 × 10−6 LSP
10q21.1 rs12241361 59279878 IPMK 341.4 C/T 0.19 I 0.282 0.057 8.64 × 10−7 LSP
10q22.3 rs16935728 79663373 RPS24 176.8 G/T 0.11 I −0.345 0.068 4.16 × 10−7 LSP
11p15.3 rs12417203 11429804 CSNK2A1P 98.3 T/G 0.23 G −0.226 0.047 1.90 × 10−6 FNP
11p15.2 rs11605876 13516168 PTH 42.0 G/C 0.20 I −0.256 0.053 1.40 × 10−6 LSP
11p12 rs10501203 38592016 LRRC4C 1500.3 A/T 0.20 I 0.261 0.056 2.66 × 10−6 LSP
11q22.1 rs10894988 99969329 ARHGAP42 94.3 G/A 0.18 I −0.264 0.056 2.05 × 10−6 LSP
15q21.2 rs2305709 49762877 SCG3 0.0 C/A 0.05 I 0.465 0.097 1.70 × 10−6 FNP
17p13.2 rs758641 3793551 ATP2A3 0.0 A/G 0.39 G −0.239 0.045 1.10 × 10−7 LSP
17q22 rs17745091 50293796 TOM1L1 39.3 T/C 0.21 I −0.238 0.051 3.72 × 10−6 LSP
17q24.3 rs9898716 67428011 SOX9 200.7 A/C 0.14 I −0.290 0.061 2.32 × 10−6 FNP
18q12.2 rs16967627 32092618 MOCOS 0.0 C/T 0.06 I −0.380 0.082 3.11 × 10−6 FNP
18q22.1 rs12607377 62565126 CDH19 142.9 T/C 0.08 I −0.298 0.065 3.97 × 10−6 LSP
19q13.11 rs10412883 39096596 KCTD15 98.1 G/A 0.09 I −0.378 0.076 7.68 × 10−7 LSP
19q13.32 rs10404733 51450642 IGFL1 24.3 A/C 0.21 I −0.308 0.061 4.39 × 10−7 LSP
21q22.11 rs2834247 33978599 ITSN1 0.0 G/A 0.11 I −0.326 0.068 1.94 × 10−6 LSP
Alleles are given in the form: major allele/minor allele. The minor allele is modeled as the eect allele. FNP = femoral
neck BMD pooled-gender. FNM = femoral neck BMD in men. FNW = femoral neck BMD in women. LSP = lumbar
spine BMD pooled-gender. LSM = lumber spine BMD in men. LSW = lumber spine BMD in women. SNP types: G =
genotyped; I = imputed.
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Figure 5.5: Association between LSBMD and HapMap SNPs around rs10501203 (11p12)
This gures displays the SNPs within a 4 Mb window centered on rs10501203, which is denoted by
a purple diamond. This a broader region than in most of the other plots, to illustrate the apparently
intergenic nature of this signal. The other SNPs are color-coded according to correlation (HapMap
Phase II YRI) with the most signicant SNP, from red indicating 0.8 < r2 < 1.0 to dark blue indicating
0.0 < r2 < 0.2. Known genes, with their exon, introns and orientation notes are plotted below the SNPs.
HapMap recombination rates (cM/Mb) are plotted as a blue line behind the SNPs. SNP coverage is
noted by tick marks above the plot.
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Figure 5.6: Association between FNBMD and HapMap SNPs around rs11717372 (3p24.1)
This gures displays the SNPs between the same putative recombination hotspots at 27.0 Mb and
27.8Mb as Figures 4.5 and 4.6. The SNP with the lowest p value in the analysis at this locus is denoted
by a purple diamond. The other SNPs are color-coded according to correlation (HapMapPhase II YRI)
with themost signicant SNP, from red indicating 0.8 < r2 < 1.0 to dark blue indicating 0.0 < r2 < 0.2.
Known genes, with their exon, introns and orientation notes are plotted below the SNPs. HapMap
recombination rates (cM/Mb) are plotted as a blue line behind the SNPs. SNP coverage is noted by
tick marks above the plot.
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Also, none of the 26 potential autosomal loci identied in the European American analyses nor
the 20 loci identied by Rivadeneira et al. [2009] showed good evidence of replication in the African
American analyses (data not shown).
.. Identication of Potential Candidate Genes under Linkage Peaks
Onemethod by which to potentially identify QTLs from a linkage analysis is to perform association
analyses of SNPs under theQTL linkage peak. As described inChapter 3, the strongest linkage signal
for QTL for bone-related traits in the Tobago Family Health Study was located on chromosome
10q26.3–qter. ThisQTL inuenced periosteal circumference of the tibia (maximumLOD = 3.12), as
well as the composite trait, PC1 (maximum LOD = 3.45). Figure 5.7 displays the association results
for LSBMD from the pooled-gender sample within the QTL region of interest. As can be seen, no
associations stand out distinctively from the background noise. There is a potential candidate gene
about 1 Mb telomeric to the peak LOD score, ADAM8, which has been shown to play a role in
osteoclastogenesis. This gene was discussed in Section 3.4.1.
. DISCUSSION
.. Association with Bone Mineral Density
Based upon genomewide scans of femoral neck and lumbar spine BMD in African Americans from
the HealthABC study, 24 potential candidate loci (or regions) have been identied with p values< 5 × 10−6, although none achieved genomewide signicance. Nevertheless, two of the 24 loci are
potentially associated with bone metabolism. On 11p15.2, a single variant, rs11605876 shows evi-
dence of association with LSBMD in the pooled-gender sample (p = 1.40×10−6). This SNP is 42 kb
upstream of PTH (parathyroid hormone), a key regular of calcium homeostasis that acts through
indirect stimulation of osteoclast dierentiation [Poole and Reeve 2005]. Variation in and around
PTH has been the subject ofmultiple studies of various aspects of bonemorphology. It has been asso-
ciated with BMD [Zhang et al. 2005; Laaksonen et al. 2009; Guo et al. 2010b], hip geometry [Tenne
et al. 2010] and fracture risk [Tenne et al. 2008] in some but not all studies [Lei et al. 2005; Zmuda
98
0
2
4
6
8
10
−
lo
g 1
0(p
−v
a
lu
e)
0
20
40
60
80
100
R
ecom
bination rate (cM/Mb)
rs2175045
l l
l l llll ll l l ll ll
l
l lll ll
ll llll l
ll ll
l l llll ll l
l
l l ll
l
l l
l
l ll llll l ll
l
l
l
ll ll l ll l ll l l l l llll l ll ll
ll llll ll l
l l l l
l
ll ll l l
l
l l l l ll l
l
lll llllll l
l l l
ll
l llll
l llll
l
l
l
l l
ll
lll l l lll ll ll ll
l
ll l ll
l llll
l
l
lll ll
lll lll
l
lllll
l l l llllll
llll lll llllll
l l ll
lll
l
ll
lll lllll
ll
ll
l
l
lll ll lllll
l l
llllll
l
ll lll
l l
l
l
l
llll
ll
l lll
l
l
l l
l
ll
l lll l lllll
l
ll l
l l lll ll
lll l
l
l
l l l
ll l
l
l l ll l ll
l
ll l
llll l l
l ll ll
l
ll l ll
ll l ll l l
l
l
ll lll
l
l
ll l
l ll
l
l
l ll l
l
l llllll lll ll lll ll
l l
l l ll l
lllll
l
l
l
ll
l l
l
ll ll
l
ll
l
ll
ll l l
ll lll ll
l
l
l
ll
l ll
l
ll l
lll ll
l
0.2
0.4
0.6
0.8
r2
9 genes
omitted
MGMT
EBF3
GLRX3 TCERG1L PPP2R2D
BNIP3
JAKMIP3
DPYSL4
STK32C
LRRC27
PWWP2B
C10orf91
INPP5A
NKX6−2
C10orf93
GPR123
KNDC1
UTF1
VENTX
MIR202
ADAM8
TUBGCP2
ZNF511
CALY
PRAP1
C10orf125
ECHS1
PAOX
131 132 133 134 135
Position on chr10 (Mb)
Plotted SNPs
Figure 5.7: Association between LSBMD and HapMap SNPs on 10q26.3–qter
This gures displays the SNPs within a 4 Mb region located under the 10q26.3–qter linkage signal for
PC1 and tibial periosteal circumference (Figure 3.2). The most signicant SNP is denoted by a purple
diamond. The other SNPs are color-coded according to correlation (HapMap Phase II YRI) with the
most signicant SNP, from red indicating 0.8 < r2 < 1.0 to dark blue indicating 0.0 < r2 < 0.2.
Known genes, with their exon, introns and orientation notes are plotted below the SNPs. HapMap
recombination rates (cM/Mb) are plotted as a blue line behind the SNPs. SNP coverage is noted by
tick marks above the plot.
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et al. 2010; Giroux et al. 2010]. rs9898716 is located on 17q24.3 near SOX9 (SRY (sex determining
region Y)-box 9) and showed suggestive association with femoral neck BMD in the pooled-gender
sample (2.32×10−6). Sox9 is an essential factor in chondrocyte dierentiation [Lefebvre et al. 1997].
None of the 24 potential candidate genes identied in African Americans overlaps with pre-
viously identied candidate genes from either the GWAS of European Americans in HealthABC
(Chapter 4) or from the GEFOS consortium [Rivadeneira et al. 2009]. There are several reasons for
this lack of concordance. First, the current study is underpowered, with just 1.5% power to detect a
SNP that accounts for 0.5% of the residual variance in FNBMD or LSBMD. Second, for many of the
24 loci, only a single SNP in the region achieves suggestive (5×10−6) signicance, so several of these
results are likely to be spurious. Third, almost all of the previous GWAS have been performed using
data on individuals with European ancestry, and we know there are signicant mean dierences in
genetic architecture of BMD across ancestral groups [Dvornyk et al. 2003; Wang et al. 2007b; Shaf-
fer et al. 2007]. Thus, some of the associations may reect true dierences between individuals with
European and African ancestry.
.. Replication of Potential Candidate Loci fromAssociationAnalyses of BMD inEuropean
Americans
... SLCA (solute carrier family , sodium bicarbonate cotransporter, member ) In the
HealthABC European Americans, the SLC4A7 locus was associated with FNBMD in the pooled-
gender sample. However, in the African Americans, this peak is seen only in men and for lumber
spine BMD, rather than femoral neck BMD, thus I was not able to denitively replicate the associ-
ation with SLC4A7. Several reasons for this lack of replication include: the original association is
spurious, the genetic architecture of BMD diers between European Americans and African Amer-
icans, and areal BMD is a crude measure with lots of “noise.” Followup replication in a population
with European ancestry will be required. Nonetheless, the association results in the African Ameri-
cans suggest that natural common variation at this locusmight be associated with variation in BMD.
... IdenticationofQTLs fromLinkageAnalyses inAfro-Caribbeans This cohort ofAfrican
Americans may also serve as a cohort for the linkage regions identied in Chapter 3. The strongest
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QTL signal for bone-related traits obtained from analyses of the Tobago Family Study (Chapter 3),
was located on chromosome 10q26.3. One gene of interest under this locus and not far (1Mb) from
the location of the peak LOD score is ADAM8 (a disinegrin-like and metallopeptidase domain–
containing protein 8), the gene for an enzyme that has been shown to aect the dierentiation of
precursor cells into osteoclasts (Section 3.4.1).
Because the linkage signals are so broad, ∼4 Mb for the QTL on chromosome 10, and because
I was not examining the same traits used in the linkage study, it is unlikely that the genes seen here
are the causal genes for the traits examined in the Tobago Family Study. However, I performed this
analysis to illustrate how a combination of linkage analyses and association analyses can be used to
identify genes inuencing body composition traits.
.. General Conclusions
A search for regions associated with femoral neck and lumbar spine bone mineral density in 1,139
healthy African American men and women reavealed 24 loci with peak SNPs with suggestive p val-
ues < 5× 10−6. Due to the small sample size, the modest anticipated eect sizes of true variants and
the number of tests performed, this study has insucient power to provide denitive associated loci.
However, several of the loci contain plausible candidate genes that are worthy of follow up and it rep-
resent the rst discovery GWAS of areal BMD of the lumbar spine and femoral neck in a population
with African ancestry.
Comparisons of the results of association studies of African Americans to the studies of Euro-
pean Americans and Afro-Caribbeans may facilitate our understanding of the genetic architecture
of bone related traits. However, such studies are hampered by dierences in population size and the
lack of similar phenotypes. Although I detected some interesting leads, additional studies will be
necessary to truly validate any associations.
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. CONCLUSIONS
The prevalence of osteoporosis, sarcopenia and changes in body fat distribution—three common,
complex, age-related disorders—is an important public health issue [Looker et al. 1997; Iannuzzi-
Sucich et al. 2002; Visser et al. 2002; Johnell and Kanis 2006; Burge et al. 2007; Chien et al. 2008].
Identication of genes that inuence these traits, or endophenotypes for these traits, could facilitate
development of interventions tomitigate the eects of these disorders. In addition, endophenotypes
(e.g., bone, muscle, and fat tissue) are known to covary [Reid et al. 1992; Glauber et al. 1995; Visser
et al. 1998a,b; Karasik and Kiel 2008; Beck et al. 2009], and this covariation may be due to develop-
mental, homeostatic, mechanical or geriatric processes [Glauber et al. 1995; Visser et al. 2002; Frost
2003; Shore et al. 2006; Lee et al. 2007; Karasik and Kiel 2008; Devaney et al. 2009; Schindeler et al.
2009]. Population variation in these processes may partly be due to genetic variation that inuences
multiple endophenotypes, that is, pleiotropy. Little is known about possible pleiotropic eects on
endophenotypes for osteoporosis, sarcopenia and body fat distribution, especially in populations
with non-European ancestry. Characterization of these eects for use in multivariate genetic analy-
ses, and/or development of composite endophenotypes, should increase power to identify specic
pleiotropic genes. Identication of such genes could eventually lead to insights regarding the genetic
architecture of these traits.
In my dissertation project, I explored pleiotropic relationships among bone, muscle, and fat en-
dophenotypes to answer three general questions: (1) “What are the phenotypic relationships among
specic bone, muscle and fat endophenotypes?” (2) “Is there evidence of pleiotropic eects on these
endophenotypes?” and (3) “Do specic genes inuence two bone endophenotypes and are these
identical in dierent ethnic groups?”
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. SUMMARYOFMAJOR RESULTS
General Question 1: What are the phenotypic relationships among measures of bone mineral density
and geometry, lean mass and fat mass at multiple skeletal sites?
To assess the phenotypic relationships among twenty-two endophenotypes for bone,muscle and
fat traits, I performed hierarchical clustering and principal components analysis using data from the
Tobago BoneHealth Study (TBHS), a study of 1,937 Afro-Caribbeanmen from the island of Tobago.
The hierarchical clustering analyses revealed that these endophenotypes fall into three groups (Fig-
ure 2.1): (1) a “density group” that comprises bone mineral density, cortical bone thickness and
endosteal circumference; (2) a “geometry group” that comprises the remainingmeasures of bone ge-
ometry and measures of lean muscle mass; and (3) a “fat mass group” that comprises the measures
of fat mass. These general patterns were similar in both younger and older men.
Principal component (PC) analysis of the Tobagonian men largely recapitulated the results of
the hierarchical clustering analysis (Table 2.4 and Figure 2.4): “geometry” traits contributed themost
to PC1, “density” traits contributed most to PC2 and “fat mass” traits contributed the most to PC3.
These PC loadings were used to generate composite phenotypes from data on 470 members of the
Tobago Family Health Study (TFS).
General Question 2: Are the bone, muscle and fat endophenotypes (both individual and composite)
heritable among individuals with African ancestry and is there evidence for pleiotropy?
All individual and composite endophenotypes were heritable in the TFS; residual heritabilities
ranged from 0.206 to 0.763 (all p < 6.10 × 10−3; Table 2.5). Furthermore, there was signicant evi-
dence for pleiotropy. For example, quantitative trait linkage analyses revealed signicant evidence
that a QTL on chromosome 10q26.3–qter inuences PC1 (comprised of multiple endophenotypes)
and tibial periosteal circumference (maximum LOD = 3.45 and 3.12 respectively). Consistent with
the linkage results, genetic correlations among the traits of the “geometry” group (which comprise
much of the variation in PC1) are moderate to high (ρG range: 0.411–0.851). These results indi-
cate that this region on chromosome 10q might harbor pleiotropic genes with variants that aect
multiple bone geometry and muscle traits.
Another QTL, on chromosome 21, signicantly inuences variation in PC3 and arm fat mass
(maximum LOD = 3.66 and 2.82 respectively), indicating pleiotropic eects on multiple “fat mass”
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endophenotypes. In addition, linkage peaks for leg fatmass and arm and leg leanmass also occurred
at the same region of chromosome 21pter–q21.1, although this evidence for linkage was not strong.
Followup bivariate linkage analyses of the measures of fat mass and muscle mass also points to a
common locus on chromosome 21. Bivariate linkage analysis of arm leanmass and fatmass revealed
a bivariate linkage peak on 21 with a suggestive maximum LOD2df score = 2.92; analysis of arm and
leg fat mass on chromosome 21 also showed a maximum LOD2df = 2.65. These linkage results are
consistent with the high genetic correlation among these traits (ρG range: 0.426–0.839), indicating
that a QTL on chromosome 21 may have pleiotropic eects on fat and muscle mass.
General Question 3: Do specic SNPs (or genes) inuence two measures of BMD: lumbar spine
and femoral neck BMD in populations with European and African ancestry?
Genomewide association studies (GWAS) were conducted in two populations of healthy older
Americans: 1,663 men and women of European descent and 1,139 men and women of African
descent. Femoral neck and lumber spine bone mineral density were examined in the European
and African Americans; total fractures and non-vertebral fractures were examined in the European
Americans only. Over 2.6million single-nucleotide polymorphisms (SNPs) and over 3million SNPs
were available for the European andAfrican Americans respectively. An additional 4.6million SNPs
were available for the European Americans from the 1000 Genomes Project and were used for tar-
geted follow-up of the most promising results from the European Americans as well as of loci iden-
tied in a previous GWAS.
One locus was identied with statistical signicance (p < 5 × 10−8), although likely a spuri-
ous results due to minor allele frequency, and an additional 71 were observed at suggestive levels
(p < 5 × 10−6) (Table 4.3, 4.5 and 5.3). One of the most promising loci on 3p24.1 (Figures 4.5, 4.6
and 5.6) is associated with femoral neck BMD and includes an excellent candidate gene, SLC4A7, en-
coding a sodium bicarbonate cotransporter expressed in the bone-interfacing surface of osteoclasts
[Riihonen et al. 2010]. Other genes identied as positional and biological candidates were BMP1,
PRKCH, PLOD2, VEGFC, SHH, GALR1, PTH, SOX9 and ADAM8.
CTNNB1, ESR1 and TNFRSF11B, genes known previously to be associated with bone mineral
density [Rivadeneira et al. 2009], were also validated in this study (Figures 4.11, 4.12 and 4.13 re-
spectively).
104
. STRENGTHS AND LIMITATIONS
This study hadmultiple strengths includingmeasures of bone derived frompQCT, which has higher
resolution than phenotypes derived fromDXA. pQCT allows themeasurement of volumetric BMD,
as opposed to areal BMD from DXA, thus removing the eect of bone size on the estimate of BMD.
pQCT also facilitates the examination of myriad bone components, such as discriminating between
BMD of trabecular and cortical bone, which might have both common and unique genetic and
environmental factors inuencing them. Unfortunately, the pQCTmeasures were only available on
the Tobago populations, and not the HealthABC population, thus limiting comparisons between
the two groups.
Another strength of the study is large population of unrelated individuals that enabled develop-
ment of composite endophenotypes and large, multigenerational families that increased the power
of heritability and linkage analyses to detect QTLs within families. The use of principal components
facilitates the targeting of the underlying phenotypic dimensions of multiple semi-correlated traits.
The advantage of the large pedigrees is mitigated somewhat by the total sample size. Only QTLs
with large eect would be detected. Additionally, of the 6,000 SNPs genotyped for the linkage panel,
75% had to be discarded to calculate multipoint identity-by-descent estimates in the large compli-
cated Tobago pedigrees. Such information could be useful if harnessed, especially given the reduced
information that (biallelic) SNPs themselves provide to trace transmission within families.
This study also included the rst GWAS of BMD with African Americans as a discovery co-
hort, whereas two prior studies that included subjects of African descent [Xiong et al. 2009; Koller
et al. 2010] examined them as follow-up replication cohorts. Conducting a genomewide scan in a
non–European population allows for the examination of variants not assessed in populations of Eu-
ropean descent. Discoveries of genes with unique eects in populations of African descent may aid
in correcting health disparities between populations with diering susceptibilities to disorders such
as osteoporosis or obesity. Another strength of the GWA analyses in this study is that genotypes
from dense SNP panels were available in European and African American men and women, and
were supplemented with imputed SNPs from the International HapMap Consortium and the 1000
Genomes Project. These dense arrays provide ample coverage for the detection of association sig-
nals. Dense coverage in both population groups enables us to conduct direct comparisons of signals
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identied in each. However, the power of this study to detect association is severely hampered by
the sizes of the samples.
. FUTURE DIRECTIONS
There are several avenues of follow-up available for this study.
.. Validation
Foremost, the raw data for all SNPs exhibiting evidence of association in this study must be exam-
ined. Misclassication of individuals into genotype clusters can result in false positive results and
must be ruled out as a source of error.
Replication is a hallmark of the scientic process, and studies that aim to reproduce the associ-
ations seen here are essential. For instance, one next step would be to replicate the SLC4A7 result
in another population. Genomewide SNP data are available for the Study of Osteoporotic Fractures
in Women (SOF) or the Study of Osteoporotic Fractures in Men (MrOS), and replication of the
genomewide association results in these populations is an obvious possibility.
.. Fine Mapping
My linkage analyses have revealed two potential QTLs. Narrowing the regions of interest would be a
helpful rst step. We used just 25% of the SNPs in our linkage panel to calculate multipoint identity-
by-descent (MIBD) estimates, and the remaining 75% can still be used.Multiallelic haplotypes could
be constructed from the full 6,000-SNP linkage panel using Mendel [Lange et al. 2001] to assign
unambiguous haplotypes within the 1 cM intervals that LOKI cannot use. Such haplotypes would
allow us to overcome LOKI’s 1 cM limitation on MIBD estimation as well as serving as stand-ins
for more informative multiallelic microsatellites. Such haplotypes could provide better tracing of
transmission between relatives. This might increase the power to detect linkage signals as well as
potentially narrowing the linkage peaks so far observed. The collection of additional families could
also increase the power of the linkage analyses.
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Nevertheless, a narrowerQTL regionmight still encompass a dozen genes, so association studies
of SNPs with dense coverage of the regions of interest or targeted resequencing and SNP discovery
in those regions could further pinpoint the causal elements. An obvious follow-up population for
the two QTLs observed here is the Tobago Bone Health Study (TBHS).
Fine mapping is also necessary as a follow-up of the GWAS results, as the most signicant SNPs
themselves are not likely to be causal, but are likely to be in linkage disequilibrium with causal
variants.
.. Functional Assessment
Given our understanding of the function of SLC4A7, hypotheses about how both deleterious and
benecial regulatory variants and deleterious functional variantswould aectNBCn1’s function and
the subsequent consequence for phenotypes could direct selection of traits to explore for association
with variants in this region.
If the SLC4A7 locus is replicated, then further studies of SLC4A7 in mice and in cultured osteo-
clasts could extend our knowledge of the implications of variation in that region on bone-related
phenotypes. Basic expression studies might reveal whether variation between 27.0 Mb and 27.8 Mb
on chromosome 3 aects the expression of NEK10, SLC4A7 or both. SLC4A7 is expressed in the
thick ascending limb and collecting duct cells of the kidney [Boron and Boulpaep 1983; Choi et al.
2000;Vorumet al. 2000], so expression assays inCOS-1 cells, which are derived from the kidney cells
of the African green monkey [Jensen et al. 1964; Gluzman 1981], might facilitate such assays. In ad-
dition, functional studies of osteoclasts induced from CD14+ cells isolated from peripheral blood of
subjects with and without rs11717372 or another correlated SNP could also reveal whether NBCn1
mRNA levels [Livak and Schmittgen 2001], cytoplasmic and membrane-bound protein levels [Vo-
rum et al. 2000] or bone resorption activity [Riihonen et al. 2010] are aected by that variation.
Finally, Slc4a7−/− mice exist [Bok et al. 2003] so it might be possible to knock in human versions of
SLC4A7 with and without identied variants to see if phenotypic dierences in bone mineral den-
sity or response of osteoclasts to chronic metabolic acidosis [Kwon et al. 2002; Riihonen et al. 2010]
arise.
107
.. Data Mining
Tremendous resources have been spent to genotype the HealthABC participants at millions of SNPs.
Additional information, beyond simply collecting themost obvious association results, can be gleaned
from such a rich data set. In addition to attempts to validate the standout loci from a GWAS, it is
imperative that we employ methods that can help us sort the many true positives from among the
false positives lying at and just below the suggestive loci threshold. Pathway-based methods [Wang
et al. 2007a; Holmans et al. 2009; Torkamani and Schork 2009; Li et al. 2010a; Gupta et al. 2011] can
be used to see if particular metabolic pathways or networks are overrepresented among the sugges-
tive signals. Allelic heterogeneity is a signicant problem for GWAS, as dierent individuals with
the same phenotype state can result from dierent alleles in the same gene. Association studies are
limited in their ability to detect such associations. Algorithms that cluster together alleles into genes
or gene families [Morgenthaler and Thilly 2007; Li and Leal 2008;Madsen and Browning 2009; Ho-
mann et al. 2010]might allow us to associate phenotypes with larger genetic elements and overcome
the limitations of weak power imposed by the small minor allele frequencies of rare SNPs.
. PUBLIC HEALTH SIGNIFICANCE
Age-related changes in body composition are a signicant public health issue. Osteoporosis aects
up to 18% of women and up to 6% of men over the age 50, with a concomitant increase in fracture
risk [Looker et al. 1997]. Accompanying changes in muscle quality and mass and in fat distribution
andmass modulate the risk of fractures as well as inuencing other aspects of quality of life [Johnell
and Kanis 2006; Burge et al. 2007]. An increased understanding of the relationships between bone,
muscle and fat tissue and the genetic architecture that underlies them could lead to interventions to
delay or mitigate the detrimental eects of aging on these components of body composition.
The eect sizes and risk ratios of genetic variants associated with changes in quantitative traits
such as bone mineral density or fat mass or with susceptibility to conditions like osteoporosis, sar-
copenia and obesity have proven to be diminutive in many cases at least in the predominantly Eu-
ropean populations most commonly examined. Although the predictive power of such variants for
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the general population is ambiguous now, the cumulative impact of discovered variants could prove
informative for a small segment of the population that carry a high burden of deleterious alleles.
While the hypothesis that common variants account for a large amount of a trait’s heritability
has not generally been borne out, rare variants that have signicant impacts on the quality of life
for families that carry them are known and eorts to discover and describe them should continue.
Furthermore, while the predictive value of naturally occurring variation is uncertain, such variation
does illuminate genes, gene products, regulatory elements, metabolic pathways and regulatory net-
works that are important to development, maintenance, disease and senescence of components of
body composition. These genes and so forth then serve as potential targets for interventions to delay
onset or mitigate the impact of conditions like osteoporosis. For instance, therapies which reduce
NBCn1 activity in osteoclasts might aid in restoring the bone remodeling imbalance that underlies
this condition.
Comparisons between populations with dierent susceptibilities to disease can lead to greater
insights into the underlying causes. The prevalence of osteoporosis is 18% in European American
women and is 6% in African American women. While a portion of the dierence in risk is likely
due to environmental dierences, a component may be genetic. Further exploration in understud-
ied groups, such as populations of African ancestry, could produce discoveries that benet both
groups.
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APPENDIX A
ABBREVIATIONS
Table A1: Abbreviations
ADAM8 a disintegrin-like and metallopeptidase (ADAM) domain–containing protein 8
ADAMTS18 ADAM with thrombospondin type 1 motif, 18
ADIPOQ adiponectin
ACVR1 activin A receptor, type I
BMD bone mineral density
BMI bone mass index
BMP1 bone morphogenetic protein 1
BMP2 bone morphogenetic protein 2
CDH8 cadherin 8, type 2
CEPH Centre d’Étude du Polymorphisme Humain
CEU Utah residents with Northern and Western European ancestry from the CEPH collection
cGMP cyclic guanosine monophosphate
chr chromosome
CIDR Center for Inherited Disease Research
cM centimorgan
CT computed tomography
CTNNB1 catenin (cadherin-associated protein), β 1, 88 kDa
CVD cardiovascular disease
DXA dual-energy x-ray absorptiometry
ESR1 estrogen receptor 1
FNBMD femoral neck bone mineral density
FRAX Fracture Risk Assessment Tool
FTO Fatso homolog (fat mass and obesity–associated)
GALR1 galanin receptor 1
GEFOS Genetic Factors for Osteoporosis
GWA genomewide association
GWAS genomewide association study
Continued on next page
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Table A1 — continued from previous page
GWLS genomewide linkage study
HealthABC Dynamics of Health, Aging and Body Composition Study
HuGE human genome epidemiology
HWE Hardy–Weinberg equilibrium
IRS insulin receptor substrate 1
kb kilobase
kDa kilodalton
LD linkage disequilibrium
LEPR leptin receptor
LOD logarithm of odds
LOD2df logarithm of odds (two-degrees-of-freedom test)
LOESS locally weighted scatterplot smoothing
LRP5 low density lipoprotein receptor–related protein 5
LRRC4C leucine rich repeat containing 4C
LSBMD lumbar spine bone mineral density
MAF minor allele frequency
Mb megabase
MC4R melanocortin 4 receptor
MIBD multipoint identity-by-descent
mRNA messenger RNA
MrOS Study of Osteoporotic Fractures in Men
MyoD myogenic dierentiation 1
NCB3 sodium bicarbonate cotransporter 3
NCBI National Center for Biotechnology Information
NCBn1 electroneutral sodium bicarbonate cotransporter 1
NDRG4 N-myc downstream regulated gene family member 4
NEK10 never in mitosis gene a (NIMA)–related kinase 10
NHGRI National Human Genome Research Institute
OPG osteoprotegerin
OPLL ossication of posterior longitudinal ligament
OR odds ratio
OSX osterix
P2RX7 purinergic receptor P2X, ligand-gated ion channel, 7
PC principle component
PDE3A phosphodiesterase 3A, cGMP-inhibited
PKCη protein kinase C, η
PLOD2 procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2
PPARG peroxisome proliferator–activated receptor γ
PPARγ peroxisome proliferator–activated receptor γ
pQCT peripheral quantitative computed tomography
PRKCH protein kinase C, η
PTH parathyroid hormone
QQ quantile–quantile
QTL quantitative trait locus
QUS quantitative ultrasound
RANK receptor activator of nuclear factor κB
Continued on next page
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Table A1 — continued from previous page
RANKL receptor activator of nuclear factor κB ligand
RNA ribonucleic acid
Runx2 Runt-related transcription factor 2
SD standard deviation
SE standard error
SHH sonic hedgehog
SLC4A7 solute carrier family 4, sodium bicarbonate cotransporter, member 7
SNP single-nucleotide polymorphism
SOF Study of Osteoporotic Fractures
SOLAR Sequential Oligogenic Linkage Analysis Routines
SOX9 SRY (sex determining region Y)-box 9
SP7 Sp7 transcription factor (osterix)
TBHS Tobago Bone Health Study
TFS Tobago Family Health Study
TGFBR3 transforming growth factor, β receptor III
TNFRSF11A tumor necrosis factor receptor superfamily, member 11a, NF-κB activator (RANK)
TNFRSF11B tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin)
TNFSF11 tumor necrosis factor (ligand) superfamily, member 11 (RANKL)
TRHR thyrotropin-releasing hormone receptor
UTR untranslated region
VDR vitamin D (1,25-dihydroxyvitamin D3) receptor
VEGFC vascular endothelial growth factor C
WHO World Health Organization
YRI Yorùbá in Ìbàdàn, Nigeria
ZBTB40 zinc nger and bric à brac–tramtrack–broad-complex (BTB) domain containing 40
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APPENDIX B
TOBAGO FAMILY HEALTH STUDY PEDIGREES
The pedigrees in this appendix were drawn using Cranefoot 3.2 [Mäkinen et al. 2005]. Symbols colored in
black represent phenotyped individuals.
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Figure B1: Pedigree 1
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Figure B2: Pedigree 2
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Figure B3: Pedigree 3
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Figure B4: Pedigree 4
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Figure B5: Pedigrees 5 and 7
118
Figure B6: Pedigree 6
119
Figure B7: Pedigree 8
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APPENDIX C
LINKAGE PLOTS
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Figure C1: Radius Length
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Figure C2: Tibia Length
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Figure C3: Arm Lean Muscle Mass
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Figure C4: Leg Lean Muscle Mass
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Figure C5: Arm Fat Mass
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Figure C6: Leg Fat Mass
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Figure C7: 4% Radius Total Area
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Figure C8: 4% Tibia Total Area
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Figure C9: 4% Radius Trabecular Bone Mineral Density
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Figure C10: 4% Tibia Trabecular Bone Mineral Density
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Figure C11: 33% Radius Cortical Area
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Figure C12: 33% Tibia Cortical Area
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Figure C13: 33% Radius Cortical Bone Mineral Density
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Figure C14: 33% Tibia Cortical Bone Mineral Density
125
0
1
2
3
4 1 3 5 7 9 11 13 15 17 19 21
2 4 6 8 10 12 14 16 18 20 22
Chromosome
LO
D
Figure C15: 33% Radius Cortical Thickness
0
1
2
3
4 1 3 5 7 9 11 13 15 17 19 21
2 4 6 8 10 12 14 16 18 20 22
Chromosome
LO
D
Figure C16: 33% Tabia Cortical Thickness
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Figure C17: 33% Radius Periosteal Circumference
126
0
1
2
3
4 1 3 5 7 9 11 13 15 17 19 21
2 4 6 8 10 12 14 16 18 20 22
Chromosome
LO
D
Figure C18: 33% Tibia Periosteal Circumference
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Figure C19: 33% Radius Endosteal Circumference
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Figure C20: 33% Tibia Endosteal Circumference
127
0
1
2
3
4 1 3 5 7 9 11 13 15 17 19 21
2 4 6 8 10 12 14 16 18 20 22
Chromosome
LO
D
Figure C21: 66% Total Bone Mineral Density
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Figure C22: 66% Tibia Cortical Bone Mineral Density
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Figure C23: Principal Component 1
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Figure C24: Principal Component 2
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Figure C25: Principal Component 3
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Figure C26: Principal Component 4
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Figure C27: Principal Component 5
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Figure C28: Principal Component 6
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Figure C29: Principal Component 7
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APPENDIX D
QUANTILE–QUANTILE PLOTS
Figure D1: QQ Plot FNBMD Eur. Am. Men Figure D2: QQ Plot FNBMD Eur. Am. Women
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Figure D3: QQ Plot LSBMD Eur. Am. Men Figure D4: QQ Plot LSBMD Eur. Am. Women
Figure D5: QQ Plot All Fx Eur. Am. Men Figure D6: QQ Plot All Fx Eur. Am. Women
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Figure D7: QQ Plot N.-V. Fx Eur. Am. Men Figure D8: QQ Plot N.-V. Fx Eur. Am. Women
Figure D9: QQ Plot FNBMD Afr. Am. Men FigureD10:QQ Plot FNBMD Afr. Am. Women
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Figure D11: QQ Plot LSBMD Afr. Am. Men Figure D12: QQ Plot LSBMD Afr. Am. Women
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APPENDIX E
MANHATTAN PLOTS
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Figure E1: Manhattan Plot for FNBMD in European American Men
Figure E2: Manhattan Plot for FNBMD in European American Women
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Figure E3: Manhattan Plot for LSBMD in European American Men
Figure E4: Manhattan Plot for LSBMD in European American Women
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Figure E5: Manhattan Plot for All Fractures in European American Men
Figure E6: Manhattan Plot for All Fractures in European American Women
138
Figure E7: Manhattan Plot for Non-Vertebral Fractures in European American Men
Figure E8: Manhattan Plot for Non-Vertebral Fractures in European American Women
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APPENDIX F
SNPSWITH SUGGESTIVE P VALUES
Table F1: FNBMD Pooled Hits – European Americans
Nearest Distance
Locus SNP Position Gene (kb) Alleles MAF Type β s.e. p
3p24.1 rs11717372 27202560 NEK10 29.5 G/A 0.26 I 0.202 0.040 5.17 × 10−7
rs11717314 27202583 NEK10 29.5 C/T 0.27 I 0.195 0.040 1.03 × 10−6
rs10510596 27203014 NEK10 29.1 G/A 0.27 I 0.195 0.040 1.03 × 10−6
rs11928525 27206723 NEK10 25.4 T/C 0.27 I 0.195 0.040 1.06 × 10−6
rs11926580 27208380 NEK10 23.7 G/T 0.27 I 0.195 0.040 1.06 × 10−6
rs11926556 27208502 NEK10 23.6 C/A 0.27 G 0.195 0.040 1.06 × 10−6
rs11928916 27210944 NEK10 21.2 C/A 0.27 I 0.195 0.040 1.06 × 10−6
rs724243 27216940 NEK10 15.2 C/A 0.27 I 0.191 0.040 1.46 × 10−6
rs724244 27217157 NEK10 14.9 C/T 0.27 G 0.191 0.040 1.46 × 10−6
rs724245 27217244 NEK10 14.9 G/T 0.27 I 0.191 0.040 1.46 × 10−6
rs17680166 27218049 NEK10 14.1 G/C 0.27 I 0.191 0.040 1.47 × 10−6
rs11923983 27218483 NEK10 13.6 A/C 0.27 I 0.191 0.040 1.47 × 10−6
rs11712907 27219569 NEK10 12.5 T/C 0.27 I 0.191 0.040 1.47 × 10−6
rs11708854 27219577 NEK10 12.5 G/A 0.27 I 0.191 0.040 1.47 × 10−6
rs11708844 27219713 NEK10 12.4 C/T 0.27 I 0.190 0.040 1.47 × 10−6
rs6792693 27220229 NEK10 11.9 A/G 0.27 G 0.190 0.040 1.47 × 10−6
rs11129268 27220397 NEK10 11.7 G/A 0.27 I 0.190 0.040 1.47 × 10−6
rs11709858 27220422 NEK10 11.7 C/T 0.27 I 0.190 0.040 1.47 × 10−6
rs4973755 27223167 NEK10 8.9 G/A 0.27 I 0.190 0.040 1.47 × 10−6
rs6793827 27224116 NEK10 8.0 C/T 0.27 I 0.190 0.040 1.47 × 10−6
rs6806213 27224288 NEK10 7.8 A/G 0.27 I 0.190 0.040 1.47 × 10−6
rs6806325 27224359 NEK10 7.7 A/G 0.27 I 0.190 0.040 1.47 × 10−6
rs13063897 27225007 NEK10 7.1 C/G 0.27 I 0.190 0.040 1.47 × 10−6
rs13079813 27225396 NEK10 6.7 G/A 0.28 I 0.191 0.040 1.55 × 10−6
rs11713802 27225862 NEK10 6.2 T/C 0.27 I 0.190 0.040 1.47 × 10−6
rs4973860 27225895 NEK10 6.2 A/G 0.27 G 0.190 0.040 1.47 × 10−6
Continued on next page
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Table F1 — continued from previous page
Nearest Distance
Locus SNP Position Gene (kb) Alleles MAF Type β s.e. p
rs4973861 27226054 NEK10 6.0 G/T 0.27 I 0.191 0.040 1.44 × 10−6
rs2120893 27227022 NEK10 5.1 G/A 0.27 I 0.191 0.040 1.38 × 10−6
rs11920408 27227707 NEK10 4.4 C/T 0.27 I 0.191 0.040 1.32 × 10−6
rs11928065 27227773 NEK10 4.3 A/G 0.27 I 0.192 0.040 1.27 × 10−6
rs11129269 27228718 NEK10 3.4 A/G 0.27 I 0.192 0.040 1.20 × 10−6
rs11715168 27230796 NEK10 1.3 G/T 0.27 I 0.193 0.040 1.11 × 10−6
rs11715136 27230868 NEK10 1.2 C/T 0.27 I 0.195 0.040 8.98 × 10−7
rs11720211 27231039 NEK10 1.1 T/A 0.27 I 0.196 0.040 7.35 × 10−7
rs13085421 27233737 NEK10 0.0 A/G 0.28 G 0.197 0.040 6.70 × 10−7
rs1596701 27236343 NEK10 0.0 T/C 0.28 I 0.194 0.040 9.79 × 10−7
rs6796032 27240555 NEK10 0.0 C/A 0.28 I 0.195 0.040 9.14 × 10−7
rs2218472 27248568 NEK10 0.0 T/C 0.27 I 0.190 0.040 1.68 × 10−6
rs2197435 27252047 NEK10 0.0 C/G 0.27 I 0.190 0.040 1.68 × 10−6
rs4586769 27254427 NEK10 0.0 G/A 0.27 I 0.190 0.040 1.69 × 10−6
rs7626869 27256693 NEK10 0.0 T/A 0.27 I 0.190 0.040 1.70 × 10−6
rs1158719 27256773 NEK10 0.0 C/A 0.27 G 0.190 0.040 1.70 × 10−6
rs11129271 27258121 NEK10 0.0 A/T 0.27 I 0.190 0.040 1.71 × 10−6
rs11925748 27260236 NEK10 0.0 A/T 0.27 I 0.190 0.040 1.72 × 10−6
rs1373769 27260670 NEK10 0.0 C/T 0.27 I 0.190 0.040 1.73 × 10−6
rs10865813 27266147 NEK10 0.0 C/T 0.27 I 0.190 0.040 1.80 × 10−6
rs11129274 27267085 NEK10 0.0 T/C 0.27 I 0.190 0.040 1.81 × 10−6
rs2120887 27269837 NEK10 0.0 A/G 0.27 G 0.190 0.040 1.82 × 10−6
rs1550769 27271800 NEK10 0.0 C/G 0.27 I 0.190 0.040 1.83 × 10−6
rs1550768 27271826 NEK10 0.0 A/T 0.27 I 0.190 0.040 1.84 × 10−6
rs12488147 27272623 NEK10 0.0 A/T 0.27 I 0.190 0.040 1.84 × 10−6
rs12494667 27272688 NEK10 0.0 C/A 0.27 G 0.190 0.040 1.84 × 10−6
rs6804742 27278400 NEK10 0.0 C/T 0.27 I 0.189 0.040 1.87 × 10−6
rs11129278 27280618 NEK10 0.0 G/C 0.27 I 0.189 0.040 1.87 × 10−6
rs12486588 27288126 NEK10 0.0 G/T 0.27 G 0.189 0.040 1.88 × 10−6
rs7635995 27289490 NEK10 0.0 T/G 0.27 I 0.189 0.040 1.88 × 10−6
rs4973868 27291923 NEK10 0.0 C/A 0.27 G 0.189 0.040 1.88 × 10−6
rs1542152 27297069 NEK10 0.0 A/T 0.27 I 0.190 0.040 1.87 × 10−6
rs11919927 27297211 NEK10 0.0 G/A 0.27 I 0.190 0.040 1.86 × 10−6
rs11129279 27297347 NEK10 0.0 A/C 0.27 I 0.190 0.040 1.87 × 10−6
rs6788621 27298386 NEK10 0.0 C/T 0.27 I 0.189 0.040 1.89 × 10−6
rs11129280 27301101 NEK10 0.0 G/T 0.27 G 0.189 0.040 1.92 × 10−6
rs10510594 27301455 NEK10 0.0 A/G 0.27 G 0.189 0.040 1.91 × 10−6
rs10510593 27304421 NEK10 0.0 A/C 0.27 I 0.189 0.040 1.86 × 10−6
rs10510592 27307824 NEK10 0.0 A/G 0.27 G 0.190 0.040 1.74 × 10−6
rs4973869 27312933 NEK10 0.0 G/A 0.27 I 0.190 0.040 1.77 × 10−6
rs4973870 27313428 NEK10 0.0 C/A 0.27 I 0.190 0.040 1.78 × 10−6
rs1445115 27320385 NEK10 0.0 G/A 0.27 I 0.189 0.040 2.01 × 10−6
rs1445112 27326290 NEK10 0.0 A/G 0.27 G 0.184 0.040 3.42 × 10−6
rs17239342 27332725 NEK10 0.0 G/C 0.27 I 0.185 0.040 3.18 × 10−6
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Nearest Distance
Locus SNP Position Gene (kb) Alleles MAF Type β s.e. p
rs12152280 27333016 NEK10 0.0 A/T 0.25 I 0.188 0.041 4.21 × 10−6
rs6795834 27335467 NEK10 0.0 C/T 0.25 I 0.189 0.041 3.76 × 10−6
5q15 rs3909479 94813710 FAM81B 1.8 C/T 0.10 G −0.272 0.058 2.48 × 10−6
rs7705631 94799340 FAM81B 0.0 A/C 0.10 I −0.267 0.058 4.00 × 10−6
8p22 rs13252590 16566118 FGF20 328.6 A/T 0.47 I 0.174 0.035 6.45 × 10−7
rs1433289 16565923 FGF20 328.8 G/A 0.40 G 0.172 0.036 1.60 × 10−6
8p21.3 rs12114940 22104735 BMP1 0.0 T/G 0.45 G 0.173 0.036 1.71 × 10−6
13q33.3 rs17382033 107839404 TNFSF13B 80.6 C/A 0.09 G 0.329 0.062 1.33 × 10−7
rs2391637 107843488 TNFSF13B 84.7 A/G 0.09 I 0.306 0.063 1.08 × 10−6
16q21 rs2962454 61494729 CDH8 866.5 G/A 0.24 G 0.191 0.040 2.33 × 10−6
rs2914486 61494154 CDH8 865.9 T/C 0.25 G 0.183 0.040 3.76 × 10−6
Table F2: FNBMDMen Hits – European Americans
Nearest Distance
Locus SNP Position Gene (kb) Alleles MAF Type β s.e. p
1q23.1 rs2054993 156772592 OR6Y1 10.9 G/T 0.44 I −0.239 0.050 1.92 × 10−6
rs9651046 156700714 OR10K1 1.3 T/G 0.40 I −0.228 0.050 4.77 × 10−6
rs1573519 156701902 OR10K1 0.1 A/G 0.40 G −0.228 0.050 4.66 × 10−6
rs12404821 156706203 OR10K1 3.3 C/T 0.40 G −0.228 0.050 4.66 × 10−6
rs10908650 156709125 OR10K1 6.2 A/G 0.40 I −0.229 0.050 4.51 × 10−6
rs11264997 156752106 OR6Y1 31.4 A/G 0.44 G −0.233 0.050 3.09 × 10−6
rs7555174 156754050 OR6Y1 29.5 G/A 0.44 I −0.233 0.050 2.97 × 10−6
rs7549581 156756328 OR6Y1 27.2 C/T 0.43 I −0.234 0.050 3.39 × 10−6
rs7512592 156756569 OR6Y1 27.0 A/G 0.43 G −0.229 0.050 3.98 × 10−6
rs10797020 156756948 OR6Y1 26.6 G/A 0.43 G −0.229 0.050 3.98 × 10−6
rs11265003 156757255 OR6Y1 26.3 T/C 0.43 I −0.229 0.050 3.83 × 10−6
rs950260 156758144 OR6Y1 25.4 A/G 0.44 I −0.230 0.050 3.57 × 10−6
rs2317969 156758377 OR6Y1 25.2 G/A 0.44 I −0.231 0.050 3.35 × 10−6
rs7518808 156758444 OR6Y1 25.1 A/G 0.44 I −0.232 0.050 3.25 × 10−6
rs2157687 156759624 OR6Y1 23.9 T/C 0.44 I −0.232 0.050 3.04 × 10−6
rs1032352 156759778 OR6Y1 23.8 T/C 0.44 I −0.233 0.050 2.78 × 10−6
rs7548349 156760350 OR6Y1 23.2 T/C 0.43 G −0.234 0.050 2.72 × 10−6
rs7514968 156760476 OR6Y1 23.1 T/A 0.43 I −0.234 0.050 2.72 × 10−6
rs7525362 156760514 OR6Y1 23.0 C/G 0.43 I −0.234 0.050 2.72 × 10−6
rs12145401 156761317 OR6Y1 22.2 G/A 0.43 I −0.234 0.050 2.72 × 10−6
rs6663277 156761625 OR6Y1 21.9 T/A 0.43 I −0.238 0.050 1.93 × 10−6
rs6699473 156761833 OR6Y1 21.7 T/C 0.43 G −0.234 0.050 2.72 × 10−6
rs6674656 156762055 OR6Y1 21.5 A/G 0.43 G −0.234 0.050 2.72 × 10−6
rs10797023 156763703 OR6Y1 19.8 C/T 0.43 I −0.234 0.050 2.72 × 10−6
rs6672789 156763763 OR6Y1 19.8 C/T 0.43 I −0.234 0.050 2.72 × 10−6
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rs10797024 156763787 OR6Y1 19.8 A/G 0.43 I −0.234 0.050 2.72 × 10−6
rs6657638 156763808 OR6Y1 19.7 G/C 0.43 I −0.234 0.050 2.72 × 10−6
rs6670343 156763882 OR6Y1 19.7 T/A 0.43 I −0.234 0.050 2.72 × 10−6
rs1578761 156764196 OR6Y1 19.3 A/G 0.43 G −0.234 0.050 2.72 × 10−6
rs12120526 156765028 OR6Y1 18.5 C/T 0.39 I −0.236 0.051 3.81 × 10−6
rs11265006 156765109 OR6Y1 18.4 G/C 0.43 I −0.234 0.050 2.72 × 10−6
rs11265007 156765146 OR6Y1 18.4 G/A 0.44 I −0.234 0.050 2.72 × 10−6
rs11265009 156765396 OR6Y1 18.1 T/C 0.44 I −0.234 0.050 2.72 × 10−6
rs11265010 156765477 OR6Y1 18.1 A/G 0.44 I −0.234 0.050 2.72 × 10−6
rs12123305 156765579 OR6Y1 18.0 A/G 0.44 I −0.234 0.050 2.72 × 10−6
rs12063320 156766047 OR6Y1 17.5 T/A 0.44 I −0.234 0.050 2.72 × 10−6
rs12064489 156766073 OR6Y1 17.5 C/T 0.44 I −0.234 0.050 2.72 × 10−6
rs10908667 156766745 OR6Y1 16.8 A/G 0.44 I −0.234 0.050 2.72 × 10−6
rs12119672 156766909 OR6Y1 16.6 A/G 0.44 I −0.234 0.050 2.72 × 10−6
rs10908671 156768784 OR6Y1 14.8 A/G 0.44 I −0.234 0.050 2.72 × 10−6
rs12075228 156768880 OR6Y1 14.7 T/C 0.44 I −0.234 0.050 2.72 × 10−6
rs11265014 156769845 OR6Y1 13.7 C/T 0.43 I −0.229 0.050 4.64 × 10−6
rs11265015 156769876 OR6Y1 13.7 A/G 0.44 I −0.234 0.050 2.72 × 10−6
rs11265016 156770409 OR6Y1 13.1 T/C 0.44 I −0.234 0.050 2.69 × 10−6
rs10908673 156770532 OR6Y1 13.0 G/T 0.44 I −0.234 0.050 2.67 × 10−6
rs10908674 156770544 OR6Y1 13.0 T/A 0.44 I −0.234 0.050 2.64 × 10−6
rs10908675 156770753 OR6Y1 12.8 C/A 0.44 I −0.234 0.050 2.63 × 10−6
rs7540999 156771194 OR6Y1 12.3 A/G 0.44 I −0.234 0.050 2.61 × 10−6
rs4575081 156771461 OR6Y1 12.1 A/C 0.44 I −0.234 0.050 2.58 × 10−6
rs4313395 156771759 OR6Y1 11.8 T/C 0.44 I −0.234 0.050 2.56 × 10−6
rs10908677 156772810 OR6Y1 10.7 G/A 0.44 I −0.235 0.050 2.53 × 10−6
rs2051067 156774022 OR6Y1 9.5 T/G 0.44 I −0.235 0.050 2.48 × 10−6
rs923663 156774356 OR6Y1 9.2 T/A 0.44 I −0.235 0.050 2.49 × 10−6
rs975118 156778069 OR6Y1 5.5 A/G 0.44 G −0.235 0.050 2.50 × 10−6
rs6697656 156787361 OR6Y1 2.8 G/A 0.44 G −0.235 0.050 2.47 × 10−6
5q14.3 rs2973839 91112451 LOC100129716 360.2 A/G 0.11 I 0.354 0.077 3.63 × 10−6
7q34 rs10954649 138789091 KLRG2 0.0 C/T 0.35 G −0.247 0.052 1.87 × 10−6
rs11763327 138789411 KLRG2 0.0 T/G 0.35 I −0.247 0.052 1.88 × 10−6
15q25.3 rs957029 85753369 NCRNA00052 167.8 G/C 0.23 I 0.296 0.059 4.91 × 10−7
rs9284311 85729504 NCRNA00052 191.7 A/C 0.24 G 0.288 0.058 8.08 × 10−7
rs8039588 85731872 NCRNA00052 189.3 A/T 0.24 I 0.288 0.058 8.19 × 10−7
rs921475 85732343 NCRNA00052 188.8 G/A 0.23 I 0.284 0.059 1.35 × 10−6
rs13379751 85737626 NCRNA00052 183.5 A/G 0.24 G 0.287 0.059 9.74 × 10−7
rs1442307 85740218 NCRNA00052 180.9 G/A 0.23 G 0.292 0.059 6.46 × 10−7
rs2881893 85741977 NCRNA00052 179.2 A/G 0.23 I 0.293 0.059 6.13 × 10−7
rs1867034 85761018 NCRNA00052 160.1 G/A 0.19 G 0.300 0.064 2.75 × 10−6
rs16940295 85761129 NCRNA00052 160.0 G/A 0.19 I 0.299 0.064 2.78 × 10−6
rs2348378 85762003 NCRNA00052 159.2 G/A 0.19 I 0.312 0.062 5.62 × 10−7
rs2679078 85773433 NCRNA00052 147.7 G/A 0.25 I 0.289 0.058 5.78 × 10−7
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rs2679072 85780757 NCRNA00052 140.4 C/T 0.24 G 0.278 0.058 1.43 × 10−6
rs2679069 85787281 NCRNA00052 133.9 C/T 0.24 I 0.282 0.058 1.21 × 10−6
rs2584136 85789315 NCRNA00052 131.8 T/C 0.23 I 0.277 0.060 3.94 × 10−6
19q12 rs2190800 33143105 LOC148189 166.4 T/G 0.42 G 0.229 0.049 3.21 × 10−6
rs2190799 33143082 LOC148189 166.4 C/T 0.40 I 0.229 0.050 4.76 × 10−6
19q13.11 rs8109254 37388860 ZNF507 139.5 A/C 0.05 I 0.514 0.111 3.66 × 10−6
Table F3: FNBMDWomen Hits – European Americans
Nearest Distance
Locus SNP Position Gene (kb) Alleles MAF Type β s.e. p
6p25.1 rs736004 5067728 LYRM4 0.0 C/T 0.10 G −0.422 0.088 1.56 × 10−6
8p21.3 rs12114940 22104735 BMP1 0.0 T/G 0.45 G 0.245 0.053 3.60 × 10−6
15q14 rs16962904 34443595 C15orf41 215.5 A/G 0.33 I −0.284 0.057 7.48 × 10−7
rs10518873 34443995 C15orf41 215.1 G/A 0.33 G −0.265 0.057 3.94 × 10−6
rs10851990 34445996 C15orf41 213.1 C/G 0.33 I −0.265 0.057 4.04 × 10−6
Xq28 rs11795763 149755133 CD99L2 0.0 T/C 0.16 I −0.338 0.069 8.67 × 10−7
rs12012611 149720754 CD99L2 0.0 G/A 0.16 G −0.341 0.071 1.70 × 10−6
rs16995749 149749844 CD99L2 0.0 C/A 0.16 G −0.340 0.070 1.23 × 10−6
rs11798706 149769906 CD99L2 0.0 T/C 0.11 G −0.490 0.106 3.80 × 10−6
rs12116022 149770664 CD99L2 0.0 G/A 0.16 I −0.339 0.069 1.09 × 10−6
rs4489434 149772149 CD99L2 0.0 G/T 0.16 G −0.336 0.069 1.20 × 10−6
rs11798121 149775837 CD99L2 0.0 T/C 0.16 G −0.330 0.070 2.58 × 10−6
rs11796789 149790994 CD99L2 0.0 T/C 0.16 G −0.328 0.070 2.36 × 10−6
rs34984949 149804623 CD99L2 0.0 G/A 0.16 G −0.331 0.070 1.99 × 10−6
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Table F4: LSBMD Pooled Hits – European Americans
Nearest Distance
Locus SNP Position Gene (kb) Alleles MAF Type β s.e. p
12q24.13 rs12309051 112610534 RBM19 128.4 C/T 0.33 G −0.171 0.037 4.69 × 10−6
rs6489916 112611438 RBM19 127.5 C/T 0.33 G −0.170 0.037 4.91 × 10−6
13q33.3 rs17382033 107839404 TNFSF13B 80.6 C/A 0.09 G 0.295 0.062 2.23 × 10−6
Xp21.1 rs331360 32169468 DMD 86.0 G/A 0.23 G −0.150 0.033 4.71 × 10−6
Table F5: LSBMDMen Hits – European Americans
Nearest Distance
Locus SNP Position Gene (kb) Alleles MAF Type β s.e. p
2q36.3 rs13010707 227250306 IRS1 54.0 C/T 0.13 I −0.356 0.075 2.09 × 10−6
3p14.1 rs9813487 69115174 C3orf64 0.0 T/C 0.20 I 0.290 0.062 3.08 × 10−6
rs6549162 69117389 C3orf64 0.0 C/G 0.19 I 0.289 0.062 3.80 × 10−6
12q24.31 rs12578256 123368433 FAM101A 1.9 T/A 0.18 I −0.296 0.063 2.33 × 10−6
16q21 rs11076239 57038674 NDRG4 16.4 G/A 0.32 I 0.247 0.054 4.39 × 10−6
Xp21.1 rs331360 32169468 DMD 86.0 G/A 0.23 G −0.176 0.038 3.40 × 10−6
Table F6: LSBMDWomen Hits – European Americans
Nearest Distance
Locus SNP Position Gene (kb) Alleles MAF Type β s.e. p
2q37.3 rs6718108 240102747 HDAC4 115.2 A/G 0.33 G 0.252 0.055 4.98 × 10−6
4p16.1 rs10804984 6700002 MRFAP1 4.7 C/A 0.32 I 0.278 0.057 1.12 × 10−6
rs4689024 6700520 MRFAP1 5.2 T/C 0.32 G 0.277 0.057 1.15 × 10−6
5q32 rs318373 143300064 HMHB1 119.6 T/C 0.47 G −0.248 0.053 3.09 × 10−6
7q21.11 rs1397005 80718618 SEMA3C 332.0 A/G 0.28 G 0.271 0.059 4.26 × 10−6
8q22.1 rs278530 94279598 LOC642924 148.3 C/T 0.31 G −0.257 0.056 4.52 × 10−6
rs278548 94287830 LOC642924 140.0 T/C 0.31 I −0.257 0.056 4.52 × 10−6
rs278542 94291954 LOC642924 135.9 A/T 0.31 I −0.256 0.056 4.69 × 10−6
rs1483455 94296725 LOC642924 131.1 C/A 0.25 G −0.271 0.059 4.73 × 10−6
rs11992459 94302355 LOC642924 125.5 G/T 0.25 G −0.271 0.059 4.73 × 10−6
13q33.1 rs640960 100560051 NALCN 0.0 C/T 0.27 G 0.295 0.058 4.26 × 10−7
14q23.1 rs1113590 61073336 PRKCH 0.0 A/C 0.09 I 0.478 0.091 1.40 × 10−7
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Table F7: All Fx Pooled Hits – European Americans
NearestDistance
Locus SNP Position Gene (kb) Alleles MAF Type OR 95%CI p
2q12.2 rs7575679 106373899 PLGLA 0.0 G/A 0.13 I 2.51 (1.71, 3.70) 3.05 × 10−6
18q23 rs12955627 73834676 GALR1 723.6 T/C 0.20 I 1.77 (1.40, 2.24) 1.53 × 10−6
Xq22.3 rs4893537 108857735 ACSL4 0.0 T/C 0.06 G 1.82 (1.41, 2.36) 4.99 × 10−6
Table F8: All Fx Men – European Americans
NearestDistance
Locus SNP Position Gene (kb) Alleles MAF Type OR 95%CI p
3q24 rs6809471 146615470 PLOD2 654.4 G/A 0.32 G 0.41 (0.29, 0.58) 3.11 × 10−7
rs11927695 146555660 PLOD2 714.3 T/C 0.32 I 0.40 (0.29, 0.57) 3.26 × 10−7
rs7430521 146563551 PLOD2 706.4 G/T 0.32 I 0.41 (0.29, 0.58) 3.60 × 10−7
rs2121848 146646417 PLOD2 623.5 C/G 0.33 I 0.44 (0.32, 0.62) 2.63 × 10−6
10p14 rs2296734 7851413 KIN 0.0 G/C 0.43 I 0.45 (0.33, 0.61) 4.64 × 10−7
rs11592018 7838976 KIN 0.0 A/G 0.43 I 0.46 (0.34, 0.63) 7.22 × 10−7
rs1887329 7844710 KIN 0.0 C/A 0.43 I 0.45 (0.33, 0.62) 5.51 × 10−7
rs2026612 7845487 KIN 0.0 C/T 0.43 G 0.45 (0.33, 0.62) 4.77 × 10−7
rs11596873 7849081 KIN 0.0 G/A 0.43 I 0.45 (0.33, 0.61) 4.66 × 10−7
rs11255351 7850077 KIN 0.0 C/T 0.47 I 0.47 (0.35, 0.64) 1.11 × 10−6
rs2148722 7853159 KIN 0.0 G/A 0.47 I 0.47 (0.35, 0.64) 1.10 × 10−6
rs12413131 7863288 KIN 0.0 G/A 0.41 I 0.46 (0.34, 0.64) 1.90 × 10−6
rs4749247 7866138 KIN 0.0 G/C 0.43 I 0.48 (0.35, 0.65) 2.50 × 10−6
rs1244462 7901028 TAF3 0.0 A/G 0.45 G 0.48 (0.35, 0.65) 2.30 × 10−6
14q13.1 rs17100963 32932268 NPAS3 0.0 G/A 0.08 G 2.98 (1.96, 4.51) 2.71 × 10−7
15q25.3 rs7164422 84331644 AGBL1 154.6 A/G 0.06 G 3.14 (2.00, 4.93) 6.28 × 10−7
Table F9: All Fx Women – European Americans
NearestDistance
Locus SNP Position Gene (kb) Alleles MAF Type OR 95%CI p
2p24.1 rs7567544 20256283 SDC1 7.8 G/C 0.45 I 0.52 (0.40, 0.68) 3.10 × 10−6
4q34.2 rs17688188 177708053 VEGFC 133.6 G/A 0.26 I 1.82 (1.41, 2.35) 4.33 × 10−6
8p23.1 rs4840583 11673355 NEIL2 0.0 C/T 0.46 G 1.80 (1.42, 2.29) 1.52 × 10−6
rs8191604 11674293 NEIL2 0.0 T/G 0.26 G 1.82 (1.41, 2.36) 4.86 × 10−6
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Table F10: NV Fx Pooled Hits – European Americans
Nearest Distance
Locus SNP Position Gene (kb) Alleles MAF Type OR 95%CI p
4p16.1 rs6849590 7483478 PSAPL1 0.0 G/A 0.26 G 0.55 (0.44, 0.71) 2.01 × 10−6
7p14.1 rs2329399 39508393 POU6F2 37.5 A/C 0.42 G 0.60 (0.49, 0.74) 3.05 × 10−6
18q23 rs12964032 73772518 GALR1 661.4 A/G 0.20 I 0.52 (0.40, 0.69) 2.81 × 10−6
rs12964230 73772973 GALR1 661.9 C/T 0.20 G 0.52 (0.40, 0.68) 2.41 × 10−6
rs12604089 73777155 GALR1 666.1 T/A 0.16 I 0.47 (0.34, 0.64) 3.01 × 10−6
Xq22.2 rs2983097 102552937 NGFRAP1 33.3 A/G 0.06 G 2.04 (1.54, 2.72) 9.25 × 10−7
Xq22.3 rs4893537 108857735 ACSL4 0.0 T/C 0.06 G 1.82 (1.41, 2.36) 4.99 × 10−6
Table F11: NV Fx Men Hits – European Americans
Nearest Distance
Locus SNP Position Gene (kb) Alleles MAF Type OR 95%CI p
3p14.3 rs9654002 54461737 ESRG 179.5 A/C 0.37 I 2.54 (1.70, 3.79) 4.82 × 10−6
6p21.31 rs9368834 34968742 ANKS1A 0.0 T/G 0.11 G 2.74 (1.81, 4.14) 1.67 × 10−6
rs1555107 34964323 TAF11 0.5 C/G 0.11 I 2.74 (1.81, 4.14) 1.76 × 10−6
rs6905468 34981636 ANKS1A 0.0 C/A 0.11 G 2.74 (1.81, 4.14) 1.67 × 10−6
7q36.3 rs288746 155299433 SHH 1.7 A/G 0.12 G 2.51 (1.70, 3.69) 3.26 × 10−6
9q31.3 rs10979528 110621948 ACTL7B 34.7 T/G 0.06 I 0.35 (0.26, 0.48) 1.61 × 10−11
rs10979533 110628107 ACTL7B 28.6 G/T 0.06 I 0.36 (0.27, 0.48) 1.73 × 10−11
rs12380226 110629373 ACTL7B 27.3 T/C 0.06 I 0.36 (0.27, 0.48) 1.81 × 10−11
rs10979537 110631575 ACTL7B 25.1 A/G 0.06 I 0.36 (0.27, 0.48) 1.86 × 10−11
rs10979538 110631689 ACTL7B 25.0 A/G 0.06 I 0.36 (0.27, 0.48) 1.89 × 10−11
rs10816737 110641875 ACTL7B 14.8 A/C 0.06 I 0.36 (0.27, 0.49) 2.79 × 10−11
rs16913584 110642927 ACTL7B 13.8 G/A 0.06 G 0.36 (0.27, 0.49) 2.79 × 10−11
rs10979546 110645197 ACTL7B 11.5 G/T 0.06 I 0.36 (0.27, 0.49) 2.70 × 10−11
rs10448264 110653174 ACTL7B 3.5 G/A 0.06 G 0.35 (0.26, 0.48) 3.38 × 10−11
12p13.2 rs2607894 10635183 KLRAP1 0.0 G/T 0.38 G 0.43 (0.31, 0.61) 1.14 × 10−6
Xp22.2 rs4073740 12206155 FRMPD4 0.0 G/A 0.24 G 1.75 (1.39, 2.20) 1.57 × 10−6
rs4830768 12197423 FRMPD4 0.0 A/G 0.19 G 1.81 (1.41, 2.32) 3.43 × 10−6
rs4073741 12205866 FRMPD4 0.0 A/G 0.24 I 1.71 (1.36, 2.15) 3.86 × 10−6
rs4511046 12206366 FRMPD4 0.0 C/A 0.24 G 1.71 (1.36, 2.15) 4.65 × 10−6
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Table F12: NV Fx Women Hits – European Americans
Nearest Distance
Locus SNP Position Gene (kb) Alleles MAF Type OR 95%CI p
4p16.1 rs6849590 7483478 PSAPL1 0.0 G/A 0.26 G 0.46 (0.33, 0.64) 3.57 × 10−6
8p21.2 rs10096579 24165000 ADAM28 42.5 G/T 0.15 G 2.15 (1.56, 2.97) 2.99 × 10−6
Table F13: FNBMD Pooled Hits – African Americans
Nearest Distance
Locus SNP Position Gene (kb) Alleles MAF Type β s.e. p
8p23.2 rs10216608 3032465 CSMD1 0.0 A/T 0.09 I −0.368 0.074 6.10 × 10−7
rs10216959 3032337 CSMD1 0.0 G/C 0.08 I −0.359 0.075 1.59 × 10−6
rs10216980 3032368 CSMD1 0.0 C/T 0.08 I −0.366 0.076 1.47 × 10−6
8q21.11 rs16939006 76043194 CRISPLD1 16.1 T/C 0.46 G 0.190 0.042 4.87 × 10−6
9p24.3 rs2279986 1032284 DMRT2 8.1 G/T 0.40 G −0.210 0.045 2.38 × 10−6
11p15.3 rs12417203 11429804 CSNK2A1P 98.3 T/G 0.23 G −0.226 0.047 1.90 × 10−6
15q21.2 rs2305709 49762877 SCG3 0.0 C/A 0.05 I 0.465 0.097 1.70 × 10−6
17q24.3 rs9898716 67428011 SOX9 200.7 A/C 0.14 I −0.290 0.061 2.32 × 10−6
18q12.2 rs16967627 32092618 MOCOS 0.0 C/T 0.06 I −0.380 0.082 3.11 × 10−6
rs10414586 39075001 KCTD15 76.5 C/T 0.10 I −0.345 0.074 3.00 × 10−6
148
Table F14: LSBMD Pooled Hits – African Americans
Nearest Distance
Locus SNP Position Gene (kb) Alleles MAF Type β s.e. p
1q25.3 rs2281415 183659468 IVNS1ABP 106.4 C/T 0.26 G 0.234 0.051 4.69 × 10−6
2p21 rs13408008 47519201 MSH2 0.0 T/G 0.08 I −0.341 0.075 4.86 × 10−6
2q32.1 rs6712733 188501483 GULP1 364.2 T/G 0.25 G 0.236 0.051 3.68 × 10−6
3q27.3 rs10937334 189237130 LOC339929 114.6 C/T 0.14 I −0.267 0.058 4.34 × 10−6
7p21.3 rs7794562 9671676 PER4 29.7 T/C 0.17 I −0.277 0.056 7.86 × 10−7
10p15.3 rs2813457 1562799 NCRNA00168 0.0 C/T 0.07 I −0.345 0.072 1.40 × 10−6
10q21.1 rs12241361 59279878 IPMK 341.4 C/T 0.19 I 0.282 0.057 8.64 × 10−7
rs6481362 59245691 IPMK 375.6 G/A 0.24 I 0.257 0.056 4.96 × 10−6
rs2393391 59249686 IPMK 371.6 G/A 0.19 I 0.286 0.060 1.63 × 10−6
rs6481366 59256869 IPMK 364.4 T/A 0.19 I 0.281 0.058 1.16 × 10−6
rs6481369 59277608 IPMK 343.7 C/T 0.19 G 0.282 0.057 8.72 × 10−7
rs2215686 59296448 IPMK 324.8 A/G 0.12 I 0.338 0.069 1.03 × 10−6
rs17704490 59312506 IPMK 308.8 C/T 0.12 I 0.330 0.071 2.85 × 10−6
rs17704609 59314226 IPMK 307.1 C/T 0.12 I 0.331 0.070 2.60 × 10−6
rs17626174 59320195 IPMK 301.1 A/C 0.12 G 0.332 0.070 2.41 × 10−6
rs17626272 59337175 IPMK 284.1 A/G 0.10 I 0.363 0.076 1.58 × 10−6
10q22.3 rs16935728 79663373 RPS24 176.8 G/T 0.11 I −0.345 0.068 4.16 × 10−7
11p15.2 rs11605876 13516168 PTH 42.0 G/C 0.20 I −0.256 0.053 1.40 × 10−6
11p12 rs10501203 38592016 LRRC4C 1500.3 A/T 0.20 I 0.261 0.056 2.66 × 10−6
rs1038254 38576316 LRRC4C 1516.0 T/G 0.21 I 0.242 0.052 3.10 × 10−6
rs4755497 38578985 LRRC4C 1513.3 A/G 0.21 G 0.242 0.052 3.07 × 10−6
rs11034878 38579595 LRRC4C 1512.7 A/C 0.21 I 0.242 0.052 3.05 × 10−6
rs11034883 38583007 LRRC4C 1509.3 T/G 0.21 I 0.248 0.054 4.16 × 10−6
rs7123927 38583500 LRRC4C 1508.8 C/G 0.20 I 0.249 0.055 4.91 × 10−6
rs11034885 38587219 LRRC4C 1505.1 A/G 0.21 I 0.245 0.052 2.86 × 10−6
11q22.1 rs10894988 99969329 ARHGAP42 94.3 G/A 0.18 I −0.264 0.056 2.05 × 10−6
17p13.2 rs758641 3793551 ATP2A3 0.0 A/G 0.39 G −0.239 0.045 1.10 × 10−7
17q22 rs17745091 50293796 TOM1L1 39.3 T/C 0.21 I −0.238 0.051 3.72 × 10−6
18q22.1 rs12607377 62565126 CDH19 142.9 T/C 0.08 I −0.298 0.065 3.97 × 10−6
rs11151300 62549968 CDH19 127.8 A/G 0.08 I −0.291 0.064 4.94 × 10−6
19q13.11 rs10412883 39096596 KCTD15 98.1 G/A 0.09 I −0.378 0.076 7.68 × 10−7
rs10419694 39087865 KCTD15 89.4 A/C 0.08 I −0.386 0.080 1.22 × 10−6
19q13.32 rs10404733 51450642 IGFL1 24.3 A/C 0.21 I −0.308 0.061 4.39 × 10−7
21q22.11 rs2834247 33978599 ITSN1 0.0 G/A 0.11 I −0.326 0.068 1.94 × 10−6
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APPENDIX G
LOCUS PLOTS OF BMD IN EUROPEAN AMERICANS
Figure G1: Eur. Am. BMD – rs2054993 Figure G2: Eur. Am. BMD – rs13010707
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Figure G3: Eur. Am. BMD – rs6718108 Figure G4: Eur. Am. BMD – rs11717372
Figure G5: Eur. Am. BMD – rs9813487 Figure G6: Eur. Am. BMD – rs10804984
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Figure G7: Eur. Am. BMD – rs2973839 Figure G8: Eur. Am. BMD – rs3909479
Figure G9: Eur. Am. BMD – rs318373 Figure G10: Eur. Am. BMD – rs736004
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Figure G11: Eur. Am. BMD – rs1397005 Figure G12: Eur. Am. BMD – rs10954649
Figure G13: Eur. Am. BMD – rs13252590 Figure G14: Eur. Am. BMD – rs12114940
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Figure G15: Eur. Am. BMD – rs278530 Figure G16: Eur. Am. BMD – rs12309051
Figure G17: Eur. Am. BMD – rs12578256 Figure G18: Eur. Am. BMD – rs640960
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Figure G19: Eur. Am. BMD – rs17382033 Figure G20: Eur. Am. BMD – rs1113590
Figure G21: Eur. Am. BMD – rs16962904 Figure G22: Eur. Am. BMD – rs957029
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Figure G23: Eur. Am. BMD – rs11076239 Figure G24: Eur. Am. BMD – rs2962454
Figure G25: Eur. Am. BMD – rs2190800 Figure G26: Eur. Am. BMD – rs8109254
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Figure G27: Eur. Am. BMD – rs331360 Figure G28: Eur. Am. BMD – rs11795763
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APPENDIX H
LOCUS PLOTS OF FRACTURE RISK IN EUROPEAN AMERICANS
Figure H1: Eur. Am. Fx – rs7567544 Figure H2: Eur. Am. Fx – rs7575679
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Figure H3: Eur. Am. Fx – rs9654002 Figure H4: Eur. Am. Fx – rs6809471
Figure H5: Eur. Am. Fx – rs6849590 Figure H6: Eur. Am. Fx – rs17688188
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Figure H7: Eur. Am. Fx – rs9368834 Figure H8: Eur. Am. Fx – rs2329399
Figure H9: Eur. Am. Fx – rs288746 Figure H10: Eur. Am. Fx – rs4840583
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Figure H11: Eur. Am. Fx – rs10096579 Figure H12: Eur. Am. Fx – rs10979528
Figure H13: Eur. Am. Fx – rs2296734 Figure H14: Eur. Am. Fx – rs2607894
161
Figure H15: Eur. Am. Fx – rs17100963 Figure H16: Eur. Am. Fx – rs7164422
Figure H17: Eur. Am. Fx – rs12955627 Figure H18: Eur. Am. Fx – rs4073740
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Figure H19: Eur. Am. Fx – rs2983097 Figure H20: Eur. Am. Fx – rs4893537
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APPENDIX I
LOCUS PLOTS OF  GENOMES REPLICATION ANALYSIS
Figure I1: 1000 Genomes – rs7524102 (ZBTB40) Figure I2: 1000 Genomes – rs1430742 (GPR177)
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Figure I3: 1000 Genomes – rs11898505
(SPTBN1)
Figure I4: 1000 Genomes – rs87938 (CTNNB1)
Figure I5: 1000 Genomes – rs1471403 (MEPE) Figure I6: 1000 Genomes – rs1366594 (MEF2C)
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Figure I7: 1000 Genomes – rs2504063 (ESR1)
Figure I8: 1000 Genomes – rs1524058
(STARD3NL)
Figure I9: 1000 Genomes – rs7781370
(FLJ42280)
Figure I10: 1000 Genomes – rs2062377 (TN-
FRSF11B)
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Figure I11: 1000 Genomes – rs7117858 (SOX6)
Figure I12: 1000 Genomes – rs16921914
(DCDC5)
Figure I13: 1000 Genomes – rs7932354
(ARHGAP1)
Figure I14: 1000 Genomes – rs599083 (LRP5)
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Figure I15: 1000 Genomes – rs2016266 (SP7)
Figure I16: 1000 Genomes – rs9533090
(AKAP11)
Figure I17: 1000 Genomes – rs10048146
(FOXL1)
Figure I18: 1000 Genomes – rs228769 (HDAC5)
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Figure I19: 1000 Genomes – rs9303521
(CRHR1)
Figure I20: 1000 Genomes – rs884205 (TN-
FRSF11A)
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APPENDIX J
LOCUS PLOTS OF BMD IN AFRICAN AMERICANS
Figure J1: Afr. Am. BMD – rs2281415 Figure J2: Afr. Am. BMD – rs13408008
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Figure J3: Afr. Am. BMD – rs6712733 Figure J4: Afr. Am. BMD – rs10937334
Figure J5: Afr. Am. BMD – rs7794562 Figure J6: Afr. Am. BMD – rs10216608
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Figure J7: Afr. Am. BMD – rs16939006 Figure J8: Afr. Am. BMD – rs2279986
Figure J9: Afr. Am. BMD – rs2813457 Figure J10: Afr. Am. BMD – rs12241361
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Figure J11: Afr. Am. BMD – rs16935728 Figure J12: Afr. Am. BMD – rs12417203
Figure J13: Afr. Am. BMD – rs11605876 Figure J14: Afr. Am. BMD – rs10501203
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Figure J15: Afr. Am. BMD – rs10894988 Figure J16: Afr. Am. BMD – rs2305709
Figure J17: Afr. Am. BMD – rs758641 Figure J18: Afr. Am. BMD – rs17745091
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Figure J19: Afr. Am. BMD – rs9898716 Figure J20: Afr. Am. BMD – rs16967627
Figure J21: Afr. Am. BMD – rs12607377 Figure J22: Afr. Am. BMD – rs10412883
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Figure J23: Afr. Am. BMD – rs10404733 Figure J24: Afr. Am. BMD – rs2834247
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